(51) International Patent Classification[7]: A61K 48/00, C12Q 1/70

(21) International Application Number: PCT/US00/34724

(22) International Filing Date:
21 December 2000 (21.12.2000)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/171,542   22 December 1999 (22.12.1999)   US

(71) Applicant (for all designated States except US): MERCK & CO., INC. [US/US]; 126 East Lincoln Avenue, Rahway, NJ 07065-0907 (US).

(72) Inventors; and
(75) Inventors/Applicants (for US only): SHIVER, John, W. [US/US]; 126 East Lincoln Avenue, Rahway, NJ 07065-0907 (US). PERRY, Helen, C. [US/US]; 126 East Lincoln Avenue, Rahway, NJ 07065-0907 (US). CASIMIRO, Danilo, R. [PH/US]; 126 East Lincoln Avenue, Rahway,

NJ 07065-0907 (US). FU, Tong-Ming [US/US]; 126 East Lincoln Avenue, Rahway, NJ 07065-0907 (US).

(74) Common Representative: MERCK & CO., INC.; 126 East Lincoln Avenue, Rahway, NJ 07065-0907 (US).

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:
— With international search report.

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: POLYNUCLEOTIDE VACCINES EXPRESSING CODON OPTIMIZED HIV-1 POL AND MODIFIED HIV-1 POL

(57) Abstract: Pharmaceutical compositions which comprise HIV Pol DNA vaccines are disclosed, along with the production and use of these DNA vaccines. The pol-based DNA vaccines of the invention are administered directly introduced into living vertebrate tissue, preferably humans, and preferably express inactivated versions of the HIV Pol protein devoid of protease, reverse transcriptase activity, RNase H activity and integrase activity, inducing a cellular immune response which specifically recognizes human immunodeficiency virus-1 (HIV-1). The DNA molecules which comprise the open reading frame of these DNA vaccines are synthetic DNA molecules encoding codon optimized HIV-1 Pol and codon optimized inactive derivatives of optimized HIV-1 Pol, including DNA molecules which encode inactive Pol proteins which comprise an amino terminal leader peptide.

TITLE OF THE INVENTION

POLYNUCLEOTIDE VACCINES EXPRESSING CODON OPTIMIZED HIV-1

5   POL AND MODIFIED HIV-1 POL

CROSS-REFERENCE TO RELATED APPLICATIONS

This application claims the benefit, under 35 U.S.C. §119(e), of U.S.

provisional application 60/171,542, filed December 22, 1999.

10

STATEMENT REGARDING FEDERALLY-SPONSORED R&D

Not Applicable

15   REFERENCE TO MICROFICHE APPENDIX

Not Applicable

FIELD OF THE INVENTION

The present invention relates to HIV Pol polynucleotide pharmaceutical

20   products, as well as the production and use thereof which, when directly introduced

into living vertebrate tissue, preferably a mammalian host such as a human or a

non-human mammal of commercial or domestic veterinary importance, express the

HIV Pol protein or biologically relevant portions thereof within the animal, inducing a

cellular immune response which specifically recognizes human immunodeficiency

25   virus-1 (HIV-1). The polynucleotides of the present invention are synthetic DNA

molecules encoding codon optimized HIV-1 Pol and derivatives of optimized HIV-1

Pol, including constructs wherein protease, reverse transcriptase, RNAse H and

integrase activity of HIV-1 Pol is inactivated. The polynucleotide vaccines of the

present invention should offer a prophylactic advantage to previously uninfected

30   individuals and/or provide a therapeutic effect by reducing viral load levels within an

infected individual, thus prolonging the asymptomatic phase of HIV-1 infection.

BACKGROUND OF THE INVENTION

Human Immunodeficiency Virus-1 (HIV-1) is the etiological agent of acquired human immune deficiency syndrome (AIDS) and related disorders. HIV-1 is an RNA virus of the Retroviridae family and exhibits the 5' LTR-*gag-pol-env*-

5   LTR 3' organization of all retroviruses. The integrated form of HIV-1, known as the provirus, is approximately 9.8 Kb in length. Each end of the viral genome contains flanking sequences known as long terminal repeats (LTRs). The HIV genes encode at least nine proteins and are divided into three classes; the major structural proteins (Gag, Pol, and Env), the regulatory proteins (Tat and Rev); and the accessory proteins

10   (Vpu, Vpr, Vif and Nef).

The *gag* gene encodes a 55-kilodalton (kDa) precursor protein (p55) which is expressed from the unspliced viral mRNA and is proteolytically processed by the HIV protease, a product of the *pol* gene. The mature p55 protein products are p17 (matrix), p24 (capsid), p9 (nucleocapsid) and p6.

15   The *pol* gene encodes proteins necessary for virus replication; a reverse transcriptase, a protease, integrase and RNAse H. These viral proteins are expressed as a Gag-Pol fusion protein, a 160 kDa precursor protein which is generated via a ribosomal frame shifting. The viral encoded protease proteolytically cleaves the Pol polypeptide away from the Gag-Pol fusion and further cleaves the Pol polypeptide to

20   the mature proteins which provide protease (Pro, P10), reverse transcriptase (RT, P50), integrase (IN, p31) and RNAse H (RNAse, p15) activities.

The *nef* gene encodes an early accessory HIV protein (Nef) which has been shown to possess several activities such as down regulating CD4 expression, disturbing T-cell activation and stimulating HIV infectivity.

25   The *env* gene encodes the viral envelope glycoprotein that is translated as a 160-kilodalton (kDa) precursor (gp160) and then cleaved by a cellular protease to yield the external 120-kDa envelope glycoprotein (gp120) and the transmembrane 41-kDa envelope glycoprotein (gp41). Gp120 and gp41 remain associated and are displayed on the viral particles and the surface of HIV-infected cells.

30   The *tat* gene encodes a long form and a short form of the Tat protein, a RNA binding protein which is a transcriptional transactivator essential for HIV-1 replication.

The *rev* gene encodes the 13 kDa Rev protein, a RNA binding protein. The Rev protein binds to a region of the viral RNA termed the Rev response element

(RRE). The Rev protein is promotes transfer of unspliced viral RNA from the nucleus to the cytoplasm. The Rev protein is required for HIV late gene expression and in turn, HIV replication.

Gp120 binds to the CD4/chemokine receptor present on the surface of helper
5   T-lymphocytes, macrophages and other target cells in addition to other co-receptor molecules. X4 (macrophage tropic) virus show tropism for CD4/CXCR4 complexes while a R5 (T-cell line tropic) virus interacts with a CD4/CCR5 receptor complex. After gp120 binds to CD4, gp41 mediates the fusion event responsible for virus entry. The virus fuses with and enters the target cell, followed by reverse transcription of its
10 single stranded RNA genome into the double-stranded DNA via a RNA dependent DNA polymerase. The viral DNA, known as provirus, enters the cell nucleus, where the viral DNA directs the production of new viral RNA within the nucleus, expression of early and late HIV viral proteins, and subsequently the production and cellular release of new virus particles. Recent advances in the ability to detect viral load
15 within the host shows that the primary infection results in an extremely high generation and tissue distribution of the virus, followed by a steady state level of virus (albeit through a continual viral production and turnover during this phase), leading ultimately to another burst of virus load which leads to the onset of clinical AIDS. Productively infected cells have a half life of several days, whereas chronically or
20 latently infected cells have a 3-week half life, followed by non-productively infected cells which have a long half life (over 100 days) but do not significantly contribute to day to day viral loads seen throughout the course of disease.

Destruction of CD4 helper T lymphocytes, which are critical to immune defense, is a major cause of the progressive immune dysfunction that is the hallmark
25 of HIV infection. The loss of CD4 T-cells seriously impairs the body's ability to fight most invaders, but it has a particularly severe impact on the defenses against viruses, fungi, parasites and certain bacteria, including mycobacteria.

Effective treatment regimens for HIV-1 infected individuals have become available recently. However, these drugs will not have a significant impact on the
30 disease in many parts of the world and they will have a minimal impact in halting the spread of infection within the human population. As is true of many other infectious diseases, a significant epidemiologic impact on the spread of HIV-1 infection will only occur subsequent to the development and introduction of an effective vaccine. There are a number of factors that have contributed to the lack of successful vaccine

development to date. As noted above, it is now apparent that in a chronically infected person there exists constant virus production in spite of the presence of anti-HIV-1 humoral and cellular immune responses and destruction of virally infected cells. As in the case of other infectious diseases, the outcome of disease is the result of a

5   balance between the kinetics and the magnitude of the immune response and the pathogen replicative rate and accessibility to the immune response. Pre-existing immunity may be more successful with an acute infection than an evolving immune response can be with an established infection. A second factor is the considerable genetic variability of the virus. Although anti-HIV-1 antibodies exist that can

10   neutralize HIV-1 infectivity in cell culture, these antibodies are generally virus isolate-specific in their activity. It has proven impossible to define serological groupings of HIV-1 using traditional methods. Rather, the virus seems to define a serological "continuum" so that individual neutralizing antibody responses, at best, are effective against only a handful of viral variants. Given this latter observation, it

15   would be useful to identify immunogens and related delivery technologies that are likely to elicit anti-HIV-1 cellular immune responses. It is known that in order to generate CTL responses antigen must be synthesized within or introduced into cells, subsequently processed into small peptides by the proteasome complex, and translocated into the endoplasmic reticulum/Golgi complex secretory pathway for

20   eventual association with major histocompatibility complex (MHC) class I proteins. $CD8^+$ T lymphocytes recognize antigen in association with class I MHC via the T cell receptor (TCR) and the CD8 cell surface protein. Activation of naive $CD8^+$ T cells into activated effector or memory cells generally requires both TCR engagement of antigen as described above as well as engagement of costimulatory proteins. Optimal

25   induction of CTL responses usually requires "help" in the form of cytokines from $CD4^+$ T lymphocytes which recognize antigen associated with MHC class II molecules via TCR and CD4 engagement.

       Larder, et al., (1987, *Nature* 327: 716-717) and Larder, et al., (1989, *Proc. Natl. Acad. Sci.* 86: 4803-4807) disclose site specific mutagenesis of HIV-1 RT and

30   the effect such changes have on *in vitro* activity and infectivity related to interaction with known inhibitors of RT.

       Davies, et al. (1991, *Science* 252:, 88-95) disclose the crystal structure of the RNase H domain of HIV-1 Pol.

Schatz, et al. (1989, *FEBS Lett.* 257: 311-314) disclose that mutations Glu478Gln and His539Phe in a complete HIV-1 RT/RNase H DNA fragment results in defective RNase activity without effecting RT activity.

Mizrahi, et al. (1990, *Nucl. Acids. Res.* 18: pp. 5359-5353) disclose additional
5   mutations Asp443Asn and Asp498Asn in the RNase region of the *pol* gene which also results in defective RNase activity. The authors note that the Asp498Asn mutant was difficult to characterize due to instability of this mutant protein.

Leavitt, et al. (1993, *J. Biol. Chem.* 268: 2113-2119) disclose several mutations, including a Asp64Val mutation, which show differing effect on HIV-1
10   integrase (IN) activity.

Wiskerchen, et al. (1995, *J. Virol.* 69: 376-386) disclose singe and double mutants, including mutation of aspartic acid residues which effect HIV-1 IN and viral replication functions.

It would be of great import in the battle against AIDS to produce a
15   prophylactic- and/or therapeutic-based HIV vaccine which generates a strong cellular immune response against an HIV infection. The present invention addresses and meets this needs by disclosing a class of DNA vaccines based on host delivery and expression of modified versions of the HIV-1 gene, *pol*.

20   SUMMARY OF THE INVENTION

The present invention relates to synthetic DNA molecules (also referred to herein as "polynucleotides") and associated DNA vaccines (also referred to herein as "polynucleotide vaccines") which elicit cellular immune and humoral responses upon administration to the host, including primates and especially humans, and also
25   including a non-human mammal of commercial or domestic veterinary importance. An effect of the cellular immune-directed vaccines of the present invention should be the lower transmission rate to previously uninfected individuals and/or reduction in the levels of the viral loads within an infected individual, so as to prolong the asymptomatic phase of HIV-1 infection. In particular, the present invention relates to
30   DNA vaccines which encode various forms of HIV-1 Pol, wherein administration, intracellular delivery and expression of the HIV-1 Pol gene of interest elicits a host CTL and Th response. The preferred synthetic DNA molecules of the present invention encode codon optimized versions of wild type HIV-1 Pol, codon optimized versions of HIV-1 Pol fusion proteins, and codon optimized versions of HIV-1 Pol

proteins and fusion protein, including but not limited to *pol* modifications involving residues within the catalytic regions responsible for RT, RNase and IN activity within the host cell.

A particular embodiment of the present invention relates to codon optimized
5   wt-pol DNA constructs wherein DNA sequences encoding the protease (PR) activity are deleted, leaving codon optimized "wild type" sequences which encode RT (reverse transcriptase and RNase H activity) and IN integrase activity. The nucleotide sequence of a DNA molecule which encodes this protein is disclosed herein as SEQ ID NO:1 and the corresponding amino acid sequence of the expressed protein is
10   disclosed herein as SEQ ID NO:2.

The present invention preferably relates to a HIV-1 DNA pol construct which is devoid of DNA sequences encoding any PR activity, as well as containing a mutation(s) which at least partially, and preferably substantially, abolishes RT, RNase and/or IN activity. One type of HIV-1 pol mutant may include but is not limited to a
15   mutated DNA molecule comprising at least one nucleotide substitution which results in a point mutation which effectively alters an active site within the RT, RNase and/or IN regions of the expressed protein, resulting in at least substantially decreased enzymatic activity for the RT, RNase H and/or IN functions of HIV-1 Pol. In a preferred embodiment of this portion of the invention, a HIV-1 DNA pol construct
20   contains a mutation or mutations within the Pol coding region which effectively abolishes RT, RNase H and IN activity. An especially preferable HIV-1 DNA pol construct in a DNA molecule which contains at least one point mutation which alters the active site of the RT, RNase H and IN domains of Pol, such that each activity is at least substantially abolished. Such a HIV-1 Pol mutant will most likely comprise at
25   least one point mutation in or around each catalytic domain responsible for RT, RNase H and IN activity, respectfully. To this end, an especially preferred HIV-1 DNA pol construct is exemplified herein and contains nine codon substitution mutations which results in an inactivated Pol protein (IA Pol: SEQ ID NO:4, Figure 2A-C) which has no PR, RT, RNase or IN activity, wherein three such point
30   mutations reside within each of the RT, RNase and IN catalytic domains. Any combination of the mutations disclosed herein may suitable and therefore may be utilized as an IA-Pol-based vaccine of the present invention. While addition and deletion mutations are contemplated and within the scope of the invention, the

preferred mutation is a point mutation resulting in a substitution of the wild type amino acid with an alternative amino acid residue.

Another aspect of the present invention is to generate HIV-1 Pol-based vaccine constructions which comprise a eukaryotic trafficking signal peptide such as the leader peptide from human tPA. To this end, the present invention relates to a DNA molecule which encodes a codon optimized wt-pol DNA construct wherein the protease (PR) activity is deleted and a human tPA leader sequence is fused to the 5' end of the coding region. A DNA molecule which encodes this protein is disclosed herein as SEQ ID NO:5, the open reading frame disclosed herein as SEQ ID NO:6.

The present invention especially relates to a HIV-1 Pol mutant such as IA-Pol (SEQ ID NO:4) which comprises a leader peptide, such as the human tPA leader, at the amino terminal portion of the protein, which may effect cellular trafficking and hence, immunogenicity of the expressed protein within the host cell. Any such HIV-1 DNA pol mutant disclosed in the above paragraphs is suitable for fusion downstream of a leader peptide, including but by no means limited to the human tPA leader sequence. Therefore, any such leader peptide-based HIV-1 pol mutant construct may include but is not limited to a mutated DNA molecule which effectively alters the catalytic activity of the RT, RNase and/or IN region of the expressed protein, resulting in at least substantially decreased enzymatic activity one or more of the RT, RNase H and/or IN functions of HIV-1 Pol. In a preferred embodiment of this portion of the invention, a leader peptide/HIV-1 DNA pol construct contains a mutation or mutations within the Pol coding region which effectively abolishes RT, RNase H and IN activity. An especially preferable HIV-1 DNA pol construct is a DNA molecule which contains at least one point mutation which alters the active site and catalytic activity within the RT, RNase H and IN domains of Pol, such that each activity is at least substantially abolished, and preferably totally abolished. Such a HIV-1 Pol mutant will most likely comprise at least one point mutation in or around each catalytic domain responsible for RT, RNase H and IN activity, respectfully. An especially preferred embodiment of this portion of the invention relates to a human tPA leader fused to the IA-Pol protein comprising the nine mutations shown in Table 1. The DNA molecule is disclosed herein as SEQ ID NO:7 and the expressed tPA-IA Pol protein comprises a fusion junction as shown in Figure 3. The complete amino acid sequence of the expressed protein is set forth in SEQ ID NO:8.

The present invention also relates to a substantially purified protein expressed from the DNA polynucleotide vaccines of the present invention, especially the purified

proteins set forth below as SEQ ID NOs: 2, 4, 6, and 8. These purified proteins may be useful as protein-based HIV vaccines.

The present invention also relates to non-codon optimized versions of DNA molecules and associated polynucleotides and associated DNA vaccines which
5   encode the various wild type and modified forms of the HIV Pol protein disclosed herein. Partial or fully codon optimized DNA vaccine expression vector constructs are preferred, but it is within the scope of the present invention to utilize "non-codon optimized" versions of the constructs disclosed herein, especially modified versions of HIV Pol which are shown to promote a substantial cellular immune and humoral
10 immune responses subsequent to host administration.

The DNA backbone of the DNA vaccines of the present invention are preferably DNA plasmid expression vectors. DNA plasmid expression vectors utilized in the present invention include but are not limited to constructs which comprise the cytomegalovirus promoter with the intron A sequence (CMV-intA) and
15 a bovine growth hormone transcription termination sequence. In addition, DNA plasmid vectors of the present invention preferably comprise an antibiotic resistance marker, including but not limited to an ampicillin resistance gene, a neomycin resistance gene or any other pharmaceutically acceptable antibiotic resistance marker. In addition, an appropriate polylinker cloning site and a prokaryotic origin of
20 replication sequence are also preferred. Specific DNA vectors exemplified herein include V1, V1J (SEQ ID NO:13), V1Jneo (SEQ ID NO:14), V1Jns (Figure 1A, SEQ ID NO:15), V1R (SEQ ID NO:26), and any of the aforementioned vectors wherein a nucleotide sequence encoding a leader peptide, preferably the human tPA leader, is fused directly downstream of the CMV-intA promoter, including but not limited to
25 V1Jns-tpa, as shown in Figure 1B and SEQ ID NO:28.

The present invention especially relates to a DNA vaccine and a pharmaceutically active vaccine composition which contains this DNA vaccine, and the use as prophylactic and/or therapeutic vaccine for host immunization, preferably human host immunization, against an HIV infection or to combat an existing HIV
30 condition. These DNA vaccines are represented by codon optimized DNA molecules encoding codon optimized HIV-1 Pol (e.g. SEQ ID NO:2), codon optimized HIV-1 Pol fused to an amino terminal localized leader sequence (e.g. SEQ ID NO:6), and especially preferable, and the essence of the present invention, biologically inactive Pol proteins (IA Pol; e.g., SEQ ID NO:4) devoid of significant PR, RT, RNase or IN

activity associated with wild type Pol and a concomitant construct which contains a leader peptide at the amino terminal region of the IA Pol protein. These constructs are ligated within an appropriate DNA plasmid vector, with or without a nucleotide sequence encoding a functional leader peptide. Preferred DNA vaccines of the

5 present invention comprise codon optimized DNA molecules encoding codon optimized HIV-1 Pol and inactivated version of Pol, ligated in DNA vectors disclosed herein, or any of the aforementioned vectors wherein a nucleotide sequence encoding a leader peptide, preferably the human tPA leader, is fused directly downstream of the CMV-intA promoter, including but not limited to V1Jns-tpa, as shown in Figure 1B

10 and SEQ ID NO:28.

Therefore, the present invention relates to DNA vaccines which include, but are in no way limited to V1Jns-WTPol (comprising the DNA molecule encoding WT Pol, as set forth in SEQ ID NO:2), V1Jns-tPA-WTPol, (comprising the DNA molecule encoding tPA Pol, as set forth in SEQ ID NO:6), V1Jns-IAPol (comprising

15 the DNA molecule encoding IA Pol, as set forth in SEQ ID NO:4), and V1Jns-tPA-IAPol, (comprising the DNA molecule encoding tPA-IA Pol, as set forth in SEQ ID NO:8). Especially preferred are V1Jns-IAPol and V1Jns-tPA-IAPol, as exemplified in Example Section 2.

The present invention also relates to HIV Pol polynucleotide

20 pharmaceutical products, as well as the production and use thereof, wherein the DNA vaccines are formulated with an adjuvant or adjuvants which may increase immunogenicity of the DNA polynucleotide vaccines of the present invention, namely by promoting an enhanced cellular and/or humoral response subsequent to inoculation. A preferred adjuvant is an aluminum phosphate-based adjuvant or a

25 calcium phosphate based adjuvant, with an aluminum phosphate adjuvant being especially preferred. Another preferred adjuvant is a non-ionic block copolymer, preferably comprising the blocks of polyoxyethylene (POE) and polyoxypropylene (POP) such as a POE-POP-POE block copolymer. These adjuvanted forms comprising the DNA vaccines disclosed herein are useful in

30 increasing cellular responses to DNA vaccination.

As used herein, a DNA vaccine or DNA polynucleotide vaccine is a DNA molecule (i.e., "nucleic acid", "polynucleotide") which contains essential regulatory elements such that upon introduction into a living, vertebrate cell, it is able to direct the cellular machinery to produce translation products encoded by the respective pol

genes of the present invention.

BRIEF DESCRIPTION OF THE FIGURES

Figure 1A-B shows schematic representation of DNA vaccine expression vectors V1Jns (A) and V1Jns-tPA (B) utilized for HIV-1 pol and HIV-1 modified pol constructs.

Figure 2A-C shows the nucleotide (SEQ ID NO:3) and amino acid sequence (SEQ ID NO:4) of IA-Pol. Underlined codons and amino acids denote mutations, as listed in Table 1.

Figure 3 shows the codon optimized nucleotide and amino acid sequences through the fusion junction of tPA-IA-Pol (contained within SEQ ID NOs: 7 and 8, respectively). The underlined portion represents the NH_2-terminal region of IA-Pol.

Figure 4 shows generation of a humoral response (measured as the geometric means of anti-RT endpoint titers) from mice immunized with one or two doses of codon optimized V1Jns-IApol and V1Jns-tpa-IApol. A portion of mice that received 30 ug of each plasmid was boosted at T=8 wks; sera from all mice were collected at 4 wk post dose 2.

Figure 5 shows the number of IFN-gamma secreting cells per 10e6 cells following stimulation with pools of either $CD4^+$ (aa641-660, aa731-750) or $CD8^+$ (aa201-220, aa311-330, aa571-590, aa781-800) specific peptides of splenocytes (pool of 5 spleens/cohort) from control mice and those vaccinated with increasing single dose of codon optimized V1Jns-IApol or 30 ug of codon optimized V1Jns-tpa-IApol (13 wks post dose 1). Mice (n=5) vaccinated with a second dose of 30 ug of either plasmid were analyzed in an Elispot assay at 6 wks post dose 2. Reported are the sums of the number of spots stimulated by each individual $CD8^+$ peptides because the spots in the wells to which the pool was added are too dense to acquire accurate counts. The $CD4^+$ cell counts are taken from the responses to the peptide pool. Error bars represent standard deviations for counts from triplicate wells per sample per antigen.

Figure 6A-C shows ELIspot analysis of peripheral blood cells collected from rhesus macaques immunized three times (T=0, 4, 8 wks) with 5 mgs of codon optimized HIV-1 Pol expressing plasmids. Antigen-specific IFN-gamma secretion was stimulated by adding one of two pools consisting of 20-mer peptides derived from vaccine sequence (mpol-1, aa1-420; mpol-2, aa411-850). (A) Frequencies of

spot-forming cells (SFC) as a function of time for 3 monkeys (Tag No. 94R008, 94R013, 94R033) vaccinated with V1Jns-IApol. The reported values are corrected for background responses without peptide restimulation. (B) Frequencies of spot-forming cells (SFC) as a function of time for 3 monkeys (Tag No. 920078, 920073,

5   94R028) vaccinated with 5mgs of V1Jns-tpa-IApol. (C) ELIspot responses were also measured from a monkey (920072) that did not receive any immunization.

Figure 7A-B show bulk CTL killing from rhesus macaques immunized with codon optimized V1Jns-IApol (A)or codon optimized V1Jns-tpa-IApol (B) at 8 weeks following the third vaccination. Restimulation was performed using recombinant

10 vaccinia virus expressing pol and target cells were prepared by pulsing with the peptide pools, mpol-1 and mpol-2.

Figure 8 shows detection of *in vitro* pol expression from cell lysates of 293 cells transfected with 10 ug of various pol constructs. Bands were detected using anti-serum from an HIV-1 seropositive human subject. Equal amounts of total protein

15 were loaded for each lane. The lanes contain the lysates from cells transfected with the following: 1: mock; 2: V1Jns-wt-pol; 3: V1Jns-IApol (codon optimized); 4: V1Jns-tpa-IApol (codon optimized); 5: V1Jns-tpa-pol (codon optimized); 6: V1R-wt-pol (codon optimized); 7: blank; and 8: 80 ng RT.

Figure 9 shows the geometric mean anti-RT titers (GMT) plus the standard

20 errors of the geometric means for cohorts of 5 mice that received one (open circles) or two doses (solid circles) of 1, 10, 100 μg of V1R-wt-pol (codon optimized) or V1Jns-wt-pol. Sera from all animals were collected at 2 weeks post dose 2 (or 7 wks post dose 1) and assayed simultaneously. Statistical analyses were performed to compare cohorts that received the same amount and number of immunization of either

25 plasmids; p values (two-tail) less than 5% are above the bars the connect the correlated cohorts to reflect statistically significant differences.

Figure 10 shows cellular immune responses in BALB/c mice vaccinated i.m. with 1 (pd1) or 2 (pd2) doses of varying amounts of either wt-pol (virus derived) or wt-pol (codon optimized) plasmids. At 3 wks post dose 2, frequencies of IFN-γ-

30 secreting splenocytes are determined from pools of 5 spleens per cohort against mixtures of either CD4[+] peptides (aa21-40, aa411-430, aa531-550, aa641-660, aa731-750, aa771-790) or CD8[+] peptides (aa201-220, aa311-330) at 4 μg/mL final concentration per peptide.

DETAILED DESCRIPTION OF THE INVENTION

The present invention relates to synthetic DNA molecules and associated DNA vaccines which elicit CTL and Th cellular immune responses upon administration to the host, including primates and especially humans. An effect of the
5   cellular immune-directed vaccines of the present invention should be a lower transmission rate to previously uninfected individuals and/or reduction in the levels of the viral loads within an infected individual, so as to prolong the asymptomatic phase of HIV-1 infection. In particular, the present invention relates to DNA vaccines which encode various forms of HIV-1 Pol, wherein administration, intracellular
10   delivery and expression of the HIV-1 Pol gene of interest elicits a host CTL and Th response. The preferred synthetic DNA molecules of the present invention encode codon optimized wild type Pol (without Pro activity) and various codon optimized inactivated HIV-1 Pol proteins. The HIV-1 *pol* constructs disclosed herein are . especially preferred for pharmaceutical uses, especially for human administration as a
15   DNA vaccine. The HIV-1 genome employs predominantly uncommon codons compared to highly expressed human genes. Therefore, the pol open reading frame has been synthetically manipulated using optimal codons for human expression. As noted above, a preferred embodiment of the present invention relates to DNA molecules which comprise a HIV-1 pol open reading frame, whether encoding full
20   length pol or a modification or fusion as described herein, wherein the codon usage has been optimized for expression in a mammal, especially a human.

The synthetic *pol* gene disclosed herein comprises the coding sequences for the reverse transcriptase (or RT which consists of a polymerase and RNase H activity) and integrase (IN). The protein sequence is based on that of Hxb2r, a clonal isolate of
25   IIIB; this sequence has been shown to be closest to the consensus clade B sequence with only 16 nonidentical residues out of 848 (Korber, et al., 1998, Human retroviruses and AIDS, Los Alamos National Laboratory, Los Alamos, New Mexico). The skilled artisan will understand after review of this specification that any available HIV-1 or HIV-2 strain provides a potential template for the generation of HIV pol
30   DNA vaccine constructs disclosed herein. It is further noted that the protease gene is excluded from the DNA vaccine constructs of the present invention to insure safety from any residual protease activity in spite of mutational inactivation. The design of the gene sequences for both wild-type (wt-pol) and inactivated pol (IA-pol) incorporates the use of human preferred ("humanized") codons for each amino acid

-12-

residue in the sequence in order to maximize *in vivo* mammalian expression (Lathe, 1985, J. Mol. Biol. 183:1-12). As can be discerned by inspecting the codon usage in SEQ ID NOs: 1, 3, 5 and 7, the following codon usage for mammalian optimization is preferred: Met (ATG), Gly (GGC), Lys (AAG), Trp (TGG), Ser (TCC), Arg (AGG),

5 Val (GTG), Pro (CCC), Thr (ACC), Glu (GAG); Leu (CTG), His (CAC), Ile (ATC), Asn (AAC), Cys (TGC), Ala (GCC), Gln (CAG), Phe (TTC) and Tyr (TAC). For an additional discussion relating to mammalian (human) codon optimization, see WO 97/31115 (PCT/US97/02294), which is hereby incorporated by reference. It is intended that the skilled artisan may use alternative versions of codon optimization or

10 may omit this step when generating HIV pol vaccine constructs within the scope of the present invention. Therefore, the present invention also relates to non-codon optimized versions of DNA molecules and associated DNA vaccines which encode the various wild type and modified forms of the HIV Pol protein disclosed herein. However, codon optimization of these constructs is a preferred embodiment of this

15 invention.

A particular embodiment of the present invention relates to codon optimized wt-pol DNA constructs (herein, "wt-pol" or "wt-pol (codon optimized))" wherein DNA sequences encoding the protease (PR) activity are deleted, leaving codon optimized "wild type" sequences which encode RT (reverse transcriptase and RNase

20 H activity) and IN integrase activity. A DNA molecule which encodes this protein is disclosed herein as SEQ ID NO:1, the open reading frame being contained from an initiating Met residue at nucleotides 10-12 to a termination codon from nucleotides 2560-2562. SEQ ID NO:1 is as follows:

```
        AGATCTACCA TGGCCCCCAT CTCCCCCATT GAGACTGTGC CTGTGAAGCT GAAGCCTGGC
25      ATGGATGGCC CCAAGGTGAA GCAGTGGCCC CTGACTGAGG AGAAGATCAA GGCCCTGGTG
        GAAATCTGCA CTGAGATGGA GAAGGAGGGC AAAATCTCCA AGATTGGCCC CGAGAACCCC
        TACAACACCC CTGTGTTTGC CATCAAGAAG AAGGACTCCA CCAAGTGGAG GAAGCTGGTG
        GACTTCAGGG AGCTGAACAA GAGGACCCAG GACTTCTGGG AGGTGCAGCT GGGCATCCCC
        CACCCCGCTG GCCTGAAGAA GAAGAAGTCT GTGACTGTGC TGGATGTGGG GGATGCCTAC
30      TTCTCTGTGC CCCTGGATGA GGACTTCAGG AAGTACACTG CCTTCACCAT CCCCTCCATC
        AACAATGAGA CCCCTGGCAT CAGGTACCAG TACAATGTGC TGCCCCAGGG CTGGAAGGGC
        TCCCCTGCCA TCTTCCAGTC CTCCATGACC AAGATCCTGG AGCCCTTCAG GAAGCAGAAC
        CCTGACATTG TGATCTACCA GTACATGGAT GACCTGTATG TGGGCTCTGA CCTGGAGATT
        GGGCAGCACA GGACCAAGAT TGAGGAGCTG AGGCAGCACC TGCTGAGGTG GGGCCTGACC
```

```
    ACCCCTGACA AGAAGCACCA GAAGGAGCCC CCCTTCCTGT GGATGGGCTA TGAGCTGCAC

    CCCGACAAGT GGACTGTGCA GCCCATTGTG CTGCCTGAGA AGGACTCCTG GACTGTGAAT

    GACATCCAGA AGCTGGTGGG CAAGCTGAAC TGGGCCTCCC AAATCTACCC TGGCATCAAG

    GTGAGGCAGC TGTGCAAGCT GCTGAGGGGC ACCAAGGCCC TGACTGAGGT GATCCCCCTG

 5  ACTGAGGAGG CTGAGCTGGA GCTGGCTGAG AACAGGGAGA TCCTGAAGGA GCCTGTGCAT

    GGGGTGTACT ATGACCCCTC CAAGGACCTG ATTGCTGAGA TCCAGAAGCA GGGCCAGGGC

    CAGTGGACCT ACCAAATCTA CCAGGAGCCC TTCAAGAACC TGAAGACTGG CAAGTATGCC

    AGGATGAGGG GGGCCCACAC CAATGATGTG AAGCAGCTGA CTGAGGCTGT GCAGAAGATC

    ACCACTGAGT CCATTGTGAT CTGGGGCAAG ACCCCCAAGT TCAAGCTGCC CATCCAGAAG

10  GAGACCTGGG AGACCTGGTG GACTGAGTAC TGGCAGGCCA CCTGGATCCC TGAGTGGGAG

    TTTGTGAACA CCCCCCCCCT GGTGAAGCTG TGGTACCAGC TGGAGAAGGA GCCCATTGTG

    GGGGCTGAGA CCTTCTATGT GGATGGGGCT GCCAACAGGG AGACCAAGCT GGGCAAGGCT

    GGCTATGTGA CCAACAGGGG CAGGCAGAAG GTGGTGACCC TGACTGACAC CACCAACCAG

    AAGACTGAGC TCCAGGCCAT CTACCTGGCC CTCCAGGACT CTGGCCTGGA GGTGAACATT

15  GTGACTGACT CCCAGTATGC CCTGGGCATC ATCCAGGCCC AGCCTGATCA GTCTGAGTCT

    GAGCTGGTGA ACCAGATCAT TGAGCAGCTG ATCAAGAAGG AGAAGGTGTA CCTGGCCTGG

    GTGCCTGCCC ACAAGGGCAT TGGGGGCAAT GAGCAGGTGG ACAAGCTGGT GTCTGCTGGC

    ATCAGGAAGG TGCTGTTCCT GGATGGCATT GACAAGGCCC AGGATGAGCA TGAGAAGTAC

    CACTCCAACT GGAGGGCTAT GGCCTCTGAC TTCAACCTGC CCCCTGTGGT GGCTAAGGAG

20  ATTGTGGCCT CCTGTGACAA GTGCCAGCTG AAGGGGGAGG CCATGCATGG GCAGGTGGAC

    TGCTCCCCTG GCATCTGGCA GCTGGACTGC ACCCACCTGG AGGGCAAGGT GATCCTGGTG

    GCTGTGCATG TGGCCTCCGG CTACATTGAG GCTGAGGTGA TCCCTGCTGA GACAGGCCAG

    GAGACTGCCT ACTTCCTGCT GAAGCTGGCT GGCAGGTGGC CTGTGAAGAC CATCCACACT

    GACAATGGCT CCAACTTCAC TGGGGCCACA GTGAGGGCTG CCTGCTGGTG GGCTGGCATC

25  AAGCAGGAGT TTGGCATCCC CTACAACCCC CAGTCCCAGG GGGTGGTGGA GTCCATGAAC

    AAGGAGCTGA AGAAGATCAT TGGGCAGGTG AGGGACCAGG CTGAGCACCT GAAGACAGCT

    GTGCAGATGG CTGTGTTCAT CCACAACTTC AAGAGGAAGG GGGGCATCGG GGGCTACTCC

    GCTGGGGAGA GGATTGTGGA CATCATTGCC ACAGACATCC AGACCAAGGA GCTCCAGAAG

    CAGATCACCA AGATCCAGAA CTTCAGGGTG TACTACAGGG ACTCCAGGAA CCCCCTGTGG

30  AAGGGCCCTG CCAAGCTGCT GTGGAAGGGG GAGGGGGCTG TGGTGATCCA GGACAACTCT

    GACATCAAGG TGGTGCCCAG GAGGAAGGCC AAGATCATCA GGGACTATGG CAAGCAGATG

    GCTGGGGATG ACTGTGTGGC CTCCAGGCAG GATGAGGACT AAAGCCCGGG CAGATCT (SEQ

    ID NO:1).
```

The open reading frame of the wild type pol construct disclosed as SEQ ID
NO:1 contains 850 amino acids, disclosed herein as SEQ ID NO:2, as follows:

Met Ala Pro Ile Ser Pro Ile Glu Thr Val Pro Val Lys Leu Lys Pro

Gly Met Asp Gly Pro Lys Val Lys Gln Trp Pro Leu Thr Glu Glu Lys

5   Ile Lys Ala Leu Val Glu Ile Cys Thr Glu Met Glu Lys Glu Gly Lys

Ile Ser Lys Ile Gly Pro Glu Asn Pro Tyr Asn Thr Pro Val Phe Ala

Ile Lys Lys Lys Asp Ser Thr Lys Trp Arg Lys Leu Val Asp Phe Arg

Glu Leu Asn Lys Arg Thr Gln Asp Phe Trp Glu Val Gln Leu Gly Ile

Pro His Pro Ala Gly Leu Lys Lys Lys Lys Ser Val Thr Val Leu Asp

10   Val Gly Asp Ala Tyr Phe Ser Val Pro Leu Asp Glu Asp Phe Arg Lys

Tyr Thr Ala Phe Thr Ile Pro Ser Ile Asn Asn Glu Thr Pro Gly Ile

Arg Tyr Gln Tyr Asn Val Leu Pro Gln Gly Trp Lys Gly Ser Pro Ala

Ile Phe Gln Ser Ser Met Thr Lys Ile Leu Glu Pro Phe Arg Lys Gln

Asn Pro Asp Ile Val Ile Tyr Gln Tyr Met Asp Asp Leu Tyr Val Gly

15   Ser Asp Leu Glu Ile Gly Gln His Arg Thr Lys Ile Glu Glu Leu Arg

Gln His Leu Leu Arg Trp Gly Leu Thr Thr Pro Asp Lys Lys His Gln

Lys Glu Pro Pro Phe Leu Trp Met Gly Tyr Glu Leu His Pro Asp Lys

Trp Thr Val Gln Pro Ile Val Leu Pro Glu Lys Asp Ser Trp Thr Val

Asn Asp Ile Gln Lys Leu Val Gly Lys Leu Asn Trp Ala Ser Gln Ile

20   Tyr Pro Gly Ile Lys Val Arg Gln Leu Cys Lys Leu Leu Arg Gly Thr

Lys Ala Leu Thr Glu Val Ile Pro Leu Thr Glu Glu Ala Glu Leu Glu

Leu Ala Glu Asn Arg Glu Ile Leu Lys Glu Pro Val His Gly Val Tyr

Tyr Asp Pro Ser Lys Asp Leu Ile Ala Glu Ile Gln Lys Gln Gly Gln

Gly Gln Trp Thr Tyr Gln Ile Tyr Gln Glu Pro Phe Lys Asn Leu Lys

25   Thr Gly Lys Tyr Ala Arg Met Arg Gly Ala His Thr Asn Asp Val Lys

Gln Leu Thr Glu Ala Val Gln Lys Ile Thr Thr Glu Ser Ile Val Ile

Trp Gly Lys Thr Pro Lys Phe Lys Leu Pro Ile Gln Lys Glu Thr Trp

Glu Thr Trp Trp Thr Glu Tyr Trp Gln Ala Thr Trp Ile Pro Glu Trp

Glu Phe Val Asn Thr Pro Pro Leu Val Lys Leu Trp Tyr Gln Leu Glu

30   Lys Glu Pro Ile Val Gly Ala Glu Thr Phe Tyr Val Asp Gly Ala Ala

Asn Arg Glu Thr Lys Leu Gly Lys Ala Gly Tyr Val Thr Asn Arg Gly

Arg Gln Lys Val Val Thr Leu Thr Asp Thr Thr Asn Gln Lys Thr Glu

Leu Gln Ala Ile Tyr Leu Ala Leu Gln Asp Ser Gly Leu Glu Val Asn

Ile Val Thr Asp Ser Gln Tyr Ala Leu Gly Ile Ile Gln Ala Gln Pro

```
     Asp Gln Ser Glu Ser Glu Leu Val Asn Gln Ile Ile Glu Gln Leu Ile

     Lys Lys Glu Lys Val Tyr Leu Ala Trp Val Pro Ala His Lys Gly Ile

     Gly Gly Asn Glu Gln Val Asp Lys Leu Val Ser Ala Gly Ile Arg Lys

     Val Leu Phe Leu Asp Gly Ile Asp Lys Ala Gln Asp Glu His Glu Lys

  5  Tyr His Ser Asn Trp Arg Ala Met Ala Ser Asp Phe Asn Leu Pro Pro

     Val Val Ala Lys Glu Ile Val Ala Ser Cys Asp Lys Cys Gln Leu Lys

     Gly Glu Ala Met His Gly Gln Val Asp Cys Ser Pro Gly Ile Trp Gln

     Leu Asp Cys Thr His Leu Glu Gly Lys Val Ile Leu Val Ala Val His

     Val Ala Ser Gly Tyr Ile Glu Ala Glu Val Ile Pro Ala Glu Thr Gly

 10  Gln Glu Thr Ala Tyr Phe Leu Leu Lys Leu Ala Gly Arg Trp Pro Val

     Lys Thr Ile His Thr Asp Asn Gly Ser Asn Phe Thr Gly Ala Thr Val

     Arg Ala Ala Cys Trp Trp Ala Gly Ile Lys Gln Glu Phe Gly Ile Pro

     Tyr Asn Pro Gln Ser Gln Gly Val Val Glu Ser Met Asn Lys Glu Leu

     Lys Lys Ile Ile Gly Gln Val Arg Asp Gln Ala Glu His Leu Lys Thr

 15  Ala Val Gln Met Ala Val Phe Ile His Asn Phe Lys Arg Lys Gly Gly

     Ile Gly Gly Tyr Ser Ala Gly Glu Arg Ile Val Asp Ile Ile Ala Thr

     Asp Ile Gln Thr Lys Glu Leu Gln Lys Gln Ile Thr Lys Ile Gln Asn

     Phe Arg Val Tyr Tyr Arg Asp Ser Arg Asn Pro Leu Trp Lys Gly Pro

     Ala Lys Leu Leu Trp Lys Gly Glu Gly Ala Val Val Ile Gln Asp Asn

 20  Ser Asp Ile Lys Val Val Pro Arg Arg Lys Ala Lys Ile Ile Arg Asp

     Tyr Gly Lys Gln Met Ala Gly Asp Asp Cys Val Ala Ser Arg Gln Asp

     Glu Asp (SEQ ID NO:2).
```

The present invention especially relates to a codon optimized HIV-1 DNA pol construct wherein, in addition to deletion of the portion of the wild type sequence encoding the protease activity, a combination of active site residue mutations are introduced which are deleterious to HIV-1 pol (RT-RH-IN) activity of the expressed protein. Therefore, the present invention preferably relates to a HIV-1 DNA pol construct which is devoid of DNA sequences encoding any PR activity, as well as containing a mutation(s) which at least partially, and preferably substantially, abolishes RT, RNase and/or IN activity. One type of HIV-1 pol mutant may include but is not limited to a mutated DNA molecule comprising at least one nucleotide substitution which results in a point mutation which effectively alters an active site within the RT, RNase and/or IN regions of the expressed protein, resulting in at least substantially decreased enzymatic activity for the RT, RNase H and/or IN functions of

HIV-1 Pol. In a preferred embodiment of this portion of the invention, a HIV-1 DNA pol construct contains a mutation or mutations within the Pol coding region which effectively abolishes RT, RNase H and IN activity. An especially preferable HIV-1 DNA pol construct in a DNA molecule which contains at least one point mutation

5   which alters the active site of the RT, RNase H and IN domains of Pol, such that each activity is at least substantially abolished. Such a HIV-1 Pol mutant will most likely comprise at least one point mutation in or around each catalytic domain responsible for RT, RNase H and IN activity, respectfully. To this end, an especially preferred HIV-1 DNA pol construct is exemplified herein and contains nine codon substitution

10   mutations which results in an inactivated Pol protein (IA Pol: SEQ ID NO:4, Figure 2A-C) which has no PR, RT, RNase or IN activity, wherein three such point mutations reside within each of the RT, RNase and IN catalytic domains. Therefore, an especially preferred exemplification is a DNA molecule which encodes IA-pol, which contains all nine mutations as shown below in Table 1. An additional preferred

15   amino acid residue for substitution is Asp551, localized within the RNase domain of Pol. Any combination of the mutations disclosed herein may suitable and therefore may be utilized as an IA-Pol-based vaccine of the present invention. While addition and deletion mutations are contemplated and within the scope of the invention, the preferred mutation is a point mutation resulting in a substitution of the wild type

20   amino acid with an alternative amino acid residue.

Table 1

wt aa	aa residue	mutant aa	enzyme function
Asp	112	Ala	RT
Asp	187	Ala	RT
Asp	188	Ala	RT
Asp	445	Ala	RNase H
Glu	480	Ala	RNase H
Asp	500	Ala	RNase H
Asp	626	Ala	IN
Asp	678	Ala	IN
Glu	714	Ala	IN

It is preferred that point mutations be incorporated into the IApol mutant vaccines of
the present invention so as to lessen the possibility of altering epitopes in and around
the active site(s) of HIV-1 Pol.

To this end, SEQ ID NO:3 discloses the nucleotide sequence which codes for

5   a codon optimized pol in addition to the nine mutations shown in Table 1, disclosed as
follows, and referred to herein as "IApol":

```
AGATCTACCA TGGCCCCCAT CTCCCCCATT GAGACTGTGC CTGTGAAGCT GAAGCCTGGC
ATGGATGGCC CCAAGGTGAA GCAGTGGCCC CTGACTGAGG AGAAGATCAA GGCCCTGGTG
GAAATCTGCA CTGAGATGGA GAAGGAGGGC AAAATCTCCA AGATTGGCCC CGAGAACCCC
TACAACACCC CTGTGTTTGC CATCAAGAAG AAGGACTCCA CCAAGTGGAG GAAGCTGGTG
GACTTCAGGG AGCTGAACAA GAGGACCCAG GACTTCTGGG AGGTGCAGCT GGGCATCCCC
CACCCCGCTG GCCTGAAGAA GAAGAAGTCT GTGACTGTGC TGGCTGTGGG GGATGCCTAC
TTCTCTGTGC CCCTGGATGA GGACTTCAGG AAGTACACTG CCTTCACCAT CCCCTCCATC
AACAATGAGA CCCCTGGCAT CAGGTACCAG TACAATGTGC TGCCCCAGGG CTGGAAGGGC
TCCCCTGCCA TCTTCCAGTC CTCCATGACC AAGATCCTGG AGCCCTTCAG GAAGCAGAAC
CCTGACATTG TGATCTACCA GTACATGGCT GCCCTGTATG TGGGCTCTGA CCTGGAGATT
GGGCAGCACA GGACCAAGAT TGAGGAGCTG AGGCAGCACC TGCTGAGGTG GGGCCTGACC
ACCCCTGACA AGAAGCACCA GAAGGAGCCC CCCTTCCTGT GGATGGGCTA TGAGCTGCAC
CCCGACAAGT GGACTGTGCA GCCCATTGTG CTGCCTGAGA AGGACTCCTG GACTGTGAAT
GACATCCAGA AGCTGGTGGG CAAGCTGAAC TGGGCCTCCC AAATCTACCC TGGCATCAAG
GTGAGGCAGC TGTGCAAGCT GCTGAGGGGC ACCAAGGCCC TGACTGAGGT GATCCCCCTG
ACTGAGGAGG CTGAGCTGGA GCTGGCTGAG AACAGGGAGA TCCTGAAGGA GCCTGTGCAT
GGGGTGTACT ATGACCCCTC CAAGGACCTG ATTGCTGAGA TCCAGAAGCA GGGCCAGGGC
CAGTGGACCT ACCAAATCTA CCAGGAGCCC TTCAAGAACC TGAAGACTGG CAAGTATGCC
AGGATGAGGG GGGCCCACAC CAATGATGTG AAGCAGCTGA CTGAGGCTGT GCAGAAGATC
ACCACTGAGT CCATTGTGAT CTGGGGCAAG ACCCCCAAGT TCAAGCTGCC CATCCAGAAG
GAGACCTGGG AGACCTGGTG GACTGAGTAC TGGCAGGCCA CCTGGATCCC TGAGTGGGAG
TTTGTGAACA CCCCCCCCCT GGTGAAGCTG TGGTACCAGC TGGAGAAGGA GCCCATTGTG
GGGGCTGAGA CCTTCTATGT GGCTGGGGCT GCCAACAGGG AGACCAAGCT GGGCAAGGCT
GGCTATGTGA CCAACAGGGG CAGGCAGAAG GTGGTGACCC TGACTGACAC CACCAACCAG
AAGACTGCCC TCCAGGCCAT CTACCTGGCC CTCCAGGACT CTGGCCTGGA GGTGAACATT
GTGACTGCCT CCCAGTATGC CCTGGGCATC ATCCAGGCCC AGCCTGATCA GTCTGAGTCT
GAGCTGGTGA ACCAGATCAT TGAGCAGCTG ATCAAGAAGG AGAAGGTGTA CCTGGCCTGG
GTGCCTGCCC ACAAGGGCAT TGGGGGCAAT GAGCAGGTGG ACAAGCTGGT GTCTGCTGGC
```

ATCAGGAAGG TGCTGTTCCT GGATGGCATT GACAAGGCCC AGGATGAGCA TGAGAAGTAC

CACTCCAACT GGAGGGCTAT GGCCTCTGAC TTCAACCTGC CCCCTGTGGT GGCTAAGGAG

ATTGTGGCCT CCTGTGACAA GTGCCAGCTG AAGGGGGAGG CCATGCATGG GCAGGTGGAC

TGCTCCCCTG GCATCTGGCA GCTGGCCTGC ACCCACCTGG AGGGCAAGGT GATCCTGGTG

5   GCTGTGCATG TGGCCTCCGG CTACATTGAG GCTGAGGTGA TCCCTGCTGA GACAGGCCAG

GAGACTGCCT ACTTCCTGCT GAAGCTGGCT GGCAGGTGGC CTGTGAAGAC CATCCACACT

GCCAATGGCT CCAACTTCAC TGGGGCCACA GTGAGGGCTG CCTGCTGGTG GGCTGGCATC

AAGCAGGAGT TTGGCATCCC CTACAACCCC CAGTCCCAGG GGGTGGTGGC CTCCATGAAC

AAGGAGCTGA AGAAGATCAT TGGGCAGGTG AGGGACCAGG CTGAGCACCT GAAGACAGCT

10 GTGCAGATGG CTGTGTTCAT CCACAACTTC AAGAGGAAGG GGGGCATCGG GGGCTACTCC

GCTGGGGAGA GGATTGTGGA CATCATTGCC ACAGACATCC AGACCAAGGA GCTCCAGAAG

CAGATCACCA AGATCCAGAA CTTCAGGGTG TACTACAGGG ACTCCAGGAA CCCCCTGTGG

AAGGGCCCTG CCAAGCTGCT GTGGAAGGGG GAGGGGGCTG TGGTGATCCA GGACAACTCT

GACATCAAGG TGGTGCCCAG GAGGAAGGCC AAGATCATCA GGGACTATGG CAAGCAGATG

15 GCTGGGGATG ACTGTGTGGC CTCCAGGCAG GATGAGGACT AAAGCCCGGG CAGATCT (SEQ ID

NO:3).

In order to produce the IA-pol DNA vaccine construction, inactivation of the enzymatic functions was achieved by replacing a total of nine active-site residues from the enzyme subunits with alanine side-chains. As shown in Table 1, all residues

20 that comprise the catalytic triad of the polymerase, namely Asp112, Asp187, and Asp188, were substituted with alanine (Ala) residues (Larder, et al., *Nature* 1987, 327: 716-717; Larder, et al., 1989, *Proc. Natl. Acad. Sci.* 1989, 86: 4803-4807). Three additional mutations were introduced at Asp445, Glu480 and Asp500 to abolish RNase H activity (Asp551 was left unchanged in this IA Pol construct), with each

25 residue being substituted for an Ala residue, respectively (Davies, et al., 1991, Science 252:, 88-95; Schatz, et al., 1989, *FEBS Lett.* 257: 311-314; Mizrahi, et al., 1990, Nucl. Acids. Res. 18: pp. 5359-5353). HIV pol integrase function was abolished through three mutations at Asp626, Asp678 and Glu714. Again, each of these residues has been substituted with an Ala residue (Wiskerchen, et al., 1995, J.

30 Virol. 69: 376-386; Leavitt, et al., 1993, J. Biol. Chem. 268: 2113-2119). Amino acid residue Pro3 of SEQ ID NO:4 marks the start of the RT gene. The complete amino acid sequence of IA-Pol is disclosed herein as SEQ ID NO:4, as follows:

Met Ala Pro Ile Ser Pro Ile Glu Thr Val Pro Val Lys Leu Lys Pro

Gly Met Asp Gly Pro Lys Val Lys Gln Trp Pro Leu Thr Glu Glu Lys

Ile Lys Ala Leu Val Glu Ile Cys Thr Glu Met Glu Lys Glu Gly Lys

Ile Ser Lys Ile Gly Pro Glu Asn Pro Tyr Asn Thr Pro Val Phe Ala

Ile Lys Lys Lys Asp Ser Thr Lys Trp Arg Lys Leu Val Asp Phe Arg

Glu Leu Asn Lys Arg Thr Gln Asp Phe Trp Glu Val Gln Leu Gly Ile

5 Pro His Pro Ala Gly Leu Lys Lys Lys Lys Ser Val Thr Val Leu Ala

Val Gly Asp Ala Tyr Phe Ser Val Pro Leu Asp Glu Asp Phe Arg Lys

Tyr Thr Ala Phe Thr Ile Pro Ser Ile Asn Asn Glu Thr Pro Gly Ile

Arg Tyr Gln Tyr Asn Val Leu Pro Gln Gly Trp Lys Gly Ser Pro Ala

Ile Phe Gln Ser Ser Met Thr Lys Ile Leu Glu Pro Phe Arg Lys Gln

10 Asn Pro Asp Ile Val Ile Tyr Gln Tyr Met Ala Ala Leu Tyr Val Gly

Ser Asp Leu Glu Ile Gly Gln His Arg Thr Lys Ile Glu Glu Leu Arg

Gln His Leu Leu Arg Trp Gly Leu Thr Thr Pro Asp Lys Lys His Gln

Lys Glu Pro Pro Phe Leu Trp Met Gly Tyr Glu Leu His Pro Asp Lys

Trp Thr Val Gln Pro Ile Val Leu Pro Glu Lys Asp Ser Trp Thr Val

15 Asn Asp Ile Gln Lys Leu Val Gly Lys Leu Asn Trp Ala Ser Gln Ile

Tyr Pro Gly Ile Lys Val Arg Gln Leu Cys Lys Leu Leu Arg Gly Thr

Lys Ala Leu Thr Glu Val Ile Pro Leu Thr Glu Glu Ala Glu Leu Glu

Leu Ala Glu Asn Arg Glu Ile Leu Lys Glu Pro Val His Gly Val Tyr

Tyr Asp Pro Ser Lys Asp Leu Ile Ala Glu Ile Gln Lys Gln Gly Gln

20 Gly Gln Trp Thr Tyr Gln Ile Tyr Gln Glu Pro Phe Lys Asn Leu Lys

Thr Gly Lys Tyr Ala Arg Met Arg Gly Ala His Thr Asn Asp Val Lys

Gln Leu Thr Glu Ala Val Gln Lys Ile Thr Thr Glu Ser Ile Val Ile

Trp Gly Lys Thr Pro Lys Phe Lys Leu Pro Ile Gln Lys Glu Thr Trp

Glu Thr Trp Trp Thr Glu Tyr Trp Gln Ala Thr Trp Ile Pro Glu Trp

25 Glu Phe Val Asn Thr Pro Pro Leu Val Lys Leu Trp Tyr Gln Leu Glu

Lys Glu Pro Ile Val Gly Ala Glu Thr Phe Tyr Val Ala Gly Ala Ala

Asn Arg Glu Thr Lys Leu Gly Lys Ala Gly Tyr Val Thr Asn Arg Gly

Arg Gln Lys Val Val Thr Leu Thr Asp Thr Thr Asn Gln Lys Thr Ala

Leu Gln Ala Ile Tyr Leu Ala Leu Gln Asp Ser Gly Leu Glu Val Asn

30 Ile Val Thr Ala Ser Gln Tyr Ala Leu Gly Ile Ile Gln Ala Gln Pro

Asp Gln Ser Glu Ser Glu Leu Val Asn Gln Ile Ile Glu Gln Leu Ile

Lys Lys Glu Lys Val Tyr Leu Ala Trp Val Pro Ala His Lys Gly Ile

Gly Gly Asn Glu Gln Val Asp Lys Leu Val Ser Ala Gly Ile Arg Lys

Val Leu Phe Leu Asp Gly Ile Asp Lys Ala Gln Asp Glu His Glu Lys

Tyr His Ser Asn Trp Arg Ala Met Ala Ser Asp Phe Asn Leu Pro Pro

Val Val Ala Lys Glu Ile Val Ala Ser Cys Asp Lys Cys Gln Leu Lys

Gly Glu Ala Met His Gly Gln Val Asp Cys Ser Pro Gly Ile Trp Gln

Leu Ala Cys Thr His Leu Glu Gly Lys Val Ile Leu Val Ala Val His

5   Val Ala Ser Gly Tyr Ile Glu Ala Glu Val Ile Pro Ala Glu Thr Gly

Gln Glu Thr Ala Tyr Phe Leu Leu Lys Leu Ala Gly Arg Trp Pro Val

Lys Thr Ile His Thr Ala Asn Gly Ser Asn Phe Thr Gly Ala Thr Val

Arg Ala Ala Cys Trp Trp Ala Gly Ile Lys Gln Glu Phe Gly Ile Pro

Tyr Asn Pro Gln Ser Gln Gly Val Val Ala Ser Met Asn Lys Glu Leu

10   Lys Lys Ile Ile Gly Gln Val Arg Asp Gln Ala Glu His Leu Lys Thr

Ala Val Gln Met Ala Val Phe Ile His Asn Phe Lys Arg Lys Gly Gly

Ile Gly Gly Tyr Ser Ala Gly Glu Arg Ile Val Asp Ile Ile Ala Thr

Asp Ile Gln Thr Lys Glu Leu Gln Lys Gln Ile Thr Lys Ile Gln Asn

Phe Arg Val Tyr Tyr Arg Asp Ser Arg Asn Pro Leu Trp Lys Gly Pro

15   Ala Lys Leu Leu Trp Lys Gly Glu Gly Ala Val Val Ile Gln Asp Asn

Ser Asp Ile Lys Val Val Pro Arg Arg Lys Ala Lys Ile Ile Arg Asp

Tyr Gly Lys Gln Met Ala Gly Asp Asp Cys Val Ala Ser Arg Gln Asp

Glu Asp (SEQ ID NO:4).

    As noted above, it will be understood that any combination of the mutations
20   disclosed above may be suitable and therefore be utilized as an IA-pol-based vaccine
of the present invention. For example, it may be possible to mutate only 2 of the 3
residues within the respective reverse transcriptase, RNase H, and integrase coding
regions while still abolishing these enzymatic activities. However, the IA-pol
construct described above and disclosed as SEQ ID NO:3, as well as the expressed
25   protein (SEQ ID NO:4) is preferred. It is also preferred that at least one mutation be
present in each of the three catalytic domains.

    Another aspect of the present invention is to generate codon optimized HIV-1
Pol-based vaccine constructions which comprise a eukaryotic trafficking signal
peptide such as from tPA (tissue-type plasminogen activator) or by a leader peptide
30   such as is found in highly expressed mammalian proteins such as immunoglobulin
leader peptides. Any functional leader peptide may be tested for efficacy. However,
a preferred embodiment of the present invention is to provide for HIV-1 Pol mutant
vaccine constructions as disclosed herein which also comprise a leader peptide,
preferably a leader peptide from human tPA. In other words, a codon optimized

HIV-1 Pol mutant such as IA-Pol (SEQ ID NO:4) may also comprise a leader peptide at the amino terminal portion of the protein, which may effect cellular trafficking and hence, immunogenicity of the expressed protein within the host cell. As shown in Figure 1A-B for the DNA vector V1Jns, a DNA vector which may be utilized to

5 practice the present invention may be modified by known recombinant DNA methodology to contain a leader signal peptide of interest, such that downstream cloning of the modified HIV-1 protein of interest results in a nucleotide sequence which encodes a modified HIV-1 tPA/Pol protein. In the alternative, as noted above, insertion of a nucleotide sequence which encodes a leader peptide may be inserted

10 into a DNA vector housing the open reading frame for the Pol protein of interest. Regardless of the cloning strategy, the end result is a polynucleotide vaccine which comprises vector components for effective gene expression in conjunction with nucleotide sequences which encode a modified HIV-1 Pol protein of interest, including but not limited to a HIV-1 Pol protein which contains a leader peptide. The

15 amino acid sequence of the human tPA leader utilized herein is as follows: MDAMKRGLCCVLLLCGAVFVSPSEISS (SEQ ID NO:28). Therefore, another aspect of the present invention is to generate HIV-1 Pol-based vaccine constructions which comprise a eukaryotic trafficking signal peptide such as from tPA. To this end, the present invention relates to a DNA molecule which encodes a codon optimized

20 wt-pol DNA construct wherein the protease (PR) activity is deleted and a human tPA leader sequence is fused to the 5' end of the coding region. A DNA molecule which encodes this protein is disclosed herein as SEQ ID NO:5, the open reading frame disclosed herein as SEQ ID NO:6.

To this end, the present invention relates to a DNA molecule which encodes a

25 codon optimized wt-pol DNA construct wherein the protease (PR) activity is deleted and a human tPA leader sequence is fused to the 5' end of the coding region (herein, "tPA-wt-pol"). A DNA molecule which encodes this protein is disclosed herein as SEQ ID NO:5, the open reading frame being contained from an initiating Met residue at nucleotides 8-10 to a termination codon from nucleotides 2633-2635. SEQ ID

30 NO:5 is as follows:

```
GATCACCATG GATGCAATGA AGAGAGGGCT CTGCTGTGTG CTGCTGCTGT GTGGAGCAGT
CTTCGTTTCG CCCAGCGAGA TCTCCGCCCC CATCTCCCCC ATTGAGACTG TGCCTGTGAA
GCTGAAGCCT GGCATGGATG GCCCCAAGGT GAAGCAGTGG CCCCTGACTG AGGAGAAGAT
CAAGGCCCTG GTGGAAATCT GCACTGAGAT GGAGAAGGAG GGCAAAATCT CCAAGATTGG
```

CCCCGAGAAC CCCTACAACA CCCCTGTGTT TGCCATCAAG AAGAAGGACT CCACCAAGTG

GAGGAAGCTG GTGGACTTCA GGGAGCTGAA CAAGAGGACC CAGGACTTCT GGGAGGTGCA

GCTGGGCATC CCCCACCCCG CTGGCCTGAA GAAGAAGAAG TCTGTGACTG TGCTGGATGT

GGGGGATGCC TACTTCTCTG TGCCCCTGGA TGAGGACTTC AGGAAGTACA CTGCCTTCAC

5   CATCCCCTCC ATCAACAATG AGACCCCTGG CATCAGGTAC CAGTACAATG TGCTGCCCCA

GGGCTGGAAG GGCTCCCCTG CCATCTTCCA GTCCTCCATG ACCAAGATCC TGGAGCCCTT

CAGGAAGCAG AACCCTGACA TTGTGATCTA CCAGTACATG GATGACCTGT ATGTGGGCTC

TGACCTGGAG ATTGGGCAGC ACAGGACCAA GATTGAGGAG CTGAGGCAGC ACCTGCTGAG

GTGGGGCCTG ACCACCCCTG ACAAGAAGCA CCAGAAGGAG CCCCCCTTCC TGTGGATGGG

10   CTATGAGCTG CACCCCGACA AGTGGACTGT GCAGCCCATT GTGCTGCCTG AGAAGGACTC

CTGGACTGTG AATGACATCC AGAAGCTGGT GGGCAAGCTG AACTGGGCCT CCCAAATCTA

CCCTGGCATC AAGGTGAGGC AGCTGTGCAA GCTGCTGAGG GGCACCAAGG CCCTGACTGA

GGTGATCCCC CTGACTGAGG AGGCTGAGCT GGAGCTGGCT GAGAACAGGG AGATCCTGAA

GGAGCCTGTG CATGGGGTGT ACTATGACCC CTCCAAGGAC CTGATTGCTG AGATCCAGAA

15   GCAGGGCCAG GGCCAGTGGA CCTACCAAAT CTACCAGGAG CCCTTCAAGA ACCTGAAGAC

TGGCAAGTAT GCCAGGATGA GGGGGGCCCA CACCAATGAT GTGAAGCAGC TGACTGAGGC

TGTGCAGAAG ATCACCACTG AGTCCATTGT GATCTGGGGC AAGACCCCCA AGTTCAAGCT

GCCCATCCAG AAGGAGACCT GGGAGACCTG GTGGACTGAG TACTGGCAGG CCACCTGGAT

CCCTGAGTGG GAGTTTGTGA ACACCCCCCC CCTGGTGAAG CTGTGGTACC AGCTGGAGAA

20   GGAGCCCATT GTGGGGGCTG AGACCTTCTA TGTGGATGGG GCTGCCAACA GGGAGACCAA

GCTGGGCAAG GCTGGCTATG TGACCAACAG GGGCAGGCAG AAGGTGGTGA CCCTGACTGA

CACCACCAAC CAGAAGACTG AGCTCCAGGC CATCTACCTG GCCCTCCAGG ACTCTGGCCT

GGAGGTGAAC ATTGTGACTG ACTCCCAGTA TGCCCTGGGC ATCATCCAGG CCCAGCCTGA

TCAGTCTGAG TCTGAGCTGG TGAACCAGAT CATTGAGCAG CTGATCAAGA AGGAGAAGGT

25   GTACCTGGCC TGGGTGCCTG CCCACAAGGG CATTGGGGGC AATGAGCAGG TGGACAAGCT

GGTGTCTGCT GGCATCAGGA AGGTGCTGTT CCTGGATGGC ATTGACAAGG CCCAGGATGA

GCATGAGAAG TACCACTCCA ACTGGAGGGC TATGGCCTCT GACTTCAACC TGCCCCCTGT

GGTGGCTAAG GAGATTGTGG CCTCCTGTGA CAAGTGCCAG CTGAAGGGGG AGGCCATGCA

TGGGCAGGTG GACTGCTCCC CTGGCATCTG GCAGCTGGAC TGCACCCACC TGGAGGGCAA

30   GGTGATCCTG GTGGCTGTGC ATGTGGCCTC CGGCTACATT GAGGCTGAGG TGATCCCTGC

TGAGACAGGC CAGGAGACTG CCTACTTCCT GCTGAAGCTG GCTGGCAGGT GGCCTGTGAA

GACCATCCAC ACTGACAATG GCTCCAACTT CACTGGGGCC ACAGTGAGGG CTGCCTGCTG

GTGGGCTGGC ATCAAGCAGG AGTTTGGCAT CCCCTACAAC CCCCAGTCCC AGGGGGTGGT

GGAGTCCATG AACAAGGAGC TGAAGAAGAT CATTGGGCAG GTGAGGGACC AGGCTGAGCA

-23-

CCTGAAGACA GCTGTGCAGA TGGCTGTGTT CATCCACAAC TTCAAGAGGA AGGGGGGCAT

CGGGGGCTAC TCCGCTGGGG AGAGGATTGT GGACATCATT GCCACAGACA TCCAGACCAA

GGAGCTCCAG AAGCAGATCA CCAAGATCCA GAACTTCAGG GTGTACTACA GGGACTCCAG

GAACCCCCTG TGGAAGGGCC CTGCCAAGCT GCTGTGGAAG GGGGAGGGGG CTGTGGTGAT

5   CCAGGACAAC TCTGACATCA AGGTGGTGCC CAGGAGGAAG GCCAAGATCA TCAGGGACTA

TGGCAAGCAG ATGGCTGGGG ATGACTGTGT GGCCTCCAGG CAGGATGAGG ACTAAAGCCC

GGGCAGATCT (SEQ ID NO:5).

The open reading frame of the wild type tPA-pol construct disclosed as SEQ
ID NO:5 contains 875 amino acids, disclosed herein as SEQ ID NO:6, as follows:

10   Met Asp Ala Met Lys Arg Gly Leu Cys Cys Val Leu Leu Leu Cys Gly

Ala Val Phe Val Ser Pro Ser Glu Ile Ser Ala Pro Ile Ser Pro Ile

Glu Thr Val Pro Val Lys Leu Lys Pro Gly Met Asp Gly Pro Lys Val

Lys Gln Trp Pro Leu Thr Glu Glu Lys Ile Lys Ala Leu Val Glu Ile

Cys Thr Glu Met Glu Lys Glu Gly Lys Ile Ser Lys Ile Gly Pro Glu

15   Asn Pro Tyr Asn Thr Pro Val Phe Ala Ile Lys Lys Lys Asp Ser Thr

Lys Trp Arg Lys Leu Val Asp Phe Arg Glu Leu Asn Lys Arg Thr Gln

Asp Phe Trp Glu Val Gln Leu Gly Ile Pro His Pro Ala Gly Leu Lys

Lys Lys Lys Ser Val Thr Val Leu Asp Val Gly Asp Ala Tyr Phe Ser

Val Pro Leu Asp Glu Asp Phe Arg Lys Tyr Thr Ala Phe Thr Ile Pro

20   Ser Ile Asn Asn Glu Thr Pro Gly Ile Arg Tyr Gln Tyr Asn Val Leu

Pro Gln Gly Trp Lys Gly Ser Pro Ala Ile Phe Gln Ser Ser Met Thr

Lys Ile Leu Glu Pro Phe Arg Lys Gln Asn Pro Asp Ile Val Ile Tyr

Gln Tyr Met Asp Asp Leu Tyr Val Gly Ser Asp Leu Glu Ile Gly Gln

His Arg Thr Lys Ile Glu Glu Leu Arg Gln His Leu Leu Arg Trp Gly

25   Leu Thr Thr Pro Asp Lys Lys His Gln Lys Glu Pro Pro Phe Leu Trp

Met Gly Tyr Glu Leu His Pro Asp Lys Trp Thr Val Gln Pro Ile Val

Leu Pro Glu Lys Asp Ser Trp Thr Val Asn Asp Ile Gln Lys Leu Val

Gly Lys Leu Asn Trp Ala Ser Gln Ile Tyr Pro Gly Ile Lys Val Arg

Gln Leu Cys Lys Leu Leu Arg Gly Thr Lys Ala Leu Thr Glu Val Ile

30   Pro Leu Thr Glu Glu Ala Glu Leu Glu Leu Ala Glu Asn Arg Glu Ile

Leu Lys Glu Pro Val His Gly Val Tyr Tyr Asp Pro Ser Lys Asp Leu

Ile Ala Glu Ile Gln Lys Gln Gly Gln Gly Gln Trp Thr Tyr Gln Ile

Tyr Gln Glu Pro Phe Lys Asn Leu Lys Thr Gly Lys Tyr Ala Arg Met

Arg Gly Ala His Thr Asn Asp Val Lys Gln Leu Thr Glu Ala Val Gln

```
    Lys Ile Thr Thr Glu Ser Ile Val Ile Trp Gly Lys Thr Pro Lys Phe
    Lys Leu Pro Ile Gln Lys Glu Thr Trp Glu Thr Trp Trp Thr Glu Tyr
    Trp Gln Ala Thr Trp Ile Pro Glu Trp Glu Phe Val Asn Thr Pro Pro
    Leu Val Lys Leu Trp Tyr Gln Leu Glu Lys Glu Pro Ile Val Gly Ala
 5  Glu Thr Phe Tyr Val Asp Gly Ala Ala Asn Arg Glu Thr Lys Leu Gly
    Lys Ala Gly Tyr Val Thr Asn Arg Gly Arg Gln Lys Val Val Thr Leu
    Thr Asp Thr Thr Asn Gln Lys Thr Glu Leu Gln Ala Ile Tyr Leu Ala
    Leu Gln Asp Ser Gly Leu Glu Val Asn Ile Val Thr Asp Ser Gln Tyr
    Ala Leu Gly Ile Ile Gln Ala Gln Pro Asp Gln Ser Glu Ser Glu Leu
10  Val Asn Gln Ile Ile Glu Gln Leu Ile Lys Lys Glu Lys Val Tyr Leu
    Ala Trp Val Pro Ala His Lys Gly Ile Gly Gly Asn Glu Gln Val Asp
    Lys Leu Val Ser Ala Gly Ile Arg Lys Val Leu Phe Leu Asp Gly Ile
    Asp Lys Ala Gln Asp Glu His Glu Lys Tyr His Ser Asn Trp Arg Ala
    Met Ala Ser Asp Phe Asn Leu Pro Pro Val Val Ala Lys Glu Ile Val
15  Ala Ser Cys Asp Lys Cys Gln Leu Lys Gly Glu Ala Met His Gly Gln
    Val Asp Cys Ser Pro Gly Ile Trp Gln Leu Asp Cys Thr His Leu Glu
    Gly Lys Val Ile Leu Val Ala Val His Val Ala Ser Gly Tyr Ile Glu
    Ala Glu Val Ile Pro Ala Glu Thr Gly Gln Glu Thr Ala Tyr Phe Leu
    Leu Lys Leu Ala Gly Arg Trp Pro Val Lys Thr Ile His Thr Asp Asn
20  Gly Ser Asn Phe Thr Gly Ala Thr Val Arg Ala Ala Cys Trp Trp Ala
    Gly Ile Lys Gln Glu Phe Gly Ile Pro Tyr Asn Pro Gln Ser Gln Gly
    Val Val Glu Ser Met Asn Lys Glu Leu Lys Lys Ile Ile Gly Gln Val
    Arg Asp Gln Ala Glu His Leu Lys Thr Ala Val Gln Met Ala Val Phe
    Ile His Asn Phe Lys Arg Lys Gly Gly Ile Gly Gly Tyr Ser Ala Gly
25  Glu Arg Ile Val Asp Ile Ile Ala Thr Asp Ile Gln Thr Lys Glu Leu
    Gln Lys Gln Ile Thr Lys Ile Gln Asn Phe Arg Val Tyr Tyr Arg Asp
    Ser Arg Asn Pro Leu Trp Lys Gly Pro Ala Lys Leu Leu Trp Lys Gly
    Glu Gly Ala Val Val Ile Gln Asp Asn Ser Asp Ile Lys Val Val Pro
    Arg Arg Lys Ala Lys Ile Ile Arg Asp Tyr Gly Lys Gln Met Ala Gly
30  Asp Asp Cys Val Ala Ser Arg Gln Asp Glu Asp (SEQ ID NO:6).
```

The present invention also relates to a codon optimized HIV-1 Pol mutant such as IA-Pol (SEQ ID NO:4) which comprises a leader peptide at the amino terminal portion of the protein, which may effect cellular trafficking and hence, immunogenicity of the expressed protein within the host cell. Any such HIV-1 DNA

pol mutant disclosed in the above paragraphs is suitable for fusion downstream of a
leader peptide, such as a leader peptide including but not limited to the human tPA
leader sequence. Therefore, any such leader peptide-based HIV-1 pol mutant
construct may include but is not limited to a mutated DNA molecule which effectively
5   alters the catalytic activity of the RT, RNase and/or IN region of the expressed protein,
resulting in at least substantially decreased enzymatic activity one or more of the RT,
RNase H and/or IN functions of HIV-1 Pol. In a preferred embodiment of this portion
of the invention, a leader peptide/HIV-1 DNA pol construct contains a mutation or
mutations within the Pol coding region which effectively abolishes RT, RNase H and
10   IN activity. An especially preferable HIV-1 DNA pol construct is a DNA molecule
which contains at least one point mutation which alters the active site and catalytic
activity within the RT, RNase H and IN domains of Pol, such that each activity is at
least substantially abolished, and preferably totally abolished. Such a HIV-1 Pol
mutant will most likely comprise at least one point mutation in or around each
15   catalytic domain responsible for RT, RNase H and IN activity, respectfully. An ·
especially preferred embodiment of this portion of the invention relates to a human
tPA leader fused to the IA-Pol protein comprising the nine mutations shown in Table
1. The DNA molecule is disclosed herein as SEQ ID NO:7 and the expressed tPA-IA
Pol protein comprises a fusion junction as shown in Figure 3. The complete amino
20   acid sequence of the expressed protein is set forth in SEQ ID NO:8. To this end, SEQ
ID NO:7 discloses the nucleotide sequence which codes for a human tPA leader fused
to the IA Pol protein comprising the nine mutations shown in Table 1 (herein, "tPA-
opt-IApol"). The open reading frame begins with the initiating Met (nucleotides 8-10)
and terminates with a "TAA" codon at nucleotides 2633-2635. The nucleotide
25   sequence encoding tPA-IAPol is also disclosed as follows:

```
GATCACCATG GATGCAATGA AGAGAGGGCT CTGCTGTGTG CTGCTGCTGT GTGGAGCAGT
CTTCGTTTCG CCCAGCGAGA TCTCCGCCCC CATCTCCCCC ATTGAGACTG TGCCTGTGAA
GCTGAAGCCT GGCATGGATG GCCCCAAGGT GAAGCAGTGG CCCCTGACTG AGGAGAAGAT
CAAGGCCCTG GTGGAAATCT GCACTGAGAT GGAGAAGGAG GGCAAAATCT CCAAGATTGG
30   CCCCGAGAAC CCCTACAACA CCCCTGTGTT TGCCATCAAG AAGAAGGACT CCACCAAGTG
GAGGAAGCTG GTGGACTTCA GGGAGCTGAA CAAGAGGACC CAGGACTTCT GGGAGGTGCA
GCTGGGCATC CCCCACCCCG CTGGCCTGAA GAAGAAGAAG TCTGTGACTG TGCTGGCTGT
GGGGGATGCC TACTTCTCTG TGCCCCTGGA TGAGGACTTC AGGAAGTACA CTGCCTTCAC
CATCCCCTCC ATCAACAATG AGACCCCTGG CATCAGGTAC CAGTACAATG TGCTGCCCCA
```

```
       GGGCTGGAAG GGCTCCCCTG CCATCTTCCA GTCCTCCATG ACCAAGATCC TGGAGCCCTT
       CAGGAAGCAG AACCCTGACA TTGTGATCTA CCAGTACATG GCTGCCCTGT ATGTGGGCTC
       TGACCTGGAG ATTGGGCAGC ACAGGACCAA GATTGAGGAG CTGAGGCAGC ACCTGCTGAG
       GTGGGGCCTG ACCACCCCTG ACAAGAAGCA CCAGAAGGAG CCCCCCTTCC TGTGGATGGG
  5    CTATGAGCTG CACCCCGACA AGTGGACTGT GCAGCCCATT GTGCTGCCTG AGAAGGACTC
       CTGGACTGTG AATGACATCC AGAAGCTGGT GGGCAAGCTG AACTGGGCCT CCCAAATCTA
       CCCTGGCATC AAGGTGAGGC AGCTGTGCAA GCTGCTGAGG GGCACCAAGG CCCTGACTGA
       GGTGATCCCC CTGACTGAGG AGGCTGAGCT GGAGCTGGCT GAGAACAGGG AGATCCTGAA
       GGAGCCTGTG CATGGGGTGT ACTATGACCC CTCCAAGGAC CTGATTGCTG AGATCCAGAA
 10    GCAGGGCCAG GGCCAGTGGA CCTACCAAAT CTACCAGGAG CCCTTCAAGA ACCTGAAGAC
       TGGCAAGTAT GCCAGGATGA GGGGGGCCCA CACCAATGAT GTGAAGCAGC TGACTGAGGC
       TGTGCAGAAG ATCACCACTG AGTCCATTGT GATCTGGGGC AAGACCCCCA AGTTCAAGCT
       GCCCATCCAG AAGGAGACCT GGGAGACCTG GTGGACTGAG TACTGGCAGG CCACCTGGAT
       CCCTGAGTGG GAGTTTGTGA ACACCCCCCC CCTGGTGAAG CTGTGGTACC AGCTGGAGAA
 15    GGAGCCCATT GTGGGGGCTG AGACCTTCTA TGTGGCTGGG GCTGCCAACA GGGAGACCAA
       GCTGGGCAAG GCTGGCTATG TGACCAACAG GGGCAGGCAG AAGGTGGTGA CCCTGACTGA
       CACCACCAAC CAGAAGACTG CCCTCCAGGC CATCTACCTG GCCCTCCAGG ACTCTGGCCT
       GGAGGTGAAC ATTGTGACTG CCTCCCAGTA TGCCCTGGGC ATCATCCAGG CCCAGCCTGA
       TCAGTCTGAG TCTGAGCTGG TGAACCAGAT CATTGAGCAG CTGATCAAGA AGGAGAAGGT
 20    GTACCTGGCC TGGGTGCCTG CCCACAAGGG CATTGGGGGC AATGAGCAGG TGGACAAGCT
       GGTGTCTGCT GGCATCAGGA AGGTGCTGTT CCTGGATGGC ATTGACAAGG CCCAGGATGA
       GCATGAGAAG TACCACTCCA ACTGGAGGGC TATGGCCTCT GACTTCAACC TGCCCCCTGT
       GGTGGCTAAG GAGATTGTGG CCTCCTGTGA CAAGTGCCAG CTGAAGGGGG AGGCCATGCA
       TGGGCAGGTG GACTGCTCCC CTGGCATCTG GCAGCTGGCC TGCACCCACC TGGAGGGCAA
 25    GGTGATCCTG GTGGCTGTGC ATGTGGCCTC CGGCTACATT GAGGCTGAGG TGATCCCTGC
       TGAGACAGGC CAGGAGACTG CCTACTTCCT GCTGAAGCTG GCTGGCAGGT GGCCTGTGAA
       GACCATCCAC ACTGCCAATG GCTCCAACTT CACTGGGGCC ACAGTGAGGG CTGCCTGCTG
       GTGGGCTGGC ATCAAGCAGG AGTTTGGCAT CCCCTACAAC CCCCAGTCCC AGGGGGTGGT
       GGCCTCCATG AACAAGGAGC TGAAGAAGAT CATTGGGCAG GTGAGGGACC AGGCTGAGCA
 30    CCTGAAGACA GCTGTGCAGA TGGCTGTGTT CATCCACAAC TTCAAGAGGA AGGGGGGCAT
       CGGGGGCTAC TCCGCTGGGG AGAGGATTGT GGACATCATT GCCACAGACA TCCAGACCAA
       GGAGCTCCAG AAGCAGATCA CCAAGATCCA GAACTTCAGG GTGTACTACA GGGACTCCAG
       GAACCCCCTG TGGAAGGGCC CTGCCAAGCT GCTGTGGAAG GGGGAGGGGG CTGTGGTGAT
       CCAGGACAAC TCTGACATCA AGGTGGTGCC CAGGAGGAAG GCCAAGATCA TCAGGGACTA
```

TGGCAAGCAG ATGGCTGGGG ATGACTGTGT GGCCTCCAGG CAGGATGAGG ACTAAAGCCC
GGGCAGATCT (SEQ ID NO:7).

The open reading frame of the tPA-IA-pol construct disclosed as SEQ ID
NO:7 contains 875 amino acids, disclosed herein as tPA-IA-Pol and SEQ ID NO:8, as
5   follows:

Met Asp Ala Met Lys Arg Gly Leu Cys Cys Val Leu Leu Leu Cys Gly

Ala Val Phe Val Ser Pro Ser Glu Ile Ser Ala Pro Ile Ser Pro Ile

Glu Thr Val Pro Val Lys Leu Lys Pro Gly Met Asp Gly Pro Lys Val

Lys Gln Trp Pro Leu Thr Glu Glu Lys Ile Lys Ala Leu Val Glu Ile

10   Cys Thr Glu Met Glu Lys Glu Gly Lys Ile Ser Lys Ile Gly Pro Glu

Asn Pro Tyr Asn Thr Pro Val Phe Ala Ile Lys Lys Lys Asp Ser Thr

Lys Trp Arg Lys Leu Val Asp Phe Arg Glu Leu Asn Lys Arg Thr Gln

Asp Phe Trp Glu Val Gln Leu Gly Ile Pro His Pro Ala Gly Leu Lys

Lys Lys Lys Ser Val Thr Val Leu Ala Val Gly Asp Ala Tyr Phe Ser

15   Val Pro Leu Asp Glu Asp Phe Arg Lys Tyr Thr Ala Phe Thr Ile Pro

Ser Ile Asn Asn Glu Thr Pro Gly Ile Arg Tyr Gln Tyr Asn Val Leu

Pro Gln Gly Trp Lys Gly Ser Pro Ala Ile Phe Gln Ser Ser Met Thr

Lys Ile Leu Glu Pro Phe Arg Lys Gln Asn Pro Asp Ile Val Ile Tyr

Gln Tyr Met Ala Ala Leu Tyr Val Gly Ser Asp Leu Glu Ile Gly Gln

20   His Arg Thr Lys Ile Glu Glu Leu Arg Gln His Leu Leu Arg Trp Gly

Leu Thr Thr Pro Asp Lys Lys His Gln Lys Glu Pro Pro Phe Leu Trp

Met Gly Tyr Glu Leu His Pro Asp Lys Trp Thr Val Gln Pro Ile Val

Leu Pro Glu Lys Asp Ser Trp Thr Val Asn Asp Ile Gln Lys Leu Val

Gly Lys Leu Asn Trp Ala Ser Gln Ile Tyr Pro Gly Ile Lys Val Arg

25   Gln Leu Cys Lys Leu Leu Arg Gly Thr Lys Ala Leu Thr Glu Val Ile

Pro Leu Thr Glu Glu Ala Glu Leu Glu Leu Ala Glu Asn Arg Glu Ile

Leu Lys Glu Pro Val His Gly Val Tyr Tyr Asp Pro Ser Lys Asp Leu

Ile Ala Glu Ile Gln Lys Gln Gly Gln Gly Gln Trp Thr Tyr Gln Ile

Tyr Gln Glu Pro Phe Lys Asn Leu Lys Thr Gly Lys Tyr Ala Arg Met

30   Arg Gly Ala His Thr Asn Asp Val Lys Gln Leu Thr Glu Ala Val Gln

Lys Ile Thr Thr Glu Ser Ile Val Ile Trp Gly Lys Thr Pro Lys Phe

Lys Leu Pro Ile Gln Lys Glu Thr Trp Glu Thr Trp Trp Thr Glu Tyr

Trp Gln Ala Thr Trp Ile Pro Glu Trp Glu Phe Val Asn Thr Pro Pro

Leu Val Lys Leu Trp Tyr Gln Leu Glu Lys Glu Pro Ile Val Gly Ala

Glu Thr Phe Tyr Val Ala Gly Ala Ala Asn Arg Glu Thr Lys Leu Gly

Lys Ala Gly Tyr Val Thr Asn Arg Gly Arg Gln Lys Val Val Thr Leu

Thr Asp Thr Thr Asn Gln Lys Thr Ala Leu Gln Ala Ile Tyr Leu Ala

Leu Gln Asp Ser Gly Leu Glu Val Asn Ile Val Thr Ala Ser Gln Tyr

5   Ala Leu Gly Ile Ile Gln Ala Gln Pro Asp Gln Ser Glu Ser Glu Leu

Val Asn Gln Ile Ile Glu Gln Leu Ile Lys Lys Glu Lys Val Tyr Leu

Ala Trp Val Pro Ala His Lys Gly Ile Gly Gly Asn Glu Gln Val Asp

Lys Leu Val Ser Ala Gly Ile Arg Lys Val Leu Phe Leu Asp Gly Ile

Asp Lys Ala Gln Asp Glu His Glu Lys Tyr His Ser Asn Trp Arg Ala

10   Met Ala Ser Asp Phe Asn Leu Pro Pro Val Val Ala Lys Glu Ile Val

Ala Ser Cys Asp Lys Cys Gln Leu Lys Gly Glu Ala Met His Gly Gln

Val Asp Cys Ser Pro Gly Ile Trp Gln Leu Ala Cys Thr His Leu Glu

Gly Lys Val Ile Leu Val Ala Val His Val Ala Ser Gly Tyr Ile Glu

Ala Glu Val Ile Pro Ala Glu Thr Gly Gln Glu Thr Ala Tyr Phe Leu

15   Leu Lys Leu Ala Gly Arg Trp Pro Val Lys Thr Ile His Thr Ala Asn

Gly Ser Asn Phe Thr Gly Ala Thr Val Arg Ala Ala Cys Trp Trp Ala

Gly Ile Lys Gln Glu Phe Gly Ile Pro Tyr Asn Pro Gln Ser Gln Gly

Val Val Ala Ser Met Asn Lys Glu Leu Lys Lys Ile Ile Gly Gln Val

Arg Asp Gln Ala Glu His Leu Lys Thr Ala Val Gln Met Ala Val Phe

20   Ile His Asn Phe Lys Arg Lys Gly Gly Ile Gly Gly Tyr Ser Ala Gly

Glu Arg Ile Val Asp Ile Ile Ala Thr Asp Ile Gln Thr Lys Glu Leu

Gln Lys Gln Ile Thr Lys Ile Gln Asn Phe Arg Val Tyr Tyr Arg Asp

Ser Arg Asn Pro Leu Trp Lys Gly Pro Ala Lys Leu Leu Trp Lys Gly

Glu Gly Ala Val Val Ile Gln Asp Asn Ser Asp Ile Lys Val Val Pro

25   Arg Arg Lys Ala Lys Ile Ile Arg Asp Tyr Gly Lys Gln Met Ala Gly

Asp Asp Cys Val Ala Ser Arg Gln Asp Glu Asp (SEQ ID NO:8).

The present invention also relates to a substantially purified protein expressed from the DNA polynucleotide vaccines of the present invention, especially the purified proteins set forth below as SEQ ID NOs: 2, 4, 6, and 8. These purified

30   proteins may be useful as protein-based HIV vaccines.

The DNA backbone of the DNA vaccines of the present invention are preferably DNA plasmid expression vectors. DNA plasmid expression vectors are well known in the art and the present DNA vector vaccines may be comprised of any such expression backbone which contains at least a promoter for RNA polymerase

transcription, and a transcriptional terminator 3' to the HIV pol coding sequence. In one preferred embodiment, the promoter is the Rous sarcoma virus (RSV) long terminal repeat (LTR) which is a strong transcriptional promoter. A more preferred promoter is the cytomegalovirus promoter with the intron A sequence (CMV-intA).

5   A preferred transcriptional terminator is the bovine growth hormone terminator. In addition, to assist in large scale preparation of an HIV pol DNA vector vaccine, an antibiotic resistance marker is also preferably included in the expression vector. Ampicillin resistance genes, neomycin resistance genes or any other pharmaceutically acceptable antibiotic resistance marker may be used. In a preferred embodiment of

10   this invention, the antibiotic resistance gene encodes a gene product for neomycin resistance. Further, to aid in the high level production of the pharmaceutical by fermentation in prokaryotic organisms, it is advantageous for the vector to contain an origin of replication and be of high copy number. Any of a number of commercially available prokaryotic cloning vectors provide these benefits. In a preferred

15   embodiment of this invention, these functionalities are provided by the commercially available vectors known as pUC. It is desirable to remove non-essential DNA sequences. Thus, the lacZ and lacI coding sequences of pUC are removed in one embodiment of the invention.

DNA expression vectors which exemplify but in no way limit the present

20   invention are disclosed in PCT International Application No. PCT/US94/02751, International Publication No. WO 94/21797, hereby incorporated by reference. A first DNA expression vector is the expression vector pnRSV, wherein the rous sarcoma virus (RSV) long terminal repeat (LTR) is used as the promoter. A second embodiment relates to plasmid V1, a mutated pBR322 vector into which the CMV

25   promoter and the BGH transcriptional terminator is cloned. Another embodiment regarding DNA vector backbones relates to plasmid V1J. Plasmid V1J is derived from plasmid V1 and removes promoter and transcription termination elements in order to place them within a more defined context, create a more compact vector, and to improve plasmid purification yields. Therefore, V1J also contains the CMVintA

30   promoter and (BGH) transcription termination elements which control the expression of the HIV pol-based genes disclosed herein. The backbone of V1J is provided by pUC18. It is known to produce high yields of plasmid, is well-characterized by sequence and function, and is of minimum size. The entire *lac* operon was removed and the remaining plasmid was purified from an agarose electrophoresis gel,

blunt-ended with the T4 DNA polymerase, treated with calf intestinal alkaline phosphatase, and ligated to the CMVintA/BGH element. In a preferred DNA expression vector, the ampicillin resistance gene is removed from V1J and replaced with a neomycin resistance gene, to generate V1Jneo. An especially preferred DNA expression vector is V1Jns, which is the same as V1J except that a unique Sfi1 restriction site has been engineered into the single Kpn1 site at position 2114 of V1J-neo. The incidence of Sfi1 sites in human genomic DNA is very low (approximately 1 site per 100,000 bases). Thus, this vector allows careful monitoring for expression vector integration into host DNA, simply by Sfi1 digestion of extracted genomic DNA. Yet another preferred DNA expression vector used as the backbone to the HIV-1 pol-based DNA vaccines of the present invention is V1R. In this vector, as much non-essential DNA as possible is "trimmed" from the vector to produce a highly compact vector. This vector is a derivative of V1Jns. This vector allows larger inserts to be used, with less concern that undesirable sequences are encoded and optimizes uptake by cells when the construct encoding specific influenza virus genes is introduced into surrounding tissue. The specific DNA vectors of the present invention include but are not limited to V1, V1J (SEQ ID NO:13), V1Jneo (SEQ ID NO:14), V1Jns (Figure 1A, SEQ ID NO:15), V1R (SEQ ID NO:26), and any of the aforementioned vectors wherein a nucleotide sequence encoding a leader peptide, preferably the human tPA leader, is fused directly downstream of the CMV-intA promoter, including but not limited to V1Jns-tpa, as shown in Figure 1B and SEQ ID NO:28.

The present invention especially relates to a DNA vaccine and a pharmaceutically active vaccine composition which contains this DNA vaccine, and the use as prophylactic and/or therapeutic vaccine for host immunization, preferably human host immunization, against an HIV infection or to combat an existing HIV condition. These DNA vaccines are represented by codon optimized DNA molecules encoding HIV-1 Pol or biologically active Pol modifications or Pol-containing fusion proteins which are ligated within an appropriate DNA plasmid vector, with or without a nucleotide sequence encoding a functional leader peptide. DNA vaccines of the present invention may comprise codon optimized DNA molecules encoding HIV-1 Pol or biologically active Pol modifications or Pol-containing fusion proteins ligated in DNA vectors V1, V1J (SEQ ID NO:14), V1Jneo (SEQ ID NO:15), V1Jns (Figure 1A, SEQ ID NO:16), V1R (SEQ ID NO:26), or any of the aforementioned vectors

-31-

wherein a nucleotide sequence encoding a leader peptide, preferably the human tPA
leader, is fused directly downstream of the CMV-intA promoter, including but not
limited to V1Jns-tpa, as shown in Figure 1B and SEQ ID NO:28. To this end,
polynucleotide vaccine constructions include , V1Jns-wtpol and V1R-wtpol

5   (comprising the DNA molecule encoding WT Pol, as set forth in SEQ ID NO:2),
V1Jns-tPA-WTPol, (comprising the DNA molecule encoding tPA Pol, as set forth in
SEQ ID NO:6), V1Jns-IAPol (comprising the DNA molecule encoding IA Pol, as set
forth in SEQ ID NO:4), and V1Jns-tPA-IAPol, (comprising the DNA molecule
encoding tPA-IA Pol, as set forth in SEQ ID NO:8).   Polynucleotide vaccine

10   constructions V1R-wtpol, V1Jns-IAPol, and V1Jns-tPA-IAPol, are exemplified in
Example Sections 3-5.

        It will be evident upon review of the teaching within this specification that
numerous vector/Pol antigen constructs may be generated. While the exemplified
constructs are preferred, any number of vector/Pol antigen combinations are within

15   the scope of the present invention, especially wild type or modified/inactivated Pol
·proteins which comprise at least one, preferably 5 or more and especially all nine
mutations as shown in Table 1, with or without the inclusion of a leader sequence
such as human tPA.

        The DNA vector vaccines of the present invention may be formulated in any

20   pharmaceutically effective formulation for host administration. Any such formulation
may be, for example, a saline solution such as phosphate buffered saline (PBS).
It will be useful to utilize pharmaceutically acceptable formulations which also
provide long-term stability of the DNA vector vaccines of the present invention.
During storage as a pharmaceutical entity, DNA plasmid vaccines undergo a

25   physiochemical change in which the supercoiled plasmid converts to the open circular
and linear form. A variety of storage conditions (low pH, high temperature, low ionic
strength) can accelerate this process. Therefore, the removal and/or chelation of trace
metal ions (with succinic or malic acid, or with chelators containing multiple
phosphate ligands) from the DNA plasmid solution, from the formulation buffers or

30   from the vials and closures, stabilizes the DNA plasmid from this degradation
pathway during storage. In addition, inclusion of non-reducing free radical
scavengers, such as ethanol or glycerol, are useful to prevent damage of the DNA
plasmid from free radical production that may still occur, even in apparently
demetalated solutions. Furthermore, the buffer type, pH, salt concentration, light

exposure, as well as the type of sterilization process used to prepare the vials, may be controlled in the formulation to optimize the stability of the DNA vaccine. Therefore, formulations that will provide the highest stability of the DNA vaccine will be one that includes a demetalated solution containing a buffer (phosphate or bicarbonate)

5   with a pH in the range of 7-8, a salt (NaCl, KCl or LiCl) in the range of 100-200 mM, a metal ion chelator (e.g., EDTA, diethylenetriaminepenta-acetic acid (DTPA), malate, inositol hexaphosphate, tripolyphosphate or polyphosphoric acid), a non-reducing free radical scavenger (e.g. ethanol, glycerol, methionine or dimethyl sulfoxide) and the highest appropriate DNA concentration in a sterile glass vial,

10   packaged to protect the highly purified, nuclease free DNA from light. A particularly preferred formulation which will enhance long term stability of the DNA vector vaccines of the present invention would comprise a Tris-HCl buffer at a pH from about 8.0 to about 9.0; ethanol or glycerol at about 3% w/v; EDTA or DTPA in a concentration range up to about 5 mM; and NaCl at a concentration from about 50

15   mM to about 500 mM. The use of such stabilized DNA vector vaccines and various alternatives to this preferred formulation range is described in detail in PCT International Application No. PCT/US97/06655 and PCT International Publication No. WO 97/40839, both of which are hereby incorporated by reference.

        The DNA vector vaccines of the present invention may also be formulated

20   with an adjuvant or adjuvants which may increase immunogenicity of the DNA polynucleotide vaccines of the present invention. A number of these adjuvants are known in the art and are available for use in a DNA vaccine, including but not limited to particle bombardment using DNA-coated gold beads, co-administration of DNA vaccines with plasmid DNA expressing cytokines, chemokines, or

25   costimulatory molecules, formulation of DNA with cationic lipids or with experimental adjuvants such as saponin, monophosphoryl lipid A or other compounds which increase immunogenicity of the DNA vaccine. Another adjuvant for use in the DNA vector vaccines of the present invention are one or more forms of an aluminum phosphate-based adjuvant wherein the aluminum

30   phosphate-based adjuvant possesses a molar PO_4/Al ratio of approximately 0.9. An additional mineral-based adjuvant may be generated from one or more forms of a calcium phosphate. These mineral-based adjuvants are useful in increasing cellular and humoral responses to DNA vaccination. These mineral-based compounds for use as DNA vaccines adjuvants are disclosed in PCT International

Application No. PCT/US98/02414, PCT International Publication No.
WO 98/35562, which is hereby incorporated by reference. Another preferred
adjuvant is a non-ionic block copolymer which shows adjuvant activity with DNA
vaccines. The basic structure comprises blocks of polyoxyethylene (POE) and

5   polyoxypropylene (POP) such as a POE-POP-POE block copolymer. Newman et
al. (1998, *Critical Reviews in Therapeutic Drug Carrier Systems* 15(2): 89-142)
review a class of non-ionic block copolymers which show adjuvant activity. The
basic structure comprises blocks of polyoxyethylene (POE) and polyoxypropylene
(POP) such as a POE-POP-POE block copolymer. Newman et al. *id.,* disclose

10   that certain POE-POP-POE block copolymers may be useful as adjuvants to an
influenza protein-based vaccine, namely higher molecular weight POE-POP-POE
block copolymers containing a central POP block having a molecular weight of
over about 9000 daltons to about 20,000 daltons and flanking POE blocks which
comprise up to about 20% of the total molecular weight of the copolymer (see also

15   U.S. Reissue Patent No. 36,665, U.S. Patent No. 5,567,859, U.S. Patent No.
5,691,387, U.S. Patent No. 5,696,298 and U.S. Patent No. 5,990,241, all issued to
Emanuele, et al., regarding these POE-POP-POE block copolymers).
WO 96/04932 further discloses higher molecular weight POE/POP block
copolymers which have surfactant characteristics and show biological efficacy as

20   vaccine adjuvants. The above cited references within this paragraph are hereby
incorporated by reference in their entirety. It is therefore within the purview of
the skilled artisan to utilize available adjuvants which may increase the immune
response of the polynucleotide vaccines of the present invention in comparison to
administration of a non-adjuvanted polynucleotide vaccine.

25   The DNA vector vaccines of the present invention are administered to the host
by any means known in the art, such as enteral and parenteral routes. These routes of
delivery include but are not limited to intramusclar injection, intraperitoneal injection,
intravenous injection, inhalation or intranasal delivery, oral delivery, sublingual
administration, subcutaneous administration, transdermal administration,

30   transcutaneous administration, percutaneous administration or any form of particle
bombardment, such as a biolostic device such as a "gene gun" or by any available
needle-free injection device. The preferred methods of delivery of the HIV-1 Pol-
based DNA vaccines disclosed herein are intramuscular injection, subcutaneous
administration and needle-free injection. An especially preferred method is

intramuscular delivery.

The amount of expressible DNA to be introduced to a vaccine recipient will depend on the strength of the transcriptional and translational promoters used in the DNA construct, and on the immunogenicity of the expressed gene product. In general, an immunologically or prophylactically effective dose of about 1 μg to greater than about 20 mg, and preferably in doses from about 1 mg to about 5 mg is administered directly into muscle tissue. As noted above, subcutaneous injection, intradermal introduction, impression through the skin, and other modes of administration such as intraperitoneal, intravenous, inhalation and oral delivery are also contemplated. It is also contemplated that booster vaccinations are to be provided in a fashion which optimizes the overall immune response to the Pol-based DNA vector vaccines of the present invention.

The aforementioned polynucleotides, when directly introduced into a vertebrate *in vivo*, express the respective HIV-1 Pol protein within the animal and in turn induce a cellular immune response within the host to the expressed Pol antigen. To this end, the present invention also relates to methods of using the HIV-1 Pol-based polynucleotide vaccines of the present invention to provide effective immunoprophylaxis, to prevent establishment of an HIV-1 infection following exposure to this virus, or as a post-HIV infection therapeutic vaccine to mitigate the acute HIV-1 infection so as to result in the establishment of a lower virus load with beneficial long term consequences. As noted above, the present invention contemplates a method of administration or use of the DNA pol-based vaccines of the present invention using an any of the known routes of introducing polynucleotides into living tissue to induce expression of proteins.

Therefore, the present invention provides for methods of using a DNA pol-based vaccine utilizing the various parameters disclosed herein as well as any additional parameters known in the art, which, upon introduction into mammalian tissue induces intracellular expression of these DNA pol-based vaccines. This intracellular expression of the Pol-based immunogen induces a cellular immune response which provides a substantial level of protection against an existing HIV-1 infection or provides a substantial level of protection against a future infection in a presently uninfected host.

The following examples are provided to illustrate the present invention without, however, limiting the same hereto.

EXAMPLE 1

Vaccine Vectors

V1 – Vaccine vector V1 was constructed from pCMVIE-AKI-DHFR (Whang

5   et al., 1987, *J. Virol.* 61: 1796). The AKI and DHFR genes were removed by cutting
the vector with EcoRI and self-ligating. This vector does not contain intron A in the
CMV promoter, so it was added as a PCR fragment that had a deleted internal SacI
site [at 1855 as numbered in Chapman, et al., 1991, *Nuc. Acids Res.* 19: 3979). The
template used for the PCR reactions was pCMVintA-Lux, made by ligating the

10   HindIII and NheI fragment from pCMV6a120 (see Chapman et al., *ibid.*), which
includes hCMV-IE1 enhancer/promoter and intron A, into the HindIII and XbaI sites
of pBL3 to generate pCMVIntBL. The 1881 base pair luciferase gene fragment
(HindIII-SmaI Klenow filled-in) from RSV-Lux (de Wet et al., 1987, *Mol. Cell Biol.*
7: 725) was ligated into the SalI site of pCMVIntBL, which was Klenow filled-in and

15   phosphatase treated. The primers that spanned intron A are: 5' primer: 5'-CTATAT
AAGCAGAGCTCGTTTAG-3' (SEQ ID NO:10); 3' primer: 5'-GTAGCAAA
GATCTAAGGACGGTGACTGCAG-3' (SEQ ID NO:11). The primers used to
remove the SacI site are: sense primer, 5'-GTATGTGTCTGAAAATGAGCG
TGGAGATTGGGCTCGCAC-3' (SEQ ID NO:12) and the antisense primer,

20   5'-GTGCGAGCCCAATCTCCACGCTCATTTTCAGAC ACATAC-3' (SEQ ID
NO:13). The PCR fragment was cut with Sac I and Bgl II and inserted into the vector
which had been cut with the same enzymes.

V1J – Vaccine vector V1J was generated to remove the promoter and
transcription termination elements from vector V1 in order to place them within a

25   more defined context, create a more compact vector, and to improve plasmid
purification yields. V1J is derived from vectors V1 and pUC18, a commercially
available plasmid. V1 was digested with SspI and EcoRI restriction enzymes
producing two fragments of DNA. The smaller of these fragments, containing the
CMVintA promoter and Bovine Growth Hormone (BGH) transcription termination

30   elements which control the expression of heterologous genes, was purified from an
agarose electrophoresis gel. The ends of this DNA fragment were then "blunted"
using the T4 DNA polymerase enzyme in order to facilitate its ligation to another
"blunt-ended" DNA fragment. pUC18 was chosen to provide the "backbone" of the
expression vector. It is known to produce high yields of plasmid, is well-

characterized by sequence and function, and is of small size. The entire *lac* operon was removed from this vector by partial digestion with the HaeII restriction enzyme. The remaining plasmid was purified from an agarose electrophoresis gel, blunt-ended with the T4 DNA polymerase treated with calf intestinal alkaline phosphatase, and

5   ligated to the CMVintA/BGH element described above. Plasmids exhibiting either of two possible orientations of the promoter elements within the pUC backbone were obtained. One of these plasmids gave much higher yields of DNA in *E. coli* and was designated V1J. This vector's structure was verified by sequence analysis of the junction regions and was subsequently demonstrated to give comparable or higher

10   expression of heterologous genes compared with V1. The nucleotide sequence of V1J is as follows:

```
     TCGCGCGTTT CGGTGATGAC GGTGAAAACC TCTGACACAT GCAGCTCCCG GAGACGGTCA
     CAGCTTGTCT GTAAGCGGAT GCCGGGAGCA GACAAGCCCG TCAGGGCGCG TCAGCGGGTG
     TTGGCGGGTG TCGGGGCTGG CTTAACTATG CGGCATCAGA GCAGATTGTA CTGAGAGTGC
15 · ACCATATGCG GTGTGAAATA CCGCACAGAT GCGTAAGGAG AAAATACCGC ATCAGATTGG
     CTATTGGCCA TTGCATACGT TGTATCCATA TCATAATATG TACATTTATA TTGGCTCATG
     TCCAACATTA CCGCCATGTT GACATTGATT ATTGACTAGT TATTAATAGT AATCAATTAC
     GGGGTCATTA GTTCATAGCC CATATATGGA GTTCCGCGTT ACATAACTTA CGGTAAATGG
     CCCGCCTGGC TGACCGCCCA ACGACCCCCG CCCATTGACG TCAATAATGA CGTATGTTCC
20   CATAGTAACG CCAATAGGGA CTTTCCATTG ACGTCAATGG GTGGAGTATT TACGGTAAAC
     TGCCCACTTG GCAGTACATC AAGTGTATCA TATGCCAAGT ACGCCCCCTA TTGACGTCAA
     TGACGGTAAA TGGCCCGCCT GGCATTATGC CCAGTACATG ACCTTATGGG ACTTTCCTAC
    .TTGGCAGTAC ATCTACGTAT TAGTCATCGC TATTACCATG GTGATGCGGT TTTGGCAGTA
     CATCAATGGG CGTGGATAGC GGTTTGACTC ACGGGGATTT CCAAGTCTCC ACCCCATTGA
25   CGTCAATGGG AGTTTGTTTT GGCACCAAAA TCAACGGGAC TTTCCAAAAT GTCGTAACAA
     CTCCGCCCCA TTGACGCAAA TGGGCGGTAG GCGTGTACGG TGGGAGGTCT ATATAAGCAG
     AGCTCGTTTA GTGAACCGTC AGATCGCCTG GAGACGCCAT CCACGCTGTT TTGACCTCCA
     TAGAAGACAC CGGGACCGAT CCAGCCTCCG CGGCCGGGAA CGGTGCATTG GAACGCGGAT
     TCCCCGTGCC AAGAGTGACG TAAGTACCGC CTATAGAGTC TATAGGCCCA CCCCCTTGGC
30   TTCTTATGCA TGCTATACTG TTTTTGGCTT GGGGTCTATA CACCCCCGCT TCCTCATGTT
     ATAGGTGATG GTATAGCTTA GCCTATAGGT GTGGGTTATT GACCATTATT GACCACTCCC
     CTATTGGTGA CGATACTTTC CATTACTAAT CCATAACATG GCTCTTTGCC ACAACTCTCT
     TTATTGGCTA TATGCCAATA CACTGTCCTT CAGAGACTGA CACGGACTCT GTATTTTTAC
     AGGATGGGGT CTCATTTATT ATTTACAAAT TCACATATAC AACACCACCG TCCCCAGTGC
```

```
    CCGCAGTTTT TATTAAACAT AACGTGGGAT CTCCACGCGA ATCTCGGGTA CGTGTTCCGG
    ACATGGGCTC TTCTCCGGTA GCGGCGGAGC TTCTACATCC GAGCCCTGCT CCCATGCCTC
    CAGCGACTCA TGGTCGCTCG GCAGCTCCTT GCTCCTAACA GTGGAGGCCA GACTTAGGCA
    CAGCACGATG CCCACCACCA CCAGTGTGCC GCACAAGGCC GTGGCGGTAG GGTATGTGTC
  5 TGAAAATGAG CTCGGGGAGC GGGCTTGCAC CGCTGACGCA TTTGGAAGAC TTAAGGCAGC
    GGCAGAAGAA GATGCAGGCA GCTGAGTTGT TGTGTTCTGA TAAGAGTCAG AGGTAACTCC
    CGTTGCGGTG CTGTTAACGG TGGAGGGCAG TGTAGTCTGA GCAGTACTCG TTGCTGCCGC
    GCGCGCCACC AGACATAATA GCTGACAGAC TAACAGACTG TTCCTTTCCA TGGGTCTTTT
    CTGCAGTCAC CGTCCTTAGA TCTGCTGTGC CTTCTAGTTG CCAGCCATCT GTTGTTTGCC
 10 CCTCCCCCGT GCCTTCCTTG ACCCTGGAAG GTGCCACTCC CACTGTCCTT TCCTAATAAA
    ATGAGGAAAT TGCATCGCAT TGTCTGAGTA GGTGTCATTC TATTCTGGGG GGTGGGGTGG
    GGCAGCACAG CAAGGGGGAG GATTGGGAAG ACAATAGCAG GCATGCTGGG GATGCGGTGG
    GCTCTATGGG TACCCAGGTG CTGAAGAATT GACCCGGTTC CTCCTGGGCC AGAAAGAAGC
    AGGCACATCC CCTTCTCTGT GACACACCCT GTCCACGCCC CTGGTTCTTA GTTCCAGCCC
 15 CACTCATAGG ACACTCATAG CTCAGGAGGG CTCCGCCTTC AATCCCACCC GCTAAAGTAC
    TTGGAGCGGT CTCTCCCTCC CTCATCAGCC CACCAAACCA AACCTAGCCT CCAAGAGTGG
    GAAGAAATTA AAGCAAGATA GGCTATTAAG TGCAGAGGGA GAGAAAATGC CTCCAACATG
    TGAGGAAGTA ATGAGAGAAA TCATAGAATT TCTTCCGCTT CCTCGCTCAC TGACTCGCTG
    CGCTCGGTCG TTCGGCTGCG GCGAGCGGTA TCAGCTCACT CAAAGGCGGT AATACGGTTA
 20 TCCACAGAAT CAGGGGATAA CGCAGGAAAG AACATGTGAG CAAAAGGCCA GCAAAAGGCC
    AGGAACCGTA AAAAGGCCGC GTTGCTGGCG TTTTTCCATA GGCTCCGCCC CCCTGACGAG
    CATCACAAAA ATCGACGCTC AAGTCAGAGG TGGCGAAACC CGACAGGACT ATAAAGATAC
    CAGGCGTTTC CCCCTGGAAG CTCCCTCGTG CGCTCTCCTG TTCCGACCCT GCCGCTTACC
    GGATACCTGT CCGCCTTTCT CCCTTCGGGA AGCGTGGCGC TTTCTCAATG CTCACGCTGT
 25 AGGTATCTCA GTTCGGTGTA GGTCGTTCGC TCCAAGCTGG GCTGTGTGCA CGAACCCCCC
    GTTCAGCCCG ACCGCTGCGC CTTATCCGGT AACTATCGTC TTGAGTCCAA CCCGGTAAGA
    CACGACTTAT CGCCACTGGC AGCAGCCACT GGTAACAGGA TTAGCAGAGC GAGGTATGTA
    GGCGGTGCTA CAGAGTTCTT GAAGTGGTGG CCTAACTACG GCTACACTAG AAGGACAGTA
    TTTGGTATCT GCGCTCTGCT GAAGCCAGTT ACCTTCGGAA AAAGAGTTGG TAGCTCTTGA
 30 TCCGGCAAAC AAACCACCGC TGGTAGCGGT GGTTTTTTTG TTTGCAAGCA GCAGATTACG
    CGCAGAAAAA AAGGATCTCA AGAAGATCCT TTGATCTTTT CTACGGGGTC TGACGCTCAG
    TGGAACGAAA ACTCACGTTA AGGGATTTTG GTCATGAGAT TATCAAAAAG GATCTTCACC
    TAGATCCTTT TAAATTAAAA ATGAAGTTTT AAATCAATCT AAAGTATATA TGAGTAAACT
    TGGTCTGACA GTTACCAATG CTTAATCAGT GAGGCACCTA TCTCAGCGAT CTGTCTATTT
```

```
     CGTTCATCCA TAGTTGCCTG ACTCCCCGTC GTGTAGATAA CTACGATACG GGAGGGCTTA
     CCATCTGGCC CCAGTGCTGC AATGATACCG CGAGACCCAC GCTCACCGGC TCCAGATTTA
     TCAGCAATAA ACCAGCCAGC CGGAAGGGCC GAGCGCAGAA GTGGTCCTGC AACTTTATCC
     GCCTCCATCC AGTCTATTAA TTGTTGCCGG GAAGCTAGAG TAAGTAGTTC GCCAGTTAAT
   5 AGTTTGCGCA ACGTTGTTGC CATTGCTACA GGCATCGTGG TGTCACGCTC GTCGTTTGGT
     ATGGCTTCAT TCAGCTCCGG TTCCCAACGA TCAAGGCGAG TTACATGATC CCCCATGTTG
     TGCAAAAAAG CGGTTAGCTC CTTCGGTCCT CCGATCGTTG TCAGAAGTAA GTTGGCCGCA
     GTGTTATCAC TCATGGTTAT GGCAGCACTG CATAATTCTC TTACTGTCAT GCCATCCGTA
     AGATGCTTTT CTGTGACTGG TGAGTACTCA ACCAAGTCAT TCTGAGAATA GTGTATGCGG
  10 CGACCGAGTT GCTCTTGCCC GGCGTCAATA CGGGATAATA CCGCGCCACA TAGCAGAACT
     TTAAAAGTGC TCATCATTGG AAAACGTTCT TCGGGGCGAA AACTCTCAAG GATCTTACCG
     CTGTTGAGAT CCAGTTCGAT GTAACCCACT CGTGCACCCA ACTGATCTTC AGCATCTTTT
     ACTTTCACCA GCGTTTCTGG GTGAGCAAAA ACAGGAAGGC AAAATGCCGC AAAAAAGGGA
     ATAAGGGCGA CACGGAAATG TTGAATACTC ATACTCTTCC TTTTTCAATA TTATTGAAGC
  15 ATTTATCAGG GTTATTGTCT CATGAGCGGA TACATATTTG AATGTATTTA GAAAAATAAA
     CAAATAGGGG TTCCGCGCAC ATTTCCCCGA AAAGTGCCAC CTGACGTCTA AGAAACCATT
     ATTATCATGA CATTAACCTA TAAAAATAGG CGTATCACGA GGCCCTTTCG TC (SEQ ID
     NO:14).
```

   V1Jneo – Construction of vaccine vector V1Jneo expression vector involved
20 removal of the amp^r gene and insertion of the kan^r gene (neomycin
   phosphotransferase). The amp^r gene from the pUC backbone of V1J was removed by
   digestion with SspI and Eam1105I restriction enzymes. The remaining plasmid was
   purified by agarose gel electrophoresis, blunt-ended with T4 DNA polymerase, and
   then treated with calf intestinal alkaline phosphatase. The commercially available
25 kan^r gene, derived from transposon 903 and contained within the pUC4K plasmid,
   was excised using the PstI restriction enzyme, purified by agarose gel electrophoresis,
   and blunt-ended with T4 DNA polymerase. This fragment was ligated with the V1J
   backbone and plasmids with the kan^r gene in either orientation were derived which
   were designated as V1Jneo #'s 1 and 3. Each of these plasmids was confirmed by
30 restriction enzyme digestion analysis, DNA sequencing of the junction regions, and
   was shown to produce similar quantities of plasmid as V1J. Expression of
   heterologous gene products was also comparable to V1J for these V1Jneo vectors.
   V1Jneo#3, referred to as V1Jneo hereafter, was selected which contains the kan^r gene
   in the same orientation as the amp^r gene in V1J as the expression construct and

provides resistance to neomycin, kanamycin and G418. The nucleotide sequence of V1Jneo is as follows:

```
     TCGCGCGTTT CGGTGATGAC GGTGAAAACC TCTGACACAT GCAGCTCCCG GAGACGGTCA
     CAGCTTGTCT GTAAGCGGAT GCCGGGAGCA GACAAGCCCG TCAGGGCGCG TCAGCGGGTG
5    TTGGCGGGTG TCGGGGCTGG CTTAACTATG CGGCATCAGA GCAGATTGTA CTGAGAGTGC
     ACCATATGCG GTGTGAAATA CCGCACAGAT GCGTAAGGAG AAAATACCGC ATCAGATTGG
     CTATTGGCCA TTGCATACGT TGTATCCATA TCATAATATG TACATTTATA TTGGCTCATG
     TCCAACATTA CCGCCATGTT GACATTGATT ATTGACTAGT TATTAATAGT AATCAATTAC
     GGGGTCATTA GTTCATAGCC CATATATGGA GTTCCGCGTT ACATAACTTA CGGTAAATGG
10   CCCGCCTGGC TGACCGCCCA ACGACCCCCG CCCATTGACG TCAATAATGA CGTATGTTCC
     CATAGTAACG CCAATAGGGA CTTTCCATTG ACGTCAATGG GTGGAGTATT TACGGTAAAC
     TGCCCACTTG GCAGTACATC AAGTGTATCA TATGCCAAGT ACGCCCCCTA TTGACGTCAA
     TGACGGTAAA TGGCCCGCCT GGCATTATGC CCAGTACATG ACCTTATGGG ACTTTCCTAC
     TTGGCAGTAC ATCTACGTAT TAGTCATCGC TATTACCATG GTGATGCGGT TTTGGCAGTA
15   CATCAATGGG CGTGGATAGC GGTTTGACTC ACGGGGATTT CCAAGTCTCC ACCCCATTGA
     CGTCAATGGG AGTTTGTTTT GGCACCAAAA TCAACGGGAC TTTCCAAAAT GTCGTAACAA
     CTCCGCCCCA TTGACGCAAA TGGGCGGTAG GCGTGTACGG TGGGAGGTCT ATATAAGCAG
     AGCTCGTTTA GTGAACCGTC AGATCGCCTG GAGACGCCAT CCACGCTGTT TTGACCTCCA
     TAGAAGACAC CGGGACCGAT CCAGCCTCCG CGGCCGGGAA CGGTGCATTG GAACGCGGAT
20   TCCCCGTGCC AAGAGTGACG TAAGTACCGC CTATAGAGTC TATAGGCCCA CCCCCTTGGC
     TTCTTATGCA TGCTATACTG TTTTTGGCTT GGGGTCTATA CACCCCCGCT TCCTCATGTT
     ATAGGTGATG GTATAGCTTA GCCTATAGGT GTGGGTTATT GACCATTATT GACCACTCCC
     CTATTGGTGA CGATACTTTC CATTACTAAT CCATAACATG GCTCTTTGCC ACAACTCTCT
     TTATTGGCTA TATGCCAATA CACTGTCCTT CAGAGACTGA CACGGACTCT GTATTTTTAC
25   AGGATGGGGT CTCATTTATT ATTTACAAAT TCACATATAC AACACCACCG TCCCCAGTGC
     CCGCAGTTTT TATTAAACAT AACGTGGGAT CTCCACGCGA ATCTCGGGTA CGTGTTCCGG
     ACATGGGCTC TTCTCCGGTA GCGGCGGAGC TTCTACATCC GAGCCCTGCT CCCATGCCTC
     CAGCGACTCA TGGTCGCTCG GCAGCTCCTT GCTCCTAACA GTGGAGGCCA GACTTAGGCA
     CAGCACGATG CCCACCACCA CCAGTGTGCC GCACAAGGCC GTGGCGGTAG GGTATGTGTC
30   TGAAAATGAG CTCGGGGAGC GGGCTTGCAC CGCTGACGCA TTTGGAAGAC TTAAGGCAGC
     GGCAGAAGAA GATGCAGGCA GCTGAGTTGT TGTGTTCTGA TAAGAGTCAG AGGTAACTCC
     CGTTGCGGTG CTGTTAACGG TGGAGGGCAG TGTAGTCTGA GCAGTACTCG TTGCTGCCGC
     GCGCGCCACC AGACATAATA GCTGACAGAC TAACAGACTG TTCCTTTCCA TGGGTCTTTT
     CTGCAGTCAC CGTCCTTAGA TCTGCTGTGC CTTCTAGTTG CCAGCCATCT GTTGTTTGCC
```

```
       CCTCCCCCGT GCCTTCCTTG ACCCTGGAAG GTGCCACTCC CACTGTCCTT TCCTAATAAA
       ATGAGGAAAT TGCATCGCAT TGTCTGAGTA GGTGTCATTC TATTCTGGGG GGTGGGGTGG
       GGCAGCACAG CAAGGGGGAG GATTGGGAAG ACAATAGCAG GCATGCTGGG GATGCGGTGG
       GCTCTATGGG TACCCAGGTG CTGAAGAATT GACCCGGTTC CTCCTGGGCC AGAAAGAAGC
  5    AGGCACATCC CCTTCTCTGT GACACACCCT GTCCACGCCC CTGGTTCTTA GTTCCAGCCC
       CACTCATAGG ACACTCATAG CTCAGGAGGG CTCCGCCTTC AATCCCACCC GCTAAAGTAC
       TTGGAGCGGT CTCTCCCTCC CTCATCAGCC CACCAAACCA AACCTAGCCT CCAAGAGTGG
       GAAGAAATTA AAGCAAGATA GGCTATTAAG TGCAGAGGGA GAGAAAATGC CTCCAACATG
       TGAGGAAGTA ATGAGAGAAA TCATAGAATT TCTTCCGCTT CCTCGCTCAC TGACTCGCTG
  10   CGCTCGGTCG TTCGGCTGCG GCGAGCGGTA TCAGCTCACT CAAAGGCGGT AATACGGTTA
       TCCACAGAAT CAGGGGATAA CGCAGGAAAG AACATGTGAG CAAAAGGCCA GCAAAAGGCC
       AGGAACCGTA AAAAGGCCGC GTTGCTGGCG TTTTTCCATA GGCTCCGCCC CCCTGACGAG
       CATCACAAAA ATCGACGCTC AAGTCAGAGG TGGCGAAACC CGACAGGACT ATAAAGATAC
       CAGGCGTTTC CCCCTGGAAG CTCCCTCGTG CGCTCTCCTG TTCCGACCCT GCCGCTTACC
  15   GGATACCTGT CCGCCTTTCT CCCTTCGGGA AGCGTGGCGC TTTCTCAATG CTCACGCTGT
       AGGTATCTCA GTTCGGTGTA GGTCGTTCGC TCCAAGCTGG GCTGTGTGCA CGAACCCCCC
       GTTCAGCCCG ACCGCTGCGC CTTATCCGGT AACTATCGTC TTGAGTCCAA CCCGGTAAGA
       CACGACTTAT CGCCACTGGC AGCAGCCACT GGTAACAGGA TTAGCAGAGC GAGGTATGTA
       GGCGGTGCTA CAGAGTTCTT GAAGTGGTGG CCTAACTACG GCTACACTAG AAGGACAGTA
  20   TTTGGTATCT GCGCTCTGCT GAAGCCAGTT ACCTTCGGAA AAAGAGTTGG TAGCTCTTGA
       TCCGGCAAAC AAACCACCGC TGGTAGCGGT GGTTTTTTTG TTTGCAAGCA GCAGATTACG
       CGCAGAAAAA AAGGATCTCA AGAAGATCCT TTGATCTTTT CTACGGGGTC TGACGCTCAG
       TGGAACGAAA ACTCACGTTA AGGGATTTTG GTCATGAGAT TATCAAAAAG GATCTTCACC
       TAGATCCTTT TAAATTAAAA ATGAAGTTTT AAATCAATCT AAAGTATATA TGAGTAAACT
  25   TGGTCTGACA GTTACCAATG CTTAATCAGT GAGGCACCTA TCTCAGCGAT CTGTCTATTT
       CGTTCATCCA TAGTTGCCTG ACTCCGGGGG GGGGGGGCGC TGAGGTCTGC CTCGTGAAGA
       AGGTGTTGCT GACTCATACC AGGCCTGAAT CGCCCCATCA TCCAGCCAGA AAGTGAGGGA
       GCCACGGTTG ATGAGAGCTT TGTTGTAGGT GGACCAGTTG GTGATTTTGA ACTTTTGCTT
       TGCCACGGAA CGGTCTGCGT TGTCGGGAAG ATGCGTGATC TGATCCTTCA ACTCAGCAAA
  30   AGTTCGATTT ATTCAACAAA GCCGCCGTCC CGTCAAGTCA GCGTAATGCT CTGCCAGTGT
       TACAACCAAT TAACCAATTC TGATTAGAAA AACTCATCGA GCATCAAATG AAACTGCAAT
       TTATTCATAT CAGGATTATC AATACCATAT TTTTGAAAAA GCCGTTTCTG TAATGAAGGA
       GAAAACTCAC CGAGGCAGTT CCATAGGATG GCAAGATCCT GGTATCGGTC TGCGATTCCG
       ACTCGTCCAA CATCAATACA ACCTATTAAT TTCCCCTCGT CAAAAATAAG GTTATCAAGT
```

```
          GAGAAATCAC CATGAGTGAC GACTGAATCC GGTGAGAATG GCAAAAGCTT ATGCATTTCT
          TTCCAGACTT GTTCAACAGG CCAGCCATTA CGCTCGTCAT CAAAATCACT CGCATCAACC
          AAACCGTTAT TCATTCGTGA TTGCGCCTGA GCGAGACGAA ATACGCGATC GCTGTTAAAA
          GGACAATTAC AAACAGGAAT CGAATGCAAC CGGCGCAGGA ACACTGCCAG CGCATCAACA
    5     ATATTTTCAC CTGAATCAGG ATATTCTTCT AATACCTGGA ATGCTGTTTT CCCGGGGATC
          GCAGTGGTGA GTAACCATGC ATCATCAGGA GTACGGATAA AATGCTTGAT GGTCGGAAGA
          GGCATAAATT CCGTCAGCCA GTTTAGTCTG ACCATCTCAT CTGTAACATC ATTGGCAACG
          CTACCTTTGC CATGTTTCAG AAACAACTCT GGCGCATCGG GCTTCCCATA CAATCGATAG
          ATTGTCGCAC CTGATTGCCC GACATTATCG CGAGCCCATT TATACCCATA TAAATCAGCA
   10     TCCATGTTGG AATTTAATCG CGGCCTCGAG CAAGACGTTT CCCGTTGAAT ATGGCTCATA
          ACACCCCTTG TATTACTGTT TATGTAAGCA GACAGTTTTA TTGTTCATGA TGATATATTT
          TTATCTTGTG CAATGTAACA TCAGAGATTT TGAGACACAA CGTGGCTTTC CCCCCCCCCC
          CATTATTGAA GCATTTATCA GGGTTATTGT CTCATGAGCG GATACATATT TGAATGTATT
          TAGAAAAATA AACAAATAGG GGTTCCGCGC ACATTTCCCC GAAAAGTGCC ACCTGACGTC
   15     TAAGAAACCA TTATTATCAT GACATTAACC TATAAAAATA GGCGTATCAC GAGGCCCTTT
          CGTC (SEQ ID NO:15).
```

   V1Jns - The expression vector V1Jns was generated by adding an SfiI site to
V1Jneo to facilitate integration studies. A commercially available 13 base pair SfiI
linker (New England BioLabs) was added at the KpnI site within the BGH sequence
   20 of the vector. V1Jneo was linearized with KpnI, gel purified, blunted by T4 DNA
polymerase, and ligated to the blunt SfiI linker. Clonal isolates were chosen by
restriction mapping and verified by sequencing through the linker. The new vector
was designated V1Jns. Expression of heterologous genes in V1Jns (with SfiI) was
comparable to expression of the same genes in V1Jneo (with KpnI).
   25   The nucleotide sequence of V1Jns is as follows:

```
          TCGCGCGTTT CGGTGATGAC GGTGAAAACC TCTGACACAT GCAGCTCCCG GAGACGGTCA
          CAGCTTGTCT GTAAGCGGAT GCCGGGAGCA GACAAGCCCG TCAGGGCGCG TCAGCGGGTG
          TTGGCGGGTG TCGGGGCTGG CTTAACTATG CGGCATCAGA GCAGATTGTA CTGAGAGTGC
          ACCATATGCG GTGTGAAATA CCGCACAGAT GCGTAAGGAG AAAATACCGC ATCAGATTGG
   30     CTATTGGCCA TTGCATACGT TGTATCCATA TCATAATATG TACATTTATA TTGGCTCATG
          TCCAACATTA CCGCCATGTT GACATTGATT ATTGACTAGT TATTAATAGT AATCAATTAC
          GGGGTCATTA GTTCATAGCC CATATATGGA GTTCCGCGTT ACATAACTTA CGGTAAATGG
          CCCGCCTGGC TGACCGCCCA ACGACCCCCG CCCATTGACG TCAATAATGA CGTATGTTCC
          CATAGTAACG CCAATAGGGA CTTTCCATTG ACGTCAATGG GTGGAGTATT TACGGTAAAC
```

```
      TGCCCACTTG GCAGTACATC AAGTGTATCA TATGCCAAGT ACGCCCCCTA TTGACGTCAA
      TGACGGTAAA TGGCCCGCCT GGCATTATGC CCAGTACATG ACCTTATGGG ACTTTCCTAC
      TTGGCAGTAC ATCTACGTAT TAGTCATCGC TATTACCATG GTGATGCGGT TTTGGCAGTA
      CATCAATGGG CGTGGATAGC GGTTTGACTC ACGGGGATTT CCAAGTCTCC ACCCCATTGA
   5  CGTCAATGGG AGTTTGTTTT GGCACCAAAA TCAACGGGAC TTTCCAAAAT GTCGTAACAA
      CTCCGCCCCA TTGACGCAAA TGGGCGGTAG GCGTGTACGG TGGGAGGTCT ATATAAGCAG
      AGCTCGTTTA GTGAACCGTC AGATCGCCTG GAGACGCCAT CCACGCTGTT TTGACCTCCA
      TAGAAGACAC CGGGACCGAT CCAGCCTCCG CGGCCGGGAA CGGTGCATTG GAACGCGGAT
      TCCCCGTGCC AAGAGTGACG TAAGTACCGC CTATAGACTC TATAGGCACA CCCCTTTGGC
  10  TCTTATGCAT GCTATACTGT TTTTGGCTTG GGGCCTATAC ACCCCCGCTT CCTTATGCTA
      TAGGTGATGG TATAGCTTAG CCTATAGGTG TGGGTTATTG ACCATTATTG ACCACTCCCC
      TATTGGTGAC GATACTTTCC ATTACTAATC CATAACATGG CTCTTTGCCA CAACTATCTC
      TATTGGCTAT ATGCCAATAC TCTGTCCTTC AGAGACTGAC ACGGACTCTG TATTTTTACA
      GGATGGGGTC CCATTTATTA TTTACAAATT CACATATACA ACAACGCCGT CCCCCGTGCC
  15  CGCAGTTTTT ATTAAACATA GCGTGGGATC TCCACGCGAA TCTCGGGTAC GTGTTCCGGA
      CATGGGCTCT TCTCCGGTAG CGGCGGAGCT TCCACATCCG AGCCCTGGTC CCATGCCTCC
      AGCGGCTCAT GGTCGCTCGG CAGCTCCTTG CTCCTAACAG TGGAGGCCAG ACTTAGGCAC
      AGCACAATGC CCACCACCAC CAGTGTGCCG CACAAGGCCG TGGCGGTAGG GTATGTGTCT
      GAAAATGAGC GTGGAGATTG GGCTCGCACG CTGACGCAG ATGGAAGACT TAAGGCAGCG
  20  GCAGAAGAAG ATGCAGGCAG CTGAGTTGTT GTATTCTGAT AAGAGTCAGA GGTAACTCCC
      GTTGCGGTGC TGTTAACGGT GGAGGGCAGT GTAGTCTGAG CAGTACTCGT TGCTGCCGCG
      CGCGCCACCA GACATAATAG CTGACAGACT AACAGACTGT TCCTTTCCAT GGGTCTTTTC
      TGCAGTCACC GTCCTTAGAT CTGCTGTGCC TTCTAGTTGC CAGCCATCTG TTGTTTGCCC
      CTCCCCCGTG CCTTCCTTGA CCCTGGAAGG TGCCACTCCC ACTGTCCTTT CCTAATAAAA
  25. TGAGGAAATT GCATCGCATT GTCTGAGTAG GTGTCATTCT ATTCTGGGGG GTGGGGTGGG
      GCAGGACAGC AAGGGGGAGG ATTGGGAAGA CAATAGCAGG CATGCTGGGG ATGCGGTGGG
      CTCTATGGCC GCTGCGGCCA GGTGCTGAAG AATTGACCCG GTTCCTCCTG GGCCAGAAAG
      AAGCAGGCAC ATCCCCTTCT CTGTGACACA CCCTGTCCAC GCCCCTGGTT CTTAGTTCCA
      GCCCCACTCA TAGGACACTC ATAGCTCAGG AGGGCTCCGC CTTCAATCCC ACCCGCTAAA
  30  GTACTTGGAG CGGTCTCTCC CTCCCTCATC AGCCCACCAA ACCAAACCTA GCCTCCAAGA
      GTGGGAAGAA ATTAAAGCAA GATAGGCTAT TAAGTGCAGA GGGAGAGAAA ATGCCTCCAA
      CATGTGAGGA AGTAATGAGA GAAATCATAG AATTTCTTCC GCTTCCTCGC TCACTGACTC
      GCTGCGCTCG GTCGTTCGGC TGCGGCGAGC GGTATCAGCT CACTCAAAGG CGGTAATACG
      GTTATCCACA GAATCAGGGG ATAACGCAGG AAAGAACATG TGAGCAAAAG GCCAGCAAAA
```

```
      GGCCAGGAAC CGTAAAAAGG CCGCGTTGCT GGCGTTTTTC CATAGGCTCC GCCCCCCTGA

      CGAGCATCAC AAAAATCGAC GCTCAAGTCA GAGGTGGCGA AACCCGACAG GACTATAAAG

      ATACCAGGCG TTTCCCCCTG GAAGCTCCCT CGTGCGCTCT CCTGTTCCGA CCCTGCCGCT

      TACCGGATAC CTGTCCGCCT TTCTCCCTTC GGGAAGCGTG GCGCTTTCTC ATAGCTCACG

   5  CTGTAGGTAT CTCAGTTCGG TGTAGGTCGT TCGCTCCAAG CTGGGCTGTG TGCACGAACC

      CCCCGTTCAG CCCGACCGCT GCGCCTTATC CGGTAACTAT CGTCTTGAGT CCAACCCGGT

      AAGACACGAC TTATCGCCAC TGGCAGCAGC CACTGGTAAC AGGATTAGCA GAGCGAGGTA

      TGTAGGCGGT GCTACAGAGT TCTTGAAGTG GTGGCCTAAC TACGGCTACA CTAGAAGAAC

      AGTATTTGGT ATCTGCGCTC TGCTGAAGCC AGTTACCTTC GGAAAAAGAG TTGGTAGCTC

  10  TTGATCCGGC AAACAAACCA CCGCTGGTAG CGGTGGTTTT TTTGTTTGCA AGCAGCAGAT

      TACGCGCAGA AAAAAGGAT CTCAAGAAGA TCCTTTGATC TTTTCTACGG GGTCTGACGC

      TCAGTGGAAC GAAAACTCAC GTTAAGGGAT TTTGGTCATG AGATTATCAA AAAGGATCTT

      CACCTAGATC CTTTTAAATT AAAAATGAAG TTTTAAATCA ATCTAAAGTA TATATGAGTA

      AACTTGGTCT GACAGTTACC AATGCTTAAT CAGTGAGGCA CCTATCTCAG CGATCTGTCT

  15  ATTTCGTTCA TCCATAGTTG CCTGACTCGG GGGGGGGGGG CGCTGAGGTC TGCCTCGTGA

      AGAAGGTGTT GCTGACTCAT ACCAGGCCTG AATCGCCCCA TCATCCAGCC AGAAAGTGAG

      GGAGCCACGG TTGATGAGAG CTTTGTTGTA GGTGGACCAG TTGGTGATTT TGAACTTTTG

      CTTTGCCACG GAACGGTCTG CGTTGTCGGG AAGATGCGTG ATCTGATCCT TCAACTCAGC

      AAAAGTTCGA TTTATTCAAC AAAGCCGCCG TCCCGTCAAG TCAGCGTAAT GCTCTGCCAG

  20  TGTTACAACC AATTAACCAA TTCTGATTAG AAAAACTCAT CGAGCATCAA ATGAAACTGC

      AATTTATTCA TATCAGGATT ATCAATACCA TATTTTTGAA AAAGCCGTTT CTGTAATGAA

      GGAGAAAACT CACCGAGGCA GTTCCATAGG ATGGCAAGAT CCTGGTATCG GTCTGCGATT

      CCGACTCGTC CAACATCAAT ACAACCTATT AATTTCCCCT CGTCAAAAAT AAGGTTATCA

      AGTGAGAAAT CACCATGAGT GACGACTGAA TCCGGTGAGA ATGGCAAAAG CTTATGCATT

  25  TCTTTCCAGA CTTGTTCAAC AGGCCAGCCA TTACGCTCGT CATCAAAATC ACTCGCATCA

      ACCAAACCGT TATTCATTCG TGATTGCGCC TGAGCGAGAC GAAATACGCG ATCGCTGTTA

      AAAGGACAAT TACAAACAGG AATCGAATGC AACCGGCGCA GGAACACTGC CAGCGCATCA

      ACAATATTTT CACCTGAATC AGGATATTCT TCTAATACCT GGAATGCTGT TTTCCCGGGG

      ATCGCAGTGG TGAGTAACCA TGCATCATCA GGAGTACGGA TAAAATGCTT GATGGTCGGA

  30  AGAGGCATAA ATTCCGTCAG CCAGTTTAGT CTGACCATCT CATCTGTAAC ATCATTGGCA

      ACGCTACCTT TGCCATGTTT CAGAAACAAC TCTGGCGCAT CGGGCTTCCC ATACAATCGA

      TAGATTGTCG CACCTGATTG CCCGACATTA TCGCGAGCCC ATTTATACCC ATATAAATCA

      GCATCCATGT TGGAATTTAA TCGCGGCCTC GAGCAAGACG TTTCCCGTTG AATATGGCTC

      ATAACACCCC TTGTATTACT GTTTATGTAA GCAGACAGTT TTATTGTTCA TGATGATATA
```

TTTTTATCTT GTGCAATGTA ACATCAGAGA TTTTGAGACA CAACGTGGCT TTCCCCCCCC
CCCCATTATT GAAGCATTTA TCAGGGTTAT TGTCTCATGA GCGGATACAT ATTTGAATGT
ATTTAGAAAA ATAAACAAAT AGGGGTTCCG CGCACATTTC CCCGAAAAGT GCCACCTGAC
GTCTAAGAAA CCATTATTAT CATGACATTA ACCTATAAAA ATAGGCGTAT CACGAGGCCC

5   TTTCGTC(SEQ ID NO:16).

The underlined nucleotides of SEQ ID NO:16 represent the Sfi1 site
introduced into the Kpn 1 site of V1Jneo.

V1Jns-tPA – The vaccine vector V1Jns-tPA was constructed in order to fuse
an heterologous leader peptide sequence to the pol DNA constructs of the present

10   invention. More specifically, the vaccine vector V1Jns was modified to include the
human tissue-specific plasminogen activator (tPA) leader. As an exemplification, but
by no means a limitation of generating a pol DNA construct comprising an amino-
terminal leader sequence, plasmid V1Jneo was modified to include the human tissue-
specific plasminogen activator (tPA) leader. Two synthetic complementary oligomers

15   were annealed and then ligated into V1Jneo which had been BglII digested. The
sense and antisense oligomers were 5'-GATCACCATGGATGCAATGAAGAG
AGGGCTCTGCTGTGTGCTGCTGCTGTGTGGAGCAGTCTTCGTTTCGCCCAG
CGA-3' (SEQ ID NO:17); and, 5'-GATCTCGCTGGGCGAAACGAAGACTGCTCC
ACACAGCAGCAGCACACAGCAGAGCCCTCTCTTCATTGCATCCATGGT-3'

20   (SEQ ID NO:18). The Kozak sequence is underlined in the sense oligomer. These
oligomers have overhanging bases compatible for ligation to BglII-cleaved sequences.
After ligation the upstream BglII site is destroyed while the downstream BglII is
retained for subsequent ligations. Both the junction sites as well as the entire tPA
leader sequence were verified by DNA sequencing. Additionally, in order to conform

25   with V1Jns (=V1Jneo with an SfiI site), an SfiI restriction site was placed at the KpnI
site within the BGH terminator region of V1Jneo-tPA by blunting the KpnI site with
T4 DNA polymerase followed by ligation with an SfiI linker (catalogue #1138, New
England Biolabs), resulting in V1Jns-tPA. This modification was verified by
restriction digestion and agarose gel electrophoresis.

30   The V1Jns-tpa vector nucleotide sequence is as follows:

TCGCGCGTTT CGGTGATGAC GGTGAAAACC TCTGACACAT GCAGCTCCCG GAGACGGTCA
CAGCTTGTCT GTAAGCGGAT GCCGGGAGCA GACAAGCCCG TCAGGGCGCG TCAGCGGGTG
TTGGCGGGTG TCGGGGCTGG CTTAACTATG CGGCATCAGA GCAGATTGTA CTGAGAGTGC
ACCATATGCG GTGTGAAATA CCGCACAGAT GCGTAAGGAG AAAATACCGC ATCAGATTGG

```
      CTATTGGCCA TTGCATACGT TGTATCCATA TCATAATATG TACATTTATA TTGGCTCATG
      TCCAACATTA CCGCCATGTT GACATTGATT ATTGACTAGT TATTAATAGT AATCAATTAC
      GGGGTCATTA GTTCATAGCC CATATATGGA GTTCCGCGTT ACATAACTTA CGGTAAATGG
      CCCGCCTGGC TGACCGCCCA ACGACCCCCG CCCATTGACG TCAATAATGA CGTATGTTCC
  5   CATAGTAACG CCAATAGGGA CTTTCCATTG ACGTCAATGG GTGGAGTATT TACGGTAAAC
      TGCCCACTTG GCAGTACATC AAGTGTATCA TATGCCAAGT ACGCCCCCTA TTGACGTCAA
      TGACGGTAAA TGGCCCGCCT GGCATTATGC CCAGTACATG ACCTTATGGG ACTTTCCTAC
      TTGGCAGTAC ATCTACGTAT TAGTCATCGC TATTACCATG GTGATGCGGT TTTGGCAGTA
      CATCAATGGG CGTGGATAGC GGTTTGACTC ACGGGGATTT CCAAGTCTCC ACCCCATTGA
 10   CGTCAATGGG AGTTTGTTTT GGCACCAAAA TCAACGGGAC TTTCCAAAAT GTCGTAACAA
      CTCCGCCCCA TTGACGCAAA TGGGCGGTAG GCGTGTACGG TGGGAGGTCT ATATAAGCAG
      AGCTCGTTTA GTGAACCGTC AGATCGCCTG GAGACGCCAT CCACGCTGTT TTGACCTCCA
      TAGAAGACAC CGGGACCGAT CCAGCCTCCG CGGCCGGGAA CGGTGCATTG GAACGCGGAT
      TCCCCGTGCC AAGAGTGACG TAAGTACCGC CTATAGACTC TATAGGCACA CCCCTTTGGC
 15   TCTTATGCAT GCTATACTGT TTTTGGCTTG GGGCCTATAC ACCCCCGCTT CCTTATGCTA
      TAGGTGATGG TATAGCTTAG CCTATAGGTG TGGGTTATTG ACCATTATTG ACCACTCCCC
      TATTGGTGAC GATACTTTCC ATTACTAATC CATAACATGG CTCTTTGCCA CAACTATCTC
      TATTGGCTAT ATGCCAATAC TCTGTCCTTC AGAGACTGAC ACGGACTCTG TATTTTTACA
      GGATGGGGTC CCATTTATTA TTTACAAATT CACATATACA ACAACGCCGT CCCCCGTGCC
 20   CGCAGTTTTT ATTAAACATA GCGTGGGATC TCCACGCGAA TCTCGGGTAC GTGTTCCGGA
      CATGGGCTCT TCTCCGGTAG CGGCGGAGCT TCCACATCCG AGCCCTGGTC CCATGCCTCC
      AGCGGCTCAT GGTCGCTCGG CAGCTCCTTG CTCCTAACAG TGGAGGCCAG ACTTAGGCAC
      AGCACAATGC CCACCACCAC CAGTGTGCCG CACAAGGCCG TGGCGGTAGG GTATGTGTCT
      GAAAATGAGC GTGGAGATTG GGCTCGCACG GCTGACGCAG ATGGAAGACT TAAGGCAGCG
 25   GCAGAAGAAG ATGCAGGCAG CTGAGTTGTT GTATTCTGAT AAGAGTCAGA GGTAACTCCC
      GTTGCGGTGC TGTTAACGGT GGAGGGCAGT GTAGTCTGAG CAGTACTCGT TGCTGCCGCG
      CGCGCCACCA GACATAATAG CTGACAGACT AACAGACTGT TCCTTTCCAT GGGTCTTTTC
      TGCAGTCACC GTCCTT̲AGAT̲ ̲CACCATGGAT̲ ̲GCAATGAAGA̲ ̲GAGGGCTCTG̲ ̲CTGTGTGCTG̲
      ̲CTGCTGTGTG̲ ̲GAGCAGTCTT̲ ̲CGTTTCGCCC̲ ̲AGCGAGATCT̲ GCTGTGCCTT CTAGTTGCCA
 30   GCCATCTGTT GTTTGCCCCT CCCCCGTGCC TTCCTTGACC CTGGAAGGTG CCACTCCCAC
      TGTCCTTTCC TAATAAAATG AGGAAATTGC ATCGCATTGT CTGAGTAGGT GTCATTCTAT
      TCTGGGGGGT GGGGTGGGGC AGGACAGCAA GGGGGAGGAT TGGGAAGACA ATAGCAGGCA
      TGCTGGGGAT GCGGTGGGCT CTAT̲GGCCGC̲ ̲TGCGGCC̲AGG TGCTGAAGAA TTGACCCGGT
      TCCTCCTGGG CCAGAAAGAA GCAGGCACAT CCCCTTCTCT GTGACACACC CTGTCCACGC
```

```
      CCCTGGTTCT TAGTTCCAGC CCCACTCATA GGACACTCAT AGCTCAGGAG GGCTCCGCCT
      TCAATCCCAC CCGCTAAAGT ACTTGGAGCG GTCTCTCCCT CCCTCATCAG CCCACCAAAC
      CAAACCTAGC CTCCAAGAGT GGGAAGAAAT TAAAGCAAGA TAGGCTATTA AGTGCAGAGG
      GAGAGAAAAT GCCTCCAACA TGTGAGGAAG TAATGAGAGA AATCATAGAA TTTCTTCCGC
 5    TTCCTCGCTC ACTGACTCGC TGCGCTCGGT CGTTCGGCTG CGGCGAGCGG TATCAGCTCA
      CTCAAAGGCG GTAATACGGT TATCCACAGA ATCAGGGGAT AACGCAGGAA AGAACATGTG
      AGCAAAAGGC CAGCAAAAGG CCAGGAACCG TAAAAAGGCC GCGTTGCTGG CGTTTTTCCA
      TAGGCTCCGC CCCCCTGACG AGCATCACAA AAATCGACGC TCAAGTCAGA GGTGGCGAAA
      CCCGACAGGA CTATAAAGAT ACCAGGCGTT CCCCCTGGA AGCTCCCTCG TGCGCTCTCC
 10   TGTTCCGACC CTGCCGCTTA CCGGATACCT GTCCGCCTTT CTCCCTTCGG GAAGCGTGGC
      GCTTTCTCAT AGCTCACGCT GTAGGTATCT CAGTTCGGTG TAGGTCGTTC GCTCCAAGCT
      GGGCTGTGTG CACGAACCCC CCGTTCAGCC CGACCGCTGC GCCTTATCCG GTAACTATCG
      TCTTGAGTCC AACCCGGTAA GACACGACTT ATCGCCACTG GCAGCAGCCA CTGGTAACAG
      GATTAGCAGA GCGAGGTATG TAGGCGGTGC TACAGAGTTC TTGAAGTGGT GGCCTAACTA
 15   CGGCTACACT AGAAGAACAG TATTTGGTAT CTGCGCTCTG CTGAAGCCAG TTACCTTCGG
      AAAAAGAGTT GGTAGCTCTT GATCCGGCAA ACAAACCACC GCTGGTAGCG GTGGTTTTTT
      TGTTTGCAAG CAGCAGATTA CGCGCAGAAA AAAAGGATCT CAAGAAGATC CTTTGATCTT
      TTCTACGGGG TCTGACGCTC AGTGGAACGA AAACTCACGT TAAGGGATTT TGGTCATGAG
      ATTATCAAAA AGGATCTTCA CCTAGATCCT TTTAAATTAA AAATGAAGTT TTAAATCAAT
 20   CTAAAGTATA TATGAGTAAA CTTGGTCTGA CAGTTACCAA TGCTTAATCA GTGAGGCACC
      TATCTCAGCG ATCTGTCTAT TTCGTTCATC CATAGTTGCC TGACTCGGGG GGGGGGGGCG
      CTGAGGTCTG CCTCGTGAAG AAGGTGTTGC TGACTCATAC CAGGCCTGAA TCGCCCCATC
      ATCCAGCCAG AAAGTGAGGG AGCCACGGTT GATGAGAGCT TTGTTGTAGG TGGACCAGTT
      GGTGATTTTG AACTTTTGCT TTGCCACGGA ACGGTCTGCG TTGTCGGGAA GATGCGTGAT
 25   CTGATCCTTC AACTCAGCAA AAGTTCGATT TATTCAACAA AGCCGCCGTC CCGTCAAGTC
      AGCGTAATGC TCTGCCAGTG TTACAACCAA TTAACCAATT CTGATTAGAA AAACTCATCG
      AGCATCAAAT GAAACTGCAA TTTATTCATA TCAGGATTAT CAATACCATA TTTTTGAAAA
      AGCCGTTTCT GTAATGAAGG AGAAAACTCA CCGAGGCAGT TCCATAGGAT GGCAAGATCC
      TGGTATCGGT CTGCGATTCC GACTCGTCCA ACATCAATAC AACCTATTAA TTTCCCCTCG
 30   TCAAAAATAA GGTTATCAAG TGAGAAATCA CCATGAGTGA CGACTGAATC CGGTGAGAAT
      GGCAAAAGCT TATGCATTTC TTTCCAGACT TGTTCAACAG GCCAGCCATT ACGCTCGTCA
      TCAAAATCAC TCGCATCAAC CAAACCGTTA TTCATTCGTG ATTGCGCCTG AGCGAGACGA
      AATACGCGAT CGCTGTTAAA AGGACAATTA CAAACAGGAA TCGAATGCAA CCGGCGCAGG
      AACACTGCCA GCGCATCAAC AATATTTTCA CCTGAATCAG GATATTCTTC TAATACCTGG
```

-47-

```
       AATGCTGTTT TCCCGGGGAT CGCAGTGGTG AGTAACCATG CATCATCAGG AGTACGGATA

       AAATGCTTGA TGGTCGGAAG AGGCATAAAT TCCGTCAGCC AGTTTAGTCT GACCATCTCA

       TCTGTAACAT CATTGGCAAC GCTACCTTTG CCATGTTTCA GAAACAACTC TGGCGCATCG

       GGCTTCCCAT ACAATCGATA GATTGTCGCA CCTGATTGCC CGACATTATC GCGAGCCCAT

  5    TTATACCCAT ATAAATCAGC ATCCATGTTG GAATTTAATC GCGGCCTCGA GCAAGACGTT

       TCCCGTTGAA TATGGCTCAT AACACCCCTT GTATTACTGT TTATGTAAGC AGACAGTTTT

       ATTGTTCATG ATGATATATT TTTATCTTGT GCAATGTAAC ATCAGAGATT TTGAGACACA

       ACGTGGCTTT CCCCCCCCCC CCATTATTGA AGCATTTATC AGGGTTATTG TCTCATGAGC

       GGATACATAT TTGAATGTAT TTAGAAAAAT AAACAAATAG GGGTTCCGCG CACATTTCCC

  10   CGAAAAGTGC CACCTGACGT CTAAGAAACC ATTATTATCA TGACATTAAC CTATAAAAAT

       AGGCGTATCA CGAGGCCCTT TCGTC (SEQ ID NO:9).
```

   V1R – Vaccine vector V1R was constructed to obtain a minimum-sized
vaccine vector without unneeded DNA sequences, which still retained the overall
optimized heterologous gene expression characteristics and high plasmid yields that
15   V1J and V1Jns afford. It was determined that (1) regions within the pUC backbone
comprising the *E. coli* origin of replication could be removed without affecting
plasmid yield from bacteria; (2) the 3'-region of the *kan*[r] gene following the
kanamycin open reading frame could be removed if a bacterial terminator was
inserted in its place; and, (3) ~300 bp from the 3'- half of the BGH terminator could
20   be removed without affecting its regulatory function (following the original KpnI
restriction enzyme site within the BGH element). V1R was constructed by using PCR
to synthesize three segments of DNA from V1Jns representing the CMVintA
promoter/BGH terminator, origin of replication, and kanamycin resistance elements,
respectively. Restriction enzymes unique for each segment were added to each
25   segment end using the PCR oligomers: SspI and XhoI for CMVintA/BGH; EcoRV
and BamHI for the *kan* [r] gene; and, BclI and SalI for the *ori* [r]. These enzyme sites
were chosen because they allow directional ligation of each of the PCR-derived DNA
segments with subsequent loss of each site: EcoRV and SspI leave blunt-ended
DNAs which are compatible for ligation while BamHI and BclI leave complementary
30   overhangs as do SalI and XhoI. After obtaining these segments by PCR each segment
was digested with the appropriate restriction enzymes indicated above and then
ligated together in a single reaction mixture containing all three DNA segments. The
5'-end of the *ori* [r] was designed to include the T2 rho independent terminator
sequence that is normally found in this region so that it could provide termination

information for the kanamycin resistance gene. The ligated product was confirmed by
restriction enzyme digestion (>8 enzymes) as well as by DNA sequencing of the
ligation junctions. DNA plasmid yields and heterologous expression using viral genes
within V1R appear similar to V1Jns. The net reduction in vector size achieved was
1346 bp (V1Jns = 4.86 kb; V1R = 3.52 kb). PCR oligomer sequences used to
synthesize V1R (restriction enzyme sites are underlined and identified in brackets
following sequence) are as follows: (1) 5'-GGTACAAATATTGGCTATTGG
CCATTGCATACG-3' (SEQ ID NO:19) [SspI]; (2) 5'-CCACATCTCGAGGAAC
CGGGTCAATTCTTCAGCACC-3' (SEQ ID NO:20) [XhoI] (for CMVintA/BGH
segment); (3) 5'-GGTACAGATATCGGAAAGCCACGTTGTG TCTCAAAATC-3'
(SEQ ID NO:21) [EcoRV]; (4) 5'-CACATGGATCCGTAAT GCTCTGCCAGTGTT
ACAACC-3' (SEQ ID NO:2) [BamHI], (for kanamycin resistance gene segment) (5)
5'-GGTACATG ATCACGTAGAAAAGATCA AAGGATCTTCTTG-3' (SEQ ID
NO:23) [BclI]; (6) 5'-CCACATGTCGACCCGTAAA AAGGCCGCGTTGCTGG-3'
(SEQ ID NO:24): [SalI], (for *E. coli* origin of replication).
The nucleotide sequence of vector V1R is as follows:

```
TCGCGCGTTT CGGTGATGAC GGTGAAAACC TCTGACACAT GCAGCTCCCG GAGACGGTCA
CAGCTTGTCT GTAAGCGGAT GCCGGGAGCA GACAAGCCCG TCAGGGCGCG TCAGCGGGTG
TTGGCGGGTG TCGGGGCTGG CTTAACTATG CGGCATCAGA GCAGATTGTA CTGAGAGTGC
ACCATATGCG GTGTGAAATA CCGCACAGAT GCGTAAGGAG AAAATACCGC ATCAGATTGG
CTATTGGCCA TTGCATACGT TGTATCCATA TCATAATATG TACATTTATA TTGGCTCATG
TCCAACATTA CCGCCATGTT GACATTGATT ATTGACTAGT TATTAATAGT AATCAATTAC
GGGGTCATTA GTTCATAGCC CATATATGGA GTTCCGCGTT ACATAACTTA CGGTAAATGG
CCCGCCTGGC TGACCGCCCA ACGACCCCG CCCATTGACG TCAATAATGA CGTATGTTCC
CATAGTAACG CCAATAGGGA CTTTCCATTG ACGTCAATGG GTGGAGTATT TACGGTAAAC
TGCCCACTTG GCAGTACATC AAGTGTATCA TATGCCAAGT ACGCCCCCTA TTGACGTCAA
TGACGGTAAA TGGCCCGCCT GGCATTATGC CCAGTACATG ACCTTATGGG ACTTTCCTAC
TTGGCAGTAC ATCTACGTAT TAGTCATCGC TATTACCATG GTGATGCGGT TTTGGCAGTA
CATCAATGGG CGTGGATAGC GGTTTGACTC ACGGGGATTT CCAAGTCTCC ACCCCATTGA
CGTCAATGGG AGTTTGTTTT GGCACCAAAA TCAACGGGAC TTTCCAAAAT GTCGTAACAA
CTCCGCCCCA TTGACGCAAA TGGGCGGTAG GCGTGTACGG TGGGAGGTCT ATATAAGCAG
AGCTCGTTTA GTGAACCGTC AGATCGCCTG GAGACGCCAT CCACGCTGTT TTGACCTCCA
TAGAAGACAC CGGGACCGAT CCAGCCTCCG CGGCCGGGAA CGGTGCATTG GAACGCGGAT
TCCCCGTGCC AAGAGTGACG TAAGTACCGC CTATAGAGTC TATAGGCCCA CCCCCTTGGC
```

```
        TTCTTATGCA  TGCTATACTG  TTTTTGGCTT  GGGGTCTATA  CACCCCCGCT  TCCTCATGTT
        ATAGGTGATG  GTATAGCTTA  GCCTATAGGT  GTGGGTTATT  GACCATTATT  GACCACTCCC
        CTATTGGTGA  CGATACTTTC  CATTACTAAT  CCATAACATG  GCTCTTTGCC  ACAACTCTCT
        TTATTGGCTA  TATGCCAATA  CACTGTCCTT  CAGAGACTGA  CACGGACTCT  GTATTTTTAC
   5    AGGATGGGGT  CTCATTTATT  ATTTACAAAT  TCACATATAC  AACACCACCG  TCCCCAGTGC
        CCGCAGTTTT  TATTAAACAT  AACGTGGGAT  CTCCACGCGA  ATCTCGGGTA  CGTGTTCCGG
        ACATGGGCTC  TTCTCCGGTA  GCGGCGGAGC  TTCTACATCC  GAGCCCTGCT  CCCATGCCTC
        CAGCGACTCA  TGGTCGCTCG  GCAGCTCCTT  GCTCCTAACA  GTGGAGGCCA  GACTTAGGCA
        CAGCACGATG  CCCACCACCA  CCAGTGTGCC  GCACAAGGCC  GTGGCGGTAG  GGTATGTGTC
  10    TGAAAATGAG  CTCGGGGAGC  GGGCTTGCAC  CGCTGACGCA  TTTGGAAGAC  TTAAGGCAGC
        GGCAGAAGAA  GATGCAGGCA  GCTGAGTTGT  TGTGTTCTGA  TAAGAGTCAG  AGGTAACTCC
        CGTTGCGGTG  CTGTTAACGG  TGGAGGGCAG  TGTAGTCTGA  GCAGTACTCG  TTGCTGCCGC
        GCGCGCCACC  AGACATAATA  GCTGACAGAC  TAACAGACTG  TTCCTTTCCA  TGGGTCTTTT
        CTGCAGTCAC  CGTCCTTAGA  TCTGCTGTGC  CTTCTAGTTG  CCAGCCATCT  GTTGTTTGCC
  15    CCTCCCCCGT  GCCTTCCTTG  ACCCTGGAAG  GTGCCACTCC  CACTGTCCTT  TCCTAATAAA
        ATGAGGAAAT  TGCATCGCAT  TGTCTGAGTA  GGTGTCATTC  TATTCTGGGG  GGTGGGGTGG
        GGCAGCACAG  CAAGGGGGAG  GATTGGGAAG  ACAATAGCAG  GCATGCTGGG  GATGCGGTGG
        GCTCTATGGG  TACCCAGGTG  CTGAAGAATT  GACCCGGTTC  CTCCTGGGCC  AGAAAGAAGC
        AGGCACATCC  CCTTCTCTGT  GACACACCCT  GTCCACGCCC  CTGGTTCTTA  GTTCCAGCCC
  20    CACTCATAGG  ACACTCATAG  CTCAGGAGGG  CTCCGCCTTC  AATCCCACCC  GCTAAAGTAC
        TTGGAGCGGT  CTCTCCCTCC  CTCATCAGCC  CACCAAACCA  AACCTAGCCT  CCAAGAGTGG
        GAAGAAATTA  AAGCAAGATA  GGCTATTAAG  TGCAGAGGGA  GAGAAAATGC  CTCCAACATG
        TGAGGAAGTA  ATGAGAGAAA  TCATAGAATT  TCTTCCGCTT  CCTCGCTCAC  TGACTCGCTG
        CGCTCGGTCG  TTCGGCTGCG  GCGAGCGGTA  TCAGCTCACT  CAAAGGCGGT  AATACGGTTA
  25    TCCACAGAAT  CAGGGGATAA  CGCAGGAAAG  AACATGTGAG  CAAAAGGCCA  GCAAAAGGCC
        AGGAACCGTA  AAAAGGCCGC  GTTGCTGGCG  TTTTTCCATA  GGCTCCGCCC  CCCTGACGAG
        CATCACAAAA  ATCGACGCTC  AAGTCAGAGG  TGGCGAAACC  CGACAGGACT  ATAAAGATAC
        CAGGCGTTTC  CCCCTGGAAG  CTCCCTCGTG  CGCTCTCCTG  TTCCGACCCT  GCCGCTTACC
        GGATACCTGT  CCGCCTTTCT  CCCTTCGGGA  AGCGTGGCGC  TTTCTCAATG  CTCACGCTGT
  30    AGGTATCTCA  GTTCGGTGTA  GGTCGTTCGC  TCCAAGCTGG  GCTGTGTGCA  CGAACCCCCC
        GTTCAGCCCG  ACCGCTGCGC  CTTATCCGGT  AACTATCGTC  TTGAGTCCAA  CCCGGTAAGA
        CACGACTTAT  CGCCACTGGC  AGCAGCCACT  GGTAACAGGA  TTAGCAGAGC  GAGGTATGTA
        GGCGGTGCTA  CAGAGTTCTT  GAAGTGGTGG  CCTAACTACG  GCTACACTAG  AAGGACAGTA
        TTTGGTATCT  GCGCTCTGCT  GAAGCCAGTT  ACCTTCGGAA  AAAGAGTTGG  TAGCTCTTGA
```

```
     TCCGGCAAAC AAACCACCGC TGGTAGCGGT GGTTTTTTTG TTTGCAAGCA GCAGATTACG

     CGCAGAAAAA AAGGATCTCA AGAAGATCCT TTGATCTTTT CTACGGGGTC TGACGCTCAG

     TGGAACGAAA ACTCACGTTA AGGGATTTTG GTCATGAGAT TATCAAAAAG GATCTTCACC

     TAGATCCTTT TAAATTAAAA ATGAAGTTTT AAATCAATCT AAAGTATATA TGAGTAAACT

 5   TGGTCTGACA GTTACCAATG CTTAATCAGT GAGGCACCTA TCTCAGCGAT CTGTCTATTT

     CGTTCATCCA TAGTTGCCTG ACTCCGGGGG GGGGGGGCGC TGAGGTCTGC CTCGTGAAGA

     AGGTGTTGCT GACTCATACC AGGCCTGAAT CGCCCCATCA TCCAGCCAGA AAGTGAGGGA

     GCCACGGTTG ATGAGAGCTT TGTTGTAGGT GGACCAGTTG GTGATTTTGA ACTTTTGCTT

     TGCCACGGAA CGGTCTGCGT TGTCGGGAAG ATGCGTGATC TGATCCTTCA ACTCAGCAAA

10   AGTTCGATTT ATTCAACAAA GCCGCCGTCC CGTCAAGTCA GCGTAATGCT CTGCCAGTGT

     TACAACCAAT TAACCAATTC TGATTAGAAA AACTCATCGA GCATCAAATG AAACTGCAAT

     TTATTCATAT CAGGATTATC AATACCATAT TTTTGAAAAA GCCGTTTCTG TAATGAAGGA

     GAAAACTCAC CGAGGCAGTT CCATAGGATG GCAAGATCCT GGTATCGGTC TGCGATTCCG

     ACTCGTCCAA CATCAATACA ACCTATTAAT TTCCCCTCGT CAAAAATAAG GTTATCAAGT

15   GAGAAATCAC CATGAGTGAC GACTGAATCC GGTGAGAATG GCAAAAGCTT ATGCATTTCT

     TTCCAGACTT GTTCAACAGG CCAGCCATTA CGCTCGTCAT CAAAATCACT CGCATCAACC

     AAACCGTTAT TCATTCGTGA TTGCGCCTGA GCGAGACGAA ATACGCGATC GCTGTTAAAA

     GGACAATTAC AAACAGGAAT CGAATGCAAC CGGCGCAGGA ACACTGCCAG CGCATCAACA

     ATATTTTCAC CTGAATCAGG ATATTCTTCT AATACCTGGA ATGCTGTTTT CCCGGGGATC

20   GCAGTGGTGA GTAACCATGC ATCATCAGGA GTACGGATAA AATGCTTGAT GGTCGGAAGA

     GGCATAAATT CCGTCAGCCA GTTTAGTCTG ACCATCTCAT CTGTAACATC ATTGGCAACG

     CTACCTTTGC CATGTTTCAG AAACAACTCT GGCGCATCGG GCTTCCCATA CAATCGATAG

     ATTGTCGCAC CTGATTGCCC GACATTATCG CGAGCCCATT TATACCCATA TAAATCAGCA

     TCCATGTTGG AATTTAATCG CGGCCTCGAG CAAGACGTTT CCCGTTGAAT ATGGCTCATA

25   ACACCCCTTG TATTACTGTT TATGTAAGCA GACAGTTTTA TTGTTCATGA TGATATATTT

     TTATCTTGTG CAATGTAACA TCAGAGATTT TGAGACACAA CGTGGCTTTC CCCCCCCCCC

     CATTATTGAA GCATTTATCA GGGTTATTGT CTCATGAGCG GATACATATT TGAATGTATT

     TAGAAAAATA AACAAATAGG GGTTCCGCGC ACATTTCCCC GAAAAGTGCC ACCTGACGTC

     TAAGAAACCA TTATTATCAT GACATTAACC TATAAAAATA GGCGTATCAC GAGGCCCTTT

30   CGTC (SEQ ID NO:25).
```

EXAMPLE 2

Codon Optimized HIV-1 Pol and HIV-1 IA Pol Derivatives as DNA Vector Vaccines

Synthesis of WT-optpol and IA-opt-pol Gene - Construction of both genes were conducted by Midland Certified Reagent Company (Midland, TX) following

5   established strategies. Ten double stranded oligonucleotides, ranging from 159 to 340 bases long and encompassing the entire pol gene, were synthesized by solid state methods and cloned separately into pUC18. For the wt-pol gene, the fragments are as follows:

*Bgl*II#1-*Ecl*136II half site at 282	= pJS6A1-7
*Pml*I half site at #285 – *Ecl*136II half site at #597	= pJS6B2-5
*Ssp*I half site at #600 - *Ecl*136II half site at #866	= pJS6C1-4
*Sma*I half site at #869 – *Apa*I #1095	= pJS6D1-4
*Apa*I #1095 - *Kpn*I #1296	= pJS6E1-4
*Kpn*I #1296 – *Xcm*I #1636	= pJS6F1-5
*Xcm*I #1636 – *Nsi*I #1847	= pJS6G1-2
*Nsi*I #1847 – *Bcl*I half site at #2174	= pJS6H1-14
*Bcl*I half site at #2174 – *Sac*I #2333	= pJS6I1-2
*Sac*I #2333 - *Bgl*II #2577	= pJS6J1-1

*Eco*RI and *Hind*III sequences were added upstream of each 5' end and downstream of

20   each 3' end, respectively, to allow cloning into the *Eco*RI-*Hind*III sites of pUC18.

The next stage of the synthesis was to consolidate these cassettes into three roughly equal fragments (alpha, beta, gamma) and was performed as follows:

Alpha: The *Ssp*I-*Hind*III small fragment of pJS6C1-4 was transferred into the *Ecl*136II-*Hind*III sites of pJS6B2-5 to give pJS6BC1-1. Into the *Eco*RI-*Pml*I sites of

25   this plasmid was inserted the *Eco*RI-*Ecl*136II small fragment of pJS6A1-7 to give pJS6α1-8.

Beta: The *Eco*RI-*Apa*I small fragment of pJS6D1-4 was inserted into the corresponding sites of pJS6E1-2 to give pJS6DE1-2. Also, the *Eco*RI-*Xcm*I small fragment of pJS6F1-5 was inserted into the corresponding sites of pJS6G1-2 to give

30   pJS6FG1-1. Then the *Eco*RI-*Kpn*I small fragment of pJS6DE1-2 was inserted into the corresponding sites of pJS6FG1-1 to give pJS6β1-1.

Gamma: The *Sac*I-*Hind*III small fragment of pJS6J1-1 was inserted into the corresponding sites of pJS6I1-2 to give pJS6IJ1-1. This plasmid was propagated through *E. coli* SCS110 (*dam-/dcm-*) to permit subsequent cleavage at the *Bcl*I site.

The *BclI-HindIII* small fragment of the unmethylated pJS6IJ1-1 was inserted into the *BglII-HindIII* sites of pJS6H1-14 to give pJS6χ1-1.

The wt-pol alpha, beta, gamma were ligated into the entire sequence as follows:

The *EcoRI-Ecl136II* small fragment of pJS6α1-8 was inserted into the *EcoRI-SmaI* sites of pJS6β1-1 to give pJS6αβ2-1.

Into the *NsiI-HindIII* sites of this plasmid was inserted the *NsiI-HindIII* small fragment of pJS6χ1-1 to give pUC18-wt-pol. This final plasmid was completely resequenced in both strands.

To construct the entire IA-pol gene, only 3 new small fragments were synthesized:

PmlI half site at #285 – *Ecl136II* half site at #597	= pJS7B1-1
KpnI #1296 – *XcmI* #1636	= pJS7F1-2
NsiI #1847 – *BglII* half site at #2174	= pJS7H1-5

These were then used in the same reconstruction strategy as described above to give pUC18-IA-pol.

Expression Vector Construction - pUC18-wt-pol and pUC18-IA-pol were digested with *BglII* in order to isolate fragments containing the entire pol genes. V1R, V1Jns, V1Jns-tpa (Shiver, et al., 1995, Immune responses to HIV gp120 elicited by DNA vaccination. In *Vaccines 95* (eds. Chanock, R. M., Brown, F., Ginsberg, H.S., & Norrby, E.) @ pp. 95-98; Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York; see also Example Section 1) were digested with *BglII*. The cut vectors were then treated with calf intestinal alkaline phosphatase. Both wt-pol and IA-pol genes were ligated into cut V1R using T4 DNA ligase (16 °C, overnight).

Competent DH5α cells were transformed with aliquots of the ligation mixtures. Colonies were screened by restriction digestion of amplified plasmid isolates. Following a similar strategy, the *BglII* fragment containing the IA-pol was subcloned into the *BglII* site of V1Jns. To ligate the IA-pol gene into V1Jns-tpa, the IA-pol gene was PCR-amplified from V1R-IA-pol using pfu polymerase and the following pair of primers: 5'-GGTACAAGATCTCCGCCCCCATCTCCCCCATTGAGA-3' (SEQ ID NO:26), and 5'-CCACATAGATCTGCCCGGGCTTTAGTCCTCATC-3' (SEQ ID NO:27). The upstream primer was designed to remove the initiation met codon and place the pol gene in frame with the tpa leader coding sequence from V1Jns-tpa. The PCR product was purified from the agarose gel slab using Sigma

DNA Purification spin columns. The purified products were digested with *Bgl*II and subcloned into the *Bgl*II site of V1Jns-tpa.

     Results - The codon humanized wt- and IA-pol genes were constructed via stepwise ligation of 10 synthetic dsDNA fragments (Ferretti, et al., 1986, *Proc. Natl.*

5   *Acad. Sci. USA* 83: 599-603). For expression in mammalian systems, the IA-pol gene was subcloned into V1R, V1Jns, and V1Jns-tpa. All these vectors place the gene under the control of the human cytomegalovirus/intron A hybrid promoter (hCMVIA). The DNA sequence of the IA-pol gene and the expressed protein product are shown in Figure 2A-B. Subcloning into V1Jns-tpa attaches the leader sequence

10   from human tissue-specific plasminogen activator (tpa) to the N-terminus of the IA-pol (Pennica, et al., 1983, *Nature* 301: 214-221) to allow secretion of the protein. The sequences of the tpa leader and the fusion junction are shown in Figure 3.

EXAMPLE 3

15   HIV-1 POL Vaccine - Rodent Studies

    Materials - *E. coli* DH5α strain, penicillin, streptomycin, ACK lysis buffer, hepes, L-glutamine, RPMI1640, and ultrapure CsCl were obtained from Gibco/BRL (Grand Island, NY). Fetal bovine serum (FBS) was purchased from Hyclone. Kanamycin, Tween 20, bovine serum albumin, hydrogen peroxide (30%),

20   concentrated sulfuric acid, β-mercaptoethanol (β-ME), and concanavalin A were obtained from Sigma (St. Louis, MO). Female balb/c mice at 4-6 wks of age were obtained from Taconic Farms (Germantown, NY). 0.3-mL insulin syringes were purchased from Myoderm. 96-well flat bottomed Maxisorp plates were obtained form NUNC (Rochester, NY). HIV-1$_{\text{IIIB}}$ RT p66 recombinant protein was obtained from

25   Advanced Biotechnologies, Inc. (Columbia, MD). 20-mer peptides were synthesized by Research Genetics (Huntsville, AL). Horseradish peroxidase (HRP)-conjugated rabbit anti-mouse IgG1 was obtained from ZYMED (San Francisco, CA). 1,2-phenylenediamine dihydrochloride (OPD) tablets was obtained from DAKO (Norway). Purified rat anti-mouse IFN-gamma (IgG1, clone R4-6A2), biotin-

30   conjugated rat anti-mouse IFN-gamma (IgG1, clone XMG 1.2), and strepavidin-alkaline phosphatase conjugate were purchased from PharMingen (San Diego, CA). 1-STEP NBT/BCIP dye was obtained from Pierce Chemicals (Rockford, IL). 96-well Multiscreen membrane plate was purchased from Millipore (France). Cell strainer was obtained from Becton-Dickinson (Franklin Lakes, NJ).

Plasmid Preparation - *E. coli* DH5α cells expressing the pol plasmids were grown to saturation in LB broth supplemented with 100 ug/mL kanamycin. Plasmid were purified by standard CsCl method and solubilized in saline at concentrations greater than 5 mg/mL until further use.

5   *Vaccination* - The plasmids were prepared in phosphate-buffered saline and administered into balb/c by needle injection (28-1/2G insulin syringe) of 50 uL aliquot into each quad muscle. V1Jns-IApol was administered at 0.3, 3, 30 ug dose and for comparison, V1Jns-tpa-IApol was given at 30 ug dose. Immunizations were conducted at T=0 and T=8 wks (for select animals from the 30-ug dose cohorts).

10   *ELISA Assay* - At T=12 wks, blood samples were collected by making an incision of a tail vein and the serum separated. Anti-RT titers were obtained following standard secondary antibody-based ELISA. Briefly, Maxisorp plates were coated by overnight incubation with 100 uL of 1 ug/mL HIV-1 RT protein (in PBS). The plates were washed with PBS/0.05% Tween 20 and incubated for approx. 2h with 15   200 uL/well of blocking solution (PBS/0.05% tween/1% BSA). The blocking solution was decanted; 100 uL aliquot of serially diluted serum samples were added per well and incubated for 2 h at room temperature. The plates were washed and 100 uL of 1/1000-diluted HRP-rabbit anti-mouse IgG were added with 1 h incubation. The plates were washed thoroughly and soaked with 100 uL OPD/H_2O_2 solution for 20   15 min. The reaction was quenched by adding 100 uL of 0.5M H_2SO4 per well. OD_{492} readings were recorded.

ELIspot - Spleens were collected from 5 mice/cohort at T=13-14 wks and pooled into a tube of 8-mL R10 medium (RPMI1640, 10% FBS, 2mM L-glutamine, 100U/mL Penicillin, 100 u/mL streptomycin, 10 mM Hepes, 50 uM β-ME). 25   Multiscreen opaque plates were coated with 100μl/well of capture mAb (purified R4-6A2 diluted in PBS to 5μg/ml) at 4°C overnight. The plates were washed with PBS/Pen/Strep in hood and blocked with 200μl/well of complete R10 medium for 37°C for at least 2 hrs. The mouse spleens were ground on steel mesh, collected into 15ml tubes and centrifuged at 1200rpm for 10min. The pellet was treated in ACK 30   buffer (4ml of lysis buffer per spleen) for 5min at room temperature to lyse red blood cells. The cell pellet was centrifuged as before, resuspended in K-medium (5ml per mouse spleen), filtered through a cell strainer and counted using a hemacytometer. Block medium was decanted from the plates and 100μl/well of cell samples (5.0x10e5 cells per well) plus antigens were added. Pol-specific CD4$^+$ cells were stimulated

using a mixture of previously identified two epitope-containing peptides (aa641-660, aa731-750). Antigen-specific CD8+ cells were stimulated using a pool of four peptide epitope-containing peptides (aa201-220, aa311-330, aa571-590, aa781-800) or with individual peptides. A final concentration of 4 ug/mL per peptide was used.

5 Each splenocyte sample is tested for IFN-gamma secretion by adding the mitogen, concanavalin A. Plates were incubated at 37°C, 5% CO_2 for 20-24 h. The plates were washed with PBS/0.05% Tween 20 and soaked with 100 uL/well of 5 ug/mL biotin-conjugated rat anti-mouse IFN- mAb (clone XMG1.2) at 4°C overnight. The plates were washed and soaked with 100 uL/well 1/2500 dilution of strepavidin-AP

10 (in PBS/0.005% Tween/5%FCS) for 30 min at 37 °C. Following a wash, spots were developed by incubating with 100µl/well 1-step NBT/BCIP for 6-10 min. The plates were washed with water and allowed to air dry. The number of spots in each wells were determined using a dissecting microscope and normalized to 10e6 cells.

Results - Single vaccination of balb/c mice with V1Jns-IApol is able to induce

15 antigen-specific antibody (Figure 4) and T cell (Figure 5) responses in a dose response manner. IFN-gamma secretion from splenocytes can be detected from 3 and 30 ug cohort following stimulation with pools of peptides that contain CD4+ and CD8+ T cell epitopes. These epitopes were identified by (1) screening 20-mer peptides that encompass the entire pol sequence and overlap by 10 amino acid for

20 ability to stimulate IFN-gamma secretion from vaccinee splenocytes, and (2) determining the T cell type (CD4+ or CD8+) by depleting either population in an Elispot assay. Addition of tpa leader sequence to the pol gene is able to induce comparable, if not slightly higher, frequencies of pol-specific CD4+ and CD8+ cells. A second immunization with either V1Jns-IApol and V1Jns-tpa-IApol resulted in

25 effective boosting of the immune responses.

EXAMPLE 4
HIV-1 Pol Vaccine - Non Human Primate Studies

Materials - *E. coli* DH5α strain, penicillin, streptomycin, and ultrapure CsCl

30 were obtained from Gibco/BRL (Grand Island, NY). Kanamycin and phytohemagluttinin (PHA-M) were obtained from Sigma (St. Louis, MO). 20-mer peptides were synthesized by SynPep (Dublin, CA) and Research Genetics (Huntsville, AL). 96-well Multiscreen Immobilon-P membrane plates were obtained from Millipore (France). Strepavidin-alkaline phosphatase conjugate were purchased

form Pharmingen (San Diego, CA). 1-Step NBT/BCIP dye was obtained form Pierce Chemicals (Rockford, IL). Rat anti-human IFN-gamma mAb and biotin-conjugated anti-human IFN-gamma reagent were obtained from R&D Systems (Minneapolis, MN). Dynabeads M-450 anti-human CD4 were obtained from Dynal (Norway).

5   HIVp24 antigen assay was purchased from Coulter Corporation (Miami, FL). HIV-1$_{IIIB}$ RT p66 recombinant protein was obtained from Advanced Biotechnologies, Inc. (Columbia, MD). Plastic 8 well strips/plates, flat bottom, Maxisorp, are obtained from NUNC (Rochester, NY). HIV+ human serum 9711234 was obtained from Biological Specialty Corp.

10   *Plasmid Preparation* - *E. coli* DH5α cells expressing the pol plasmids were grown to saturation in LB supplemented with 100 ug/mL kanamycin. Plasmid were purified by standard CsCl method and solubilized in saline at concentrations greater than 5 mg/mL until further use.

Vaccination - Cohorts of 3 rhesus macaques (approx. 5-10 kg) were
15   vaccinated with 5 mg dose of either V1Jns-IApol or V1Jns-tpa-IApol. The vaccine was administered by needle injection of two 0.5 mL aliquots of 5 mg/mL plasmid solution (in phosphate-buffered saline, pH 7.2) into both deltoid muscles. Prior to vaccination, the monkeys were chemically restraint with i.m. injection of 10 mg/kg ketamine. The animals were immunized 3x at 4 week intervals (T=0, 4, 8 wks).

20   *Sample Collection* - Blood samples were collected at T = 0, 4, 8, 12, 16, 18 wks; sera and PBMCs were isolated using established protocols.

ELIspot Assay - Immobilon-IP plates were coated with 100 uL/well of rat anti-human IFN-gamma mAb at 15 ug/mL at 4 °C overnight. The plates are then washed with PBS and block by adding 200 uL/well of R10 medium. 4x10e5 peripheral blood
25   cells were plated per well and to each well, either media or one of the pol peptide pools (final concentration of 4 ug/mL per peptide) or PHA, a known mitogen, is added to a final volume of 100 uL. Duplicate wells were set up per sample per antigen and stimulation was performed for 20-24 h at 37 °C. The plates are then washed; biotinylated anti-human IFN-gamma reagent is added (0.1 ug/mL, 100 uL
30   per well) and allowed to incubate for overnight at 4 °C. The plates are again washed and 100 uL of 1:2500 dilution of the strepavidin-alkaline phosphatase reagent (in PBS/0.005% Tween/5% FCS) is added and allowed to incubate for 2 h at ambient room temperature. After another wash, spots are developed by incubating with 100 uL/well of 1-step NBT/BCIP for 6-10 min. CD4- T cell depletion was performed by

adding 1 bead particle/10 cell of Dynabeads M450 anti-human CD4, prewashed with PBS, and incubating on the shaker at 4 °C for 30 min. The beads are fractionated magnetically and the unbound cells collected and quantified before plating onto the ELISpot assay plates (at 4x10e5 cells per well).

5   *CTL Assay* - Procedures for establishing bulk CTL culture with fresh or cryopreserved peripheral blood mononuclear cells (PBMC) are as follows. Twenty percent total PBMC were infected in 0.5 ml volume with recombinant vaccinia virus, Vac-tpaPol, respectively, at multiplicity of infection (moi) of 5 for 1 hr at 37°C, and then combined with the remaining PBMC sample. The cells were washed once in 10

10   ml R-10 medium, and plated in a 12 well plate at approximately 5 to 10 x 10^6 cells/well in 4 ml R-10 medium. Recombinant human IL-7 was added to the culture at the concentration of 330 U/ml. Two or three days later, one milliliter of R-10 containing recombinant human IL-2 (100 U/ml) was added to each well. And twice weekly thereafter, two milliliters of cultured media were replaced with 2 ml fresh R-

15   10 medium with rhIL-2 (100 U/ml). The lymphocytes were cultured at 37°C in the presence of 5% CO_2 for approximately 2 weeks, and used in cytotoxicity assay as described below. The effector cells harvested from bulk CTL cultures were tested against autologous B lymphoid cell lines (BLCL) sensitized with peptide pools. To prepare for the peptide-sensitized targets, the BLCL cells were washed once with

20   R-10 medium, enumerated, and pulsed with peptide pool (about 4 to 8 μg/ml concentration for each individual peptide) in 1 ml volume overnight. A mock target was prepared by pulsing cells with peptide-free DMSO diluent to match the DMSO concentration in the peptide-pulsed targets. The cells were enumerated the next morning, and 1 x 10^6 cells were resuspended in 0.5 ml R-10 medium. Five to ten

25   microliters of Na^{51}CrO$_4$ were added to the tubes at the same time, and the cells were incubated for 1 to 2 hr 37°C. The cells were then washed 3 times and resuspended at 5x10^4 cells/ml in R-10 medium to be used as target cells. The cultured lymphocytes were plated with target cells at designated effector to target (E:T) ratios in triplicates in 96-well plates, and incubated at 37°C for 4 hours in the presence of 5% CO_2. A

30   sample of 30 μl supernatant from each well of cell mixture was harvested onto a well of a Lumaplate-96 (Packard Instrument, Meriden, CT), and the plate was allowed to air dry overnight. The amount of ^{51}Cr in the well was determined through beta-particle emission, using a plate counter from Packard Instrument. The percentage of specific lysis was calculated using the formula as: % specific lysis = $(E\text{-}S) / (M\text{-}S)$.

The symbol E represents the average cpm released from target cells in the presence of effector cells, S is the spontaneous cpm released in the presence of medium only, and M is the maximum cpm released in the presence of 2% Triton X-100.

ELISA Assay - The pol-specific antibodies in the monkeys were measured in a
5   competitive RT EIA assay, wherein sample activity is determined by the ability to block RT antigen from binding to coating antibody on the plate well. Briefly, Maxisorp plates were coated with saturating amounts of pol positive human serum (97111234). 250 uL of each sample is incubated with 15 uL of 266 ng/mL RT recombinant protein (in RCM 563, 1% BSA, 0.1% tween, 0.1% NaN_3) and 20 uL of
10   lysis buffer (Coulter p24 antigen assay kit) for 15 min at room temperature. Similar mixtures are prepared using serially diluted samples of a standard and a negative control which defines maximum RT binding. 200 uL/well of each sample and standard were added to the washed plate and the plate incubated 16-24 h at room temperature. Bound RT is quantified following the procedures described in Coulter
15   p24 assay kit and reported in milliMerck units per mL arbitrarily defined by the chosen standard.

Results - Repeated vaccinations with V1Jns-IApol induced in 1 of 3 monkeys (94R033) significant levels of antigen-specific T cell activation (Figure 6A-C and Table 2) and CTL killing of peptide-pulsed autologous cells (Figure 7A-B). A
20   significant CD8+ component to the T cell responses in this animal was confirmed by peptide-stimulation of CD4-depleted PBMCs in an ELIspot assay (Table 2).

Immunization with V1Jns-tpa-IApol produced T cell responses from all 3 vaccinees (Figures 6A-C, Figure 7A-B; Table 2). Two (920078, 94R028) exhibited bulk CTL activity and detectable CD8+ components as measured by Elispot analyses
25   of CD4-depleted PBMCs. For the third monkey (920073), the activated T cells were largely CD4+ (Table 2). Table 3 shows the time course data on the frequency of IFN-gamma secreting cells (SFC/million cells) upon antigen-specific stimulation for monkeys vaccinated 3x with either V1Jns-IApol or V1Jns-tpa-IApol (5 mg dose). At T=18 wks, CD4-cell depletion were performed; the reported values are the number of
30   spots per million of fractionated cells and are not corrected for the resultant enrichment of CD8+ T cells. PBMCs were stimulated with peptide pools that represent either IA pol protein (mpol-1, mpol-2) or wt Pol (wtpol-1, wtpol-2).

TABLE 2

Vaccine	Animal No.	Antigen	T=0 wk Dose 1	T=4 Wk Dose 2	T=8 Wk Dose 3	T=12 Wk	T=18 Wk	CD4-Depl
VIJns-IApd 5 mgs	94R008	medum	1	15	6	11	11	11
		mpd-1	3	69	28	61	20	15
		mpd-2	0	25	21	19	28	16
		wtpd-1		49	20	53	18	
		wtpd-2		34	24	24	19	
	94R013	medum	0	14	6	9	18	11
		mpd-1	0	9	63	25	34	9
		mpd-2	1	15	24	36	24	15
		wtpd-1		9	50	33	18	
		wtpd-2		6	21	29	25	
	94R033	medum	4	15	11	14	13	8
		mpd-1	3	29	86	51	41	24
		mpd-2	0	24	25	43	59	64
		wtpd-1		30	38	60	53	
		wtpd-2		48	46	86	61	
VIJns-tpcd Apd 5 mgs	920078	medum	0	24	13	11	14	11
		mpd-1	3	110	120	119	155	11
		mpd-2	1	221	130	561	289	145
		wtpd-1		115	53	70	116	
		wtpd-2		218	204	490	194	
	920073	medum	0	13	3	15	15	6
		mpd-1	0	36	51	113	90	14
		mpd-2	0	29	16	83	115	34
		wtpd-1		20	35	100	74	
		wtpd-2		25	16	79	61	
	94R028	medum	0	18	11	18	19	9
		mpd-1	1	30	24	29	30	28
		mpd-2	1	24	23	66	59	95
		wtpd-1		23	25	34	29	
		wtpd-2		26	28	71	40	
Naïve	920072	medum	1	19	3	38	9	4
		mpd-1	0	24	11	25	4	6
		mpd-2	1	24	5	28	6	5
		wtpd-1		18	13	20	6	
		wtpd-2		23	14	33	14	

5

For the Elispot assay, antigen specific stimulation were performed by using pools of 20-mer peptide pools based on the vaccine sequence. The vaccine pol sequence differs from the wild-type HIV-1 sequence by 9 point mutations, thereby affecting 16 of the 20-mer peptides in the pool. Comparable responses were observed in the vaccinees when these peptides are replaced with those using the wild-type sequences.

Four of the vaccinees gave anti-RT titers above background after 3 dosages of the plasmids (Table 2).

TABLE 3

Anti-RT levels in Rhesus Macaques Vaccinated 3x (4 week intervals) with 5 mgs of V1Jns-IApol or V1Jns-tpa-IApol expressed in mMU/mL.

Vaccine/Monkey	T=0 Wk	T=4	T=8	T=12	T=16
	DOSE 1	DOSE 2	DOSE 3		
V1Jns-IApol, 5 mg					
94R008	ND	<10	<10	15	14
94R013	ND	<10	<10	<10	<10
94R033	ND	<10	<10	25	19
V1Jns-tpa-IApol, 5 mg					
920078	ND	<10	<10	35	17
920073	ND	<10	<10	<10	<10
94R028	ND	<10	<10	20	63

EXAMPLE 5

Effect of Codon Optimization on In Vivo Expression and Cellular Immune Response of wt-pol

Materials and Methods - Extraction of virus-derived pol gene - The gene for RT-IN (wt-pol; a non-codon optimized wild type pol gene derived directly from the HIV IIIB genome) was extracted and amplified from the HIV IIIB genome using two primers, 5'-CAG GCG AGA TCT ACC ATG GCC CCC ATT AGC CCT ATT GAG ACT GTA-3' (SEQ ID NO:29) and 5'-CAG GCG AGA TCT GCC CGG GCT TTA ATC CTC ATC CTG TCT ACT TGC CAC-3' (SEQ ID NO:30), containing *Bgl*II sites. The reaction contained 200 nmol of each primer, 2.5 U of pfu Turbo DNA polymerase (Stratagene, La Jolla, CA), 0.2 mM of each dNTPs, and the template DNA in 10mM KCl, 10mM $(NH_4)_2SO_4$, 20mM Tris-HCl pH 8.75, 2mM $MgSO_4$, 0.1% TritonX-100, 0.1mg/ml bovine serum albumin (BSA). Thermocycling

conditions were as follows: 20 cycles of 1 min at 95 °C, 1 min at 56 °C, and 4 mins at 72 °C with 15-min capping at 72 °C. The digested PCR fragment was subcloned into the *BglII* site of the expression plasmid V1Jns (Shiver, et al., 1995, Immune responses to HIV gp120 elicited by DNA vaccination. In Chanock, R. M., Brown, F., Ginsberg,

5   H. S., and Norrby, E. (Eds.) *Vaccines 95.* Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York, pp 95-98; see also Example section 1 herein) expression plasmid following similar procedures as described above. The ligation mixtures were then used to transform competent *E. coli* DH5 cells and screened by PCR amplification of individual colonies. Sequence of the entire gene insert was

10   confirmed. All plasmid constructs for animal immunization were purified by CsCl method (Sambrook, et al., 1989, Fritsch and Maniatis, T. (Eds) *Molecular cloning: a laboratory manual.* Cold Spring Harbor Laboratory Press, Cold Spring Harbor).

      In vitro expression in mammalian cells - 1.5×10^6 293 cells were transfected with 1 or 10 µg of V1R-wt-pol (codon optimized) and V1Jns-wt-pol (virus derived)

15   using the Cell Phect kit and incubated for 48 h at 37 °C, 5% CO_2, 90% humidity. Supernatants and cell lysates were prepared and assayed for protein content using Pierce Protein Assay reagent (Rockford, IL). Aliquots containing equal amounts of total protein were loaded unto 10-20% Tris glycine gel (Novex, San Diego, CA) along with the appropriate molecular weight markers. The pol product was detected using

20   anti-serum from a seropositive patient (Scripps Clinic, San Diego, CA) diluted 1:1000 and the bands developed using goat anti-human IgG-HRP (Bethyl, Montgomery, TX) at 1:2000 dilution and standard ECL reagent kit (Pharmacia LKB Biotechnology, Uppsala, Sweden).

      Ultrasensitive RT activity assay of pol constructs - RT activities from codon

25   optimized wt-pol and IA pol plasmids were analyzed by the Product-Enhanced Reverse Transcriptase (PERT) assay using Perkin Elmer 7700, Taqman technology (Arnold, et al., 1999, One-step fluorescent probe product-enhanced reverse transcriptase assay. In McClelland, M., Pardee, A. (Eds.) *Expression genetics: accelerated and high-throughput methods.* Biotechniques Books, Natick, MA, pp.

30   201-210). Background levels for this assay were determined using 1:100,000 dilution of lysates from mock (chemical treatment only, no vector) transfected 293 cells. This background range is set as RT/reaction tube of 0.00 to 56.28 which is taken from the mean value of 13.80 +/- 3 standard deviations (sd=14.16). Any individual value >56.28 would be considered positive for PERT assay. Cells lysates were prepared

-62-

similarly for the following samples: mock transfection with empty V1Jns vector; no
vector control; transfection with V1Jns-tpa-pol (codon optimized); and transfection
with V1Jns-IApol (codon optimized). Samples were serially diluted to 1:100,000 in
PERT buffer and 24 replicates for each sample at this dilution were assayed for RT

5   activity.

Rodent immunization with optimized and virus-derived pol plasmids - To
compare the immunogenic properties of wt-pol (codon optimized) and virus-derived
pol gene, cohorts of BALB/c mice (N=10) were vaccinated with 1 μg, 10 μg, and 100
μg doses of V1R-wt-pol (codon optimized) and V1Jns-wt-pol plasmid (virus derived).

10   At 5 weeks post dose 1, 5 of 10 mice per cohort were boosted with the same dose of
plasmid they initially received. In all cases, the vaccines were suspended or diluted in
6 mM sodium phosphate, 150 mM sodium chloride, pH 7.2, and the total dose was
injected to both quadricep muscles in 50 μL aliquots using a 0.3-mL insulin syringe
with 28-1/2G needles (Becton-Dickinson, Franklin Lakes, NJ).

15   Anti-RT ELISA - Anti-RT titers were obtained following standard secondary
antibody-based ELISA. Maxisorp plates (NUNC, Rochester, NY) were coated by
overnight incubation with 100 μL of 1 μg /mL HIV-1 RT protein (Advanced
Biotechnologies, Columbia, MD) in PBS. The plates were washed with PBS/0.05%
Tween 20 using Titertek MAP instrument (Hunstville, AL) and incubated for

20   approximately 2h with 200 μL/well of blocking solution (PBS/0.05% tween/1%
BSA). The blocking solution was decanted; 100 μL aliquot of serially diluted serum
samples were added per well and incubated for 2 h at room temperature. An initial
dilution of 100-fold is performed followed by 4-fold serial dilution. The plates were
washed and 100 μL of 1/1000-diluted HRP-rabbit anti-mouse IgG (ZYMED, San

25   Francisco, CA) were added with 1 h incubation. The plates were washed thoroughly
and soaked with 100 μL 1,2-phenylenediamine dihydrochloride/hydrogen peroxide
(DAKO, Norway) solution for 15 min. The reaction was quenched by adding 100 μL
of 0.5M H_2SO4 per well. OD_{492} readings were recorded using Titertek Multiskan
MCC/340 with S20 stacker. Endpoint titers were defined as the highest serum

30   dilution that resulted in an absorbance value of greater than or equal to 0.1 OD_{492} (2.5
times the background value).

ELIspot assay - Antigen-specific INFγ-secreting cells from mouse spleens
were detected using the ELIspot assay (Miyahira, et al., 1995, Quantification of
antigen specific CD8+ T cells using an ELISPOT assay. J. Immunol. Methods 1995,

181, 45-54). Typically, spleens were collected from 3-5 mice/cohort and pooled into a tube of 8-mL complete RPMI media (RPMI1640, 10% FBS, 2mM L-glutamine, 100U/mL Penicillin, 100 u/mL streptomycin, 10 mM Hepes, 50 uM β-ME). Multiscreen opaque plates (Millipore, France) were coated with 100 μL/well of 5

5   μg/mL purified rat anti-mouse IFN-γ IgG1, clone R4-6A2 (Pharmingen, San Diego, CA), in PBS at 4°C overnight. The plates were washed with PBS/penicillin/streptomycin in hood and blocked with 200 μL/well of complete RPMI media for 37 °C for at least 2 h. The mouse spleens were ground on steel mesh, collected into 15ml tubes and centrifuged at 1200rpm for 10 min. The pellet

10   was treated with 4 mL ACK buffer (Gibco/BRL) for 5 min at room temperature to lyse red blood cells. The cell pellet was centrifuged as before, resuspended in complete RPMI media (5 ml per mouse spleen), filtered through a cell strainer and counted using a hemacytometer. Block media was decanted from the plates and to each well, 100 μL of cell samples ($5x10^5$ cells per well) and 100 μL of the antigen

15   solution were added. To the control well, 100 μL of the media were added; for specific responses, peptide pools containing either $CD4^+$ or $CD8^+$ epitopes were added. In all cases, a final concentration of 4 μg/mL per peptide was used. Each sample/antigen mixture were performed in triplicate wells. Plates were incubated at 37°C, 5% CO_2, 90% humidity for 20-24 h. The plates were washed with PBS/0.05%

20   Tween 20 and incubated with 100 μL/well of 1.25 μg/mL biotin-conjugated rat anti-mouse IFN-γ mAb, clone XMG1.2 (Pharmingen) at 4°C overnight. The plates were washed and incubated with 100 μL/well 1/2500 dilution of strepavidin-alkaline phosphatase conjugate (Pharmingen) in PBS/0.005% Tween/5% FBS for 30 min at 37 °C. Following a wash, spots were developed by incubating with 100 μl/well 1-step

25   NBT/BCIP (Pierce Chemicals) for 6-10 min. The plates were washed with water and allowed to air dry. The number of spots in each well was determined using a dissecting microscope and the data normalized to 10^6 cell input.

        Results - In vitro expression of Pol in mammalian cells - Heterologous expression of the optimized wt or IA pol genes (V1R-wt-pol (codon optimized),

30   V1Jns-IApol (codon optimized), V1Jns-tpa-IApol (codon optimized)) in 293 cells (Figure 8) yielded a single polypeptide of correct approximate molecular size (90-kDa) for the RT-IN fusion product. In contrast, no expression could be detected by transfecting cells with 1 and 10 μg of the V1Jns-wt-pol, which bears the virus-derived *pol*.

Ultrasensitive RT assay of cells transfected with Pol constructs - Table 4
summarizes the levels of polymerase activity from mock (vector only) control, IApol
(codon optimized)and wt-pol plasmids (codon optimized). Results indicate that the
wild-type POL transfected cells contained RT activity approximately 4-5 logs higher

5   than the 293 cell only baseline values. Mock transfected cells contained activity no
higher than baseline values. The RT activity from opt-IApol-transfected cells was
also found to be no different than baseline values; no individual reaction tube resulted
in RT activity higher than the established cut-off value of 56.

10   Table 4

Sample	Avg. RT/tube	Standard deviation	Minimum	Maximum
Vector only	16.25	18.52	0.0	42.99
IApol (codon optimized)	2.99	8.01	0.0	35.20
Wt-pol (codon optimized)	126147	21338	68973	152007

Comparative immunogenicity of optimized and virus-derived pol plasmid - To
compare the *in vivo* potencies of both constructs, BALB/c mice (N=10 per group)

15   were vaccinated with escalating doses (1, 10, 100 µg) of either V1Jns-wt-pol (virus
derived) or V1R-wt-pol (codon optimized). At 5 wks post dose 1, 5 of 10 animals
were randomly boosted with the same vaccine and dose they received initially.
Figure 9 shows the geometric mean titers of the BALB/c cohorts determined at 2 wks
past boost. No significant anti-RT titers can be observed from animals immunized

20   with one or two doses of the wt-pol plasmid (virus derived). In contrast, animals
vaccinated with the humanized gene construct gave cohort anti-RT titers (>1000)
significantly above background levels at doses above 10 ug. The responses seen at 10
and 100 ug dose of V1R-wt-pol (codon optimized) were boosted approximately
10-fold with a second immunization, reaching titers as high as 10^6.

25   Spleens from all mice in each of the cohorts were collected to be analyzed for IFN-γ
secretion following stimulation with mixtures of either CD4+ peptide epitopes or
CD8+ peptide epitopes. The results are shown in Figure 10. All wt-pol vaccinees did

not show any significant cellular response above the background controls. In contrast, strong antigen-stimulated IFN-γ secretion were observed in a dose-responsive manner from animals vaccinated with one or two doses of 10 or more μg of the wt-pol (codon optimized) construct.

5   The present invention is not to be limited in scope by the specific embodiments described herein. Indeed, various modifications of the invention in addition to those described herein will become apparent to those skilled in the art from the foregoing description. Such modifications are intended to fall within the scope of the appended claims.

10

WHAT IS CLAIMED IS:

1.   A pharmaceutically acceptable DNA vaccine composition, which comprises:

    (a)   a DNA expression vector; and,

    (b)   a DNA molecule containing a codon optimized open reading frame encoding a Pol protein or inactivated Pol derivative thereof,

wherein upon administration of the DNA vaccine to a host the Pol protein or inactivated Pol derivative is expressed and generates a cellular immune response against HIV-1 infection.

2.   The DNA vaccine of claim 1 wherein the DNA molecule encodes wild type Pol.

3.   The DNA vaccine of claim 2 wherein the DNA molecule comprises the nucleotide sequence as set forth in SEQ ID NO:1.

4.   The DNA vaccine of claim 3 which is V1Jns-wt-pol.

5.   The DNA vaccine of claim 1 wherein the DNA molecule encodes an inactivated Pol derivative which contains a nucleotide sequence encoding a human tissue plasminogen activator leader peptide.

6..   The DNA vaccine of claim 5 wherein the DNA molecule comprises the nucleotide sequence as set forth in SEQ ID NO:5

7.   The DNA vaccine of claim 6 which is V1Jns-tPA-wt-pol.

8.   The DNA vaccine of claim 1 wherein the inactivated Pol protein contains at least one amino acid modification within each region of the Pol protein responsible for reverse transcriptase activity, RNase H activity and integrase activity, such that the inactivated Pol protein shows no substantial reverse transcriptase activity, RNase H activity and integrase activity.

9.   The DNA vaccine of claim 8 wherein the DNA molecule comprises the nucleotide sequence as set forth in SEQ ID NO:3

10.   The DNA vaccine of claim 9 which is VlJns-IAPol.

5

11.   The DNA vaccine of claim 8 wherein the DNA molecule encodes an inactivated Pol derivative which contains a nucleotide sequence encoding a human tissue plasminogen activator leader peptide.

10   12.   The DNA vaccine of claim 11 wherein the DNA molecule comprises the nucleotide sequence as set forth in SEQ ID NO:7.

13.   The DNA vaccine of claim 7 which is VlJns-tPA-IAPol.

15   14.   A method for inducing an immune response against infection or disease caused by virulent strains of HIV which comprises administering into the tissue of a mammalian host a pharmaceutically acceptable DNA vaccine composition which comprises a DNA expression vector and a DNA molecule containing a codon optimized open reading frame encoding a Pol protein or inactivated Pol derivative

20   thereof, wherein upon administration of the DNA vaccine to the vertebrate host the Pol protein or inactivated Pol derivative is expressed and generates the immune response.

15.   The method of claim 16 wherein the mammalian host is a human.

25

16.   The method of claim 17 wherein the DNA vaccine is selected from the group consisting of VlJns-WTPol, VlJns-tPA-WTPol, VlJns-IAPol and VlJns-tPA-IAPol.

30   17.   A substantially purified protein which comprises an amino acid sequence selected from the group consisting of SEQ ID NO:4, SEQ ID NO:6, and SEQ ID NO:8.

FIG.1A

FIG.1B

AGATCTACCATGGCCCCCATCTCCCCCATTGAGACTGTGCCTGTGAAGCTGAAGCCTGGCATGGATGGCCCCAAGGTGAA
Bg/II   MetAlaProIleSerProIleGluThrValProValLysLeuLysProGlyMetAspGlyProLysValLy
       1   10   20

GCAGTGGCCCCTGACTGAGGAGAAGATCAAGGCCCTGGTGGAAATCTGCACTGAGATGGAGAAGGAGGGCAAAATCTCCA
sGlnTrpProLeuThrGluGluLysIleLysAlaLeuValGluIleCysThrGluMetGluLysGluGlyLysIleSerL
                  30   40   50

AGATTGGCCCCGAGAACCCCTACAACACCCCTGTGTTTGCCATCAAGAAGAAGGACTCCACCAAGTGGAGGAAGCTGGTG
ysIleGlyProGluAsnProTyrAsnThrProValPheAlaIleLysLysLysAspSerThrLysTrpArgLysLeuVal
                          60   70

GACTTCAGGGAGCTGAACAAGAGGACCCAGGACTTCTGGGAGGTGCAGCTGGGCATCCCCCACCCCGCTGGCCTGAAGAA
AspPheArgGluLeuAsnLysArgThrGlnAspPheTrpGluValGlnLeuGlyIleProHisProAlaGlyLeuLysLy
           80   90   100

GAAGAAGTCTGTGACTGTGCTGGCTGTGGGGGATGCCTACTTCTCTGTGCCCCTGGATGAGGACTTCAGGAAGTACACTG
sLysLysSerValThrValLeuAlaValGlyAspAlaTyrPheSerValProLeuAspGluAspPheArgLysTyrThrA
                  110   120   130

CCTTCACCATCCCCTCCATCAACAATGAGACCCCTGGCATCAGGTACCAGTACAATGTGCTGCCCCAGGGCTGGAAGGGC
laPheThrIleProSerIleAsnAsnGluThrProGlyIleArgTyrGlnTyrAsnValLeuProGlnGlyTrpLysGly
                          140   150

TCCCCTGCCATCTTCCAGTCCTCCATGACCAAGATCCTGGAGCCCTTCAGGAAGCAGAACCCTGACATTGTGATCTACCA
SerProAlaIlePheGlnSerSerMetThrLysIleLeuGluProPheArgLysGlnAsnProAspIleValIleTyrGl
           160   170   180

GTACATGGCTGCCCTGTATGTGGGCTCTGACCTGGAGATTGGGCAGCACAGGACCAAGATTGAGGAGCTGAGGCAGCACC
nTyrMetAlaAlaLeuTyrValGlySerAspLeuGluIleGlyGlnHisArgThrLysIleGluGluLeuArgGlnHisL
                  190   200   210

TGCTGAGGTGGGGGCCTGACCACCCCTGACAAGAAGCACCAGAAGGAGCCCCCCTTCCTGTGGATGGGCTATGAGCTGCAC
euLeuArgTrpGlyLeuThrThrProAspLysLysHisGlnLysGluProProPheLeuTrpMetGlyTyrGluLeuHis
                          220   230

CCCGACAAGTGGACTGTGCAGCCCATTGTGCTGCCCTGAGAAGGACTCCTGGACTGTGAATGACATCCAGAAGCTGGTGGG
ProAspLysTrpThrValGlnProIleValLeuProGluLysAspSerTrpThrValAsnAspIleGlnLysLeuValGl
           240   250   260

CAAGCTGAACTGGGCCTCCCAAATCTACCCTGGCATCAAGGTGAGGCAGCTGTGCAAGCTGCTGAGGGGCACCAAGGCCC
yLysLeuAsnTrpAlaSerGlnIleTyrProGlyIleLysValArgGlnLeuCysLysLeuLeuArgGlyThrLysAlaL
                  270   280   290

FIG.2A

SUBSTITUTE SHEET (RULE 26)

TGACTGAGGTGATCCCCCTGACTGAGGAGGCTGAGCTGGAGCTGGCTGAGAACAGGGAGATCCTGAAGGAGCCTGTGCAT
EuThrGluVal I leProLeuThrGluGl uAl aGl uLeuGl uLeuAl aGl uAsnArgGl ul I eLeuLysGl uProVal His
300   310

GGGGTGTACTATGACCCCTCCAAGGACCTGATTGCTGAGATCCAGAAGCAGGGCCAGGGCCAGTGGACCTACCAAATCTA
Gl yVal TyrTyrAspProSerLysAspLeu I l eAl aGl ul I eGl nLysGl nGl yGl nGl yGl nTrpThrTyrGl nl I eTy
320   330   340

CCAGGAGCCCTTCAAGAACCTGAAGACTGGCAAGTATGCCAGGATGAGGGGGGCCCACACCAATGATGTGAAGCAGCTGA
rGl nGl uProPheLysAsnLeuLysThrGl yLysTyrAl aArgMetArgGl yAl aHi sThrAsnAspVal LysGl nLeuT
350   360   370

CTGAGGCTGTGCAGAAGATCACCACTGAGTCCATTGTGATCTGGGGCAAGACCCCCAAGTTCAAGCTGCCCATCCAGAAG
hrGl uAl aVal Gl nLys I l eThrThrGl uSer I l eVal I l eTrpGl yLysThrProLysPheLysLeuPro I l eGl nLys
380   390

GAGACCTGGGAGACCTGGTGGACTGAGTACTGGCAGGCCACCTGGATCCCTGAGTGGGAGTTTGTGAACACCCCCCCCCT
Gl uThrTrpGl uThrTrpTrpThrGl uTyrTrpGl nAl aThrTrp I l eProGl uTrpGl uPheVal AsnThrProProLe
400   410   420

GGTGAAGCTGTGGTACCAGCTGGAGAAGGAGCCCATTGTGGGGGCTGAGACCTTCTATGTGGCTGGGGCTGCCAACAGGG
uVal LysLeuTrpTyrGl nLeuGl uLysGl uPro I l eVal Gl yAl aGl uThrPheTyrVal Al aGl yAl aAl aAsnArgG
430   440   450

AGACCAAGCTGGGCAAGGCTGGCTATGTGACCAACAGGGGCAGGCAGAAGGTGGTGACCCTGACTGACACCACCAACCAG
l uThrLysLeuGl yLysAl aGl yTyrVal ThrAsnArgGl yArgGl nLysVal Val ThrLeuThrAspThrThrAsnGl n
460   470

AAGACTGCCCTCCAGGCCATCTACCTGGCCCTCCAGGACTCTGGCCTGGAGGTGAACATTGTGACTGCCTCCCAGTATGC
LysThrAl aLeuGl nAl al I eTyrLeuAl aLeuGl nAspSerGl yLeuGl uVal Asn I l eVal ThrAl aSerGl nTyrAl
480   490   500

CCTGGGCATCATCCAGGCCCAGCCTGATCAGTCTGAGTCTGAGCTGGTGAACCAGATCATTGAGCAGCTGATCAAGAAGG
aLeuGl y I l e I l eGl nAl aGl nProAspGl nSerGl uSerGl uLeuVal AsnGl n I l e I l eGl uGl nLeu I l eLysLysG
510   520   530

AGAAGGTGTACCTGGCCTGGGTGCCTGCCCACAAGGGCATTGGGGGCAATGAGCAGGTGGACAAGCTGGTGTCTGCTGGC
l uLysVal TyrLeuAl aTrpVal ProAl aHi sLysGl y I l eGl yGl yAsnGl uGl nVal AspLysLeuVal SerAl aGl y
540   550

ATCAGGAAGGTGCTGTTCCTGGATGGCATTGACAAGGCCCAGGATGAGCATGAGAAGTACCACTCCAACTGGAGGGCTAT
I l eArgLysVal LeuPheLeuAspGl y I l eAspLysAl aGl nAspGl uHi sGl uLysTyrHi sSerAsnTrpArgAl aMe
560   570   580

FIG.2B

4/11

GGCCTCTGACTTCAACCTGCCCCCTGTGGTGGCTAAGGAGATTGTGGCCTCCTGTGACAAGTGCCAGCTGAAGGGGGAGG
tAlaSerAspPheAsnLeuProProValValAlaLysGluIleValAlaSerCysAspLysCysGlnLeuLysGlyGluA
      590   600   610

CCATGCATGGGCAGGTGGACTGCTCCCCTGGCATCTGGCAGCTGGCCTGCACCCACCTGGAGGGCAAGGTGATCCTGGTG
laMetHisGlyGlnValAspCysSerProGlyIleTrpGlnLeuAlaCysThrHisLeuGluGlyLysValIleLeuVal
       620   630

GCTGTGCATGTGGCCTCCGGCTACATTGAGGCTGAGGTGATCCCTGCTGAGACAGGCCAGGAGACTGCCTACTTCCTGCT
AlaValHisValAlaSerGlyTyrIleGluAlaGluValIleProAlaGluThrGlyGlnGluThrAlaTyrPheLeuLe
     640   650   660

GAAGCTGGCTGGCAGGTGGCCTGTGAAGACCATCCACACTGCCAATGGCTCCAACTTCACTGGGGGCCACAGTGAGGGCTG
uLysLeuAlaGlyArgTrpProValLysThrIleHisThrAlaAsnGlySerAsnPheThrGlyAlaThrValArgAlaA
      670   680   690

CCTGCTGGTGGGCTGGCATCAAGCAGGAGTTTGGCATCCCCTACAACCCCCAGTCCCAGGGGGTGGTGGCCTCCATGAAC
laCysTrpTrpAlaGlyIleLysGlnGluPheGlyIleProTyrAsnProGlnSerGlnGlyValValAlaSerMetAsn
       700   710

AAGGAGCTGAAGAAGATCATTGGGCAGGTGAGGGACCAGGCTGAGCACCTGAAGACAGCTGTGCAGATGGCTGTGTTCAT
LysGluLeuLysLysIleIleGlyGlnValArgAspGlnAlaGluHisLeuLysThrAlaValGlnMetAlaValPheI
     720   730   740

CCACAACTTCAAGAGGAAGGGGGGGCATCGGGGGCTACTCCGCTGGGGAGAGGATTGTGGACATCATTGCCACAGACATCC
eHisAsnPheLysArgLysGlyGlyIleGlyGlyTyrSerAlaGlyGluArgIleValAspIleIleAlaThrAspIleG
     750   760   770

AGACCAAGGAGCTCCAGAAGCAGATCACCAAGATCCAGAACTTCAGGGTGTACTACAGGGACTCCAGGAACCCCCTGTGG
lnThrLysGluLeuGlnLysGlnIleThrLysIleGlnAsnPheArgValTyrTyrArgAspSerArgAsnProLeuTrp
      780   790

AAGGGCCCTGCCAAGCTGCTGTGGAAGGGGGAGGGGGCTGTGGTGATCCAGGACAACTCTGACATCAAGGTGGTGCCCAG
LysGlyProAlaLysLeuLeuTrpLysGlyGluGlyAlaValValIleGlnAspAsnSerAspIleLysValValProAr
     800   810   820

GAGGAAGGCCAAGATCATCAGGGACTATGGCAAGCAGATGGCTGGGGATGACTGTGTGGCCTCCAGGCAGGATGAGGACT
gArgLysAlaLysIleIleArgAspTyrGlyLysGlnMetAlaGlyAspAspCysValAlaSerArgGlnAspGluAspx
     830   840   850

AAAGCCCCGGGCAGATCT (SEQ ID NO: 3)
Xx   *BglII*

FIG.2C

```
GATCACCACCATGGATGCAATGAAGAGAGAGGGCTCTGCTCTGTCTGCTGTGTGTGAGCAGTCTTCGTTTCGC
         MetAspAlaMetLysArgGlyLeuLeuCysCysValLeuLeuLeuCysGlyAlaValPheValSerP
         -25                                -20                       -10

CCAGCGAGATCTCCGCCCCCATCTCCCCATTGAGACTGTGCCTGTGAAGCTGAAGCTGGCATGGATGGC    (within SEQ ID NO: 7)
RoSerGluIleSerProIleGluThrValProValLysProValLysLeuLysProGlyMetAspGly       (within SEQ ID NO: 8)
   -1  2                               10                       20
```

FIG.3

FIG.4

FIG.5

FIG.6A

FIG.6B

FIG.6C

FIG.7A

FIG.7B

FIG.8

FIG.9

FIG.10

SEQUENCE LISTING

<110> Merck & Co., Inc.

<120> POLYNUCLEOTIDE VACCINES EXPRESSING CODON
OPTIMIZED HIV-1 POL AND MODIFIED HIV-1 POL

<130> 20608Y PCT

<160> 30

<170> FastSEQ for Windows Version 4.0

<210> 1
<211> 2577
<212> DNA
<213> Human Immunodeficiency Virus-1

<220>
<221> CDS
<222> (10)...(2562)

<400> 1

```
agatctacc atg gcc ccc atc tcc ccc att gag act gtg cct gtg aag ctg        51
          Met Ala Pro Ile Ser Pro Ile Glu Thr Val Pro Val Lys Leu
           1               5                   10

aag cct ggc atg gat ggc ccc aag gtg aag cag tgg ccc ctg act gag        99
Lys Pro Gly Met Asp Gly Pro Lys Val Lys Gln Trp Pro Leu Thr Glu
 15                  20                  25                  30

gag aag atc aag gcc ctg gtg gaa atc tgc act gag atg gag aag gag        147
Glu Lys Ile Lys Ala Leu Val Glu Ile Cys Thr Glu Met Glu Lys Glu
                 35                  40                  45

ggc aaa atc tcc aag att ggc ccc gag aac ccc tac aac acc cct gtg        195
Gly Lys Ile Ser Lys Ile Gly Pro Glu Asn Pro Tyr Asn Thr Pro Val
             50                  55                  60

ttt gcc atc aag aag aag gac tcc acc aag tgg agg aag ctg gtg gac        243
Phe Ala Ile Lys Lys Lys Asp Ser Thr Lys Trp Arg Lys Leu Val Asp
         65                  70                  75

ttc agg gag ctg aac aag agg acc cag gac ttc tgg gag gtg cag ctg        291
Phe Arg Glu Leu Asn Lys Arg Thr Gln Asp Phe Trp Glu Val Gln Leu
     80                  85                  90

ggc atc ccc cac ccc gct ggc ctg aag aag aag aag tct gtg act gtg        339
Gly Ile Pro His Pro Ala Gly Leu Lys Lys Lys Lys Ser Val Thr Val
 95                  100                 105                 110

ctg gat gtg ggg gat gcc tac ttc tct gtg ccc ctg gat gag gac ttc        387
Leu Asp Val Gly Asp Ala Tyr Phe Ser Val Pro Leu Asp Glu Asp Phe
                 115                 120                 125

agg aag tac act gcc ttc acc atc ccc tcc atc aac aat gag acc cct        435
Arg Lys Tyr Thr Ala Phe Thr Ile Pro Ser Ile Asn Asn Glu Thr Pro
             130                 135                 140
```

```
ggc atc agg tac cag tac aat gtg ctg ccc cag ggc tgg aag ggc tcc         483
Gly Ile Arg Tyr Gln Tyr Asn Val Leu Pro Gln Gly Trp Lys Gly Ser
        145              150                  155

cct gcc atc ttc cag tcc tcc atg acc aag atc ctg gag ccc ttc agg         531
Pro Ala Ile Phe Gln Ser Ser Met Thr Lys Ile Leu Glu Pro Phe Arg
    160              165                  170

aag cag aac cct gac att gtg atc tac cag tac atg gat gac ctg tat         579
Lys Gln Asn Pro Asp Ile Val Ile Tyr Gln Tyr Met Asp Asp Leu Tyr
175              180                  185                  190

gtg ggc tct gac ctg gag att ggg cag cac agg acc aag att gag gag         627
Val Gly Ser Asp Leu Glu Ile Gly Gln His Arg Thr Lys Ile Glu Glu
                195                  200                  205

ctg agg cag cac ctg ctg agg tgg ggc ctg acc acc cct gac aag aag         675
Leu Arg Gln His Leu Leu Arg Trp Gly Leu Thr Thr Pro Asp Lys Lys
            210                  215                  220

cac cag aag gag ccc ccc ttc ctg tgg atg ggc tat gag ctg cac ccc         723
His Gln Lys Glu Pro Pro Phe Leu Trp Met Gly Tyr Glu Leu His Pro
            225                  230                  235

gac aag tgg act gtg cag ccc att gtg ctg cct gag aag gac tcc tgg         771
Asp Lys Trp Thr Val Gln Pro Ile Val Leu Pro Glu Lys Asp Ser Trp
    240                  245                  250

act gtg aat gac atc cag aag ctg gtg ggc aag ctg aac tgg gcc tcc         819
Thr Val Asn Asp Ile Gln Lys Leu Val Gly Lys Leu Asn Trp Ala Ser
255                  260                  265                  270

caa atc tac cct ggc atc aag gtg agg cag ctg tgc aag ctg ctg agg         867
Gln Ile Tyr Pro Gly Ile Lys Val Arg Gln Leu Cys Lys Leu Leu Arg
                275                  280                  285

ggc acc aag gcc ctg act gag gtg atc ccc ctg act gag gag gct gag         915
Gly Thr Lys Ala Leu Thr Glu Val Ile Pro Leu Thr Glu Glu Ala Glu
            290                  295                  300

ctg gag ctg gct gag aac agg gag atc ctg aag gag cct gtg cat ggg         963
Leu Glu Leu Ala Glu Asn Arg Glu Ile Leu Lys Glu Pro Val His Gly
            305                  310                  315

gtg tac tat gac ccc tcc aag gac ctg att gct gag atc cag aag cag        1011
Val Tyr Tyr Asp Pro Ser Lys Asp Leu Ile Ala Glu Ile Gln Lys Gln
    320                  325                  330

ggc cag ggc cag tgg acc tac caa atc tac cag gag ccc ttc aag aac        1059
Gly Gln Gly Gln Trp Thr Tyr Gln Ile Tyr Gln Glu Pro Phe Lys Asn
335                  340                  345                  350

ctg aag act ggc aag tat gcc agg atg agg ggg gcc cac acc aat gat        1107
Leu Lys Thr Gly Lys Tyr Ala Arg Met Arg Gly Ala His Thr Asn Asp
                355                  360                  365

gtg aag cag ctg act gag gct gtg cag aag atc acc act gag tcc att        1155
Val Lys Gln Leu Thr Glu Ala Val Gln Lys Ile Thr Thr Glu Ser Ile
                370                  375                  380
```

```
gtg atc tgg ggc aag acc ccc aag ttc aag ctg ccc atc cag aag gag      1203
Val Ile Trp Gly Lys Thr Pro Lys Phe Lys Leu Pro Ile Gln Lys Glu
        385             390             395

acc tgg gag acc tgg tgg act gag tac tgg cag gcc acc tgg atc cct      1251
Thr Trp Glu Thr Trp Trp Thr Glu Tyr Trp Gln Ala Thr Trp Ile Pro
        400             405             410

gag tgg gag ttt gtg aac acc ccc ccc ctg gtg aag ctg tgg tac cag      1299
Glu Trp Glu Phe Val Asn Thr Pro Pro Leu Val Lys Leu Trp Tyr Gln
415             420             425             430

ctg gag aag gag ccc att gtg ggg gct gag acc ttc tat gtg gat ggg      1347
Leu Glu Lys Glu Pro Ile Val Gly Ala Glu Thr Phe Tyr Val Asp Gly
                435             440             445

gct gcc aac agg gag acc aag ctg ggc aag gct ggc tat gtg acc aac      1395
Ala Ala Asn Arg Glu Thr Lys Leu Gly Lys Ala Gly Tyr Val Thr Asn
            450             455             460

agg ggc agg cag aag gtg gtg acc ctg act gac acc acc aac cag aag      1443
Arg Gly Arg Gln Lys Val Val Thr Leu Thr Asp Thr Thr Asn Gln Lys
        465             470             475

act gag ctc cag gcc atc tac ctg gcc ctc cag gac tct ggc ctg gag      1491
Thr Glu Leu Gln Ala Ile Tyr Leu Ala Leu Gln Asp Ser Gly Leu Glu
        480             485             490

gtg aac att gtg act gac tcc cag tat gcc ctg ggc atc atc cag gcc      1539
Val Asn Ile Val Thr Asp Ser Gln Tyr Ala Leu Gly Ile Ile Gln Ala
495             500             505             510

cag cct gat cag tct gag tct gag ctg gtg aac cag atc att gag cag      1587
Gln Pro Asp Gln Ser Glu Ser Glu Leu Val Asn Gln Ile Ile Glu Gln
                515             520             525

ctg atc aag aag gag aag gtg tac ctg gcc tgg gtg cct gcc cac aag      1635
Leu Ile Lys Lys Glu Lys Val Tyr Leu Ala Trp Val Pro Ala His Lys
            530             535             540

ggc att ggg ggc aat gag cag gtg gac aag ctg gtg tct gct ggc atc      1683
Gly Ile Gly Gly Asn Glu Gln Val Asp Lys Leu Val Ser Ala Gly Ile
        545             550             555

agg aag gtg ctg ttc ctg gat ggc att gac aag gcc cag gat gag cat      1731
Arg Lys Val Leu Phe Leu Asp Gly Ile Asp Lys Ala Gln Asp Glu His
        560             565             570

gag aag tac cac tcc aac tgg agg gct atg gcc tct gac ttc aac ctg      1779
Glu Lys Tyr His Ser Asn Trp Arg Ala Met Ala Ser Asp Phe Asn Leu
575             580             585             590

ccc cct gtg gtg gct aag gag att gtg gcc tcc tgt gac aag tgc cag      1827
Pro Pro Val Val Ala Lys Glu Ile Val Ala Ser Cys Asp Lys Cys Gln
                595             600             605

ctg aag ggg gag gcc atg cat ggg cag gtg gac tgc tcc cct ggc atc      1875
Leu Lys Gly Glu Ala Met His Gly Gln Val Asp Cys Ser Pro Gly Ile
            610             615             620
```

```
tgg cag ctg gac tgc acc cac ctg gag ggc aag gtg atc ctg gtg gct      1923
Trp Gln Leu Asp Cys Thr His Leu Glu Gly Lys Val Ile Leu Val Ala
        625             630                 635

gtg cat gtg gcc tcc ggc tac att gag gct gag gtg atc cct gct gag      1971
Val His Val Ala Ser Gly Tyr Ile Glu Ala Glu Val Ile Pro Ala Glu
        640             645                 650

aca ggc cag gag act gcc tac ttc ctg ctg aag ctg gct ggc agg tgg      2019
Thr Gly Gln Glu Thr Ala Tyr Phe Leu Leu Lys Leu Ala Gly Arg Trp
655             660             665                 670

cct gtg aag acc atc cac act gac aat ggc tcc aac ttc act ggg gcc      2067
Pro Val Lys Thr Ile His Thr Asp Asn Gly Ser Asn Phe Thr Gly Ala
                675             680             685

aca gtg agg gct gcc tgc tgg tgg gct ggc atc aag cag gag ttt ggc      2115
Thr Val Arg Ala Ala Cys Trp Trp Ala Gly Ile Lys Gln Glu Phe Gly
            690             695             700

atc ccc tac aac ccc cag tcc cag ggg gtg gtg gag tcc atg aac aag      2163
Ile Pro Tyr Asn Pro Gln Ser Gln Gly Val Val Glu Ser Met Asn Lys
            705             710             715

gag ctg aag aag atc att ggg cag gtg agg gac cag gct gag cac ctg      2211
Glu Leu Lys Lys Ile Ile Gly Gln Val Arg Asp Gln Ala Glu His Leu
        720             725             730

aag aca gct gtg cag atg gct gtg ttc atc cac aac ttc aag agg aag      2259
Lys Thr Ala Val Gln Met Ala Val Phe Ile His Asn Phe Lys Arg Lys
735             740             745                 750

ggg ggc atc ggg ggc tac tcc gct ggg gag agg att gtg gac atc att      2307
Gly Gly Ile Gly Gly Tyr Ser Ala Gly Glu Arg Ile Val Asp Ile Ile
                755             760             765

gcc aca gac atc cag acc aag gag ctc cag aag cag atc acc aag atc      2355
Ala Thr Asp Ile Gln Thr Lys Glu Leu Gln Lys Gln Ile Thr Lys Ile
            770             775             780

cag aac ttc agg gtg tac tac agg gac tcc agg aac ccc ctg tgg aag      2403
Gln Asn Phe Arg Val Tyr Tyr Arg Asp Ser Arg Asn Pro Leu Trp Lys
            785             790             795

ggc cct gcc aag ctg ctg tgg aag ggg gag ggg gct gtg gtg atc cag      2451
Gly Pro Ala Lys Leu Leu Trp Lys Gly Glu Gly Ala Val Val Ile Gln
        800             805             810

gac aac tct gac atc aag gtg gtg ccc agg agg aag gcc aag atc atc      2499
Asp Asn Ser Asp Ile Lys Val Val Pro Arg Arg Lys Ala Lys Ile Ile
815             820             825                 830

agg gac tat ggc aag cag atg gct ggg gat gac tgt gtg gcc tcc agg      2547
Arg Asp Tyr Gly Lys Gln Met Ala Gly Asp Asp Cys Val Ala Ser Arg
                835             840             845

cag gat gag gac taa agcccgggca gatct                                 2577
Gln Asp Glu Asp *
            850
```

<210> 2

-4-

```
<211> 850
<212> PRT
<213> Human Immunodeficiency Virus-1

<400> 2
Met Ala Pro Ile Ser Pro Ile Glu Thr Val Pro Val Lys Leu Lys Pro
 1               5                  10                  15
Gly Met Asp Gly Pro Lys Val Lys Gln Trp Pro Leu Thr Glu Glu Lys
            20                  25                  30
Ile Lys Ala Leu Val Glu Ile Cys Thr Glu Met Glu Lys Glu Gly Lys
        35                  40                  45
Ile Ser Lys Ile Gly Pro Glu Asn Pro Tyr Asn Thr Pro Val Phe Ala
    50                  55                  60
Ile Lys Lys Lys Asp Ser Thr Lys Trp Arg Lys Leu Val Asp Phe Arg
65                  70·                  75                  80
Glu Leu Asn Lys Arg Thr Gln Asp Phe Trp Glu Val Gln Leu Gly Ile
                85                  90                  95
Pro His Pro Ala Gly Leu Lys Lys Lys Ser Val Thr Val Leu Asp
            100                 105                 110
Val Gly Asp Ala Tyr Phe Ser Val Pro Leu Asp Glu Asp Phe Arg Lys
        115                 120                 125
Tyr Thr Ala Phe Thr Ile Pro Ser Ile Asn Asn Glu Thr Pro Gly Ile
    130                 135                 140
Arg Tyr Gln Tyr Asn Val Leu Pro Gln Gly Trp Lys Gly Ser Pro Ala
145                 150                 155                 160
Ile Phe Gln Ser Ser Met Thr Lys Ile Leu Glu Pro Phe Arg Lys Gln
                165                 170                 175
Asn Pro Asp Ile Val Ile Tyr Gln Tyr Met Asp Asp Leu Tyr Val Gly
            180                 185                 190
Ser Asp Leu Glu Ile Gly Gln His Arg Thr Lys Ile Glu Glu Leu Arg
        195                 200                 205
Gln His Leu Leu Arg Trp Gly Leu Thr Thr Pro Asp Lys Lys His Gln
    210                 215                 220
Lys Glu Pro Pro Phe Leu Trp Met Gly Tyr Glu Leu His Pro Asp Lys
225                 230                 235                 240
Trp Thr Val Gln Pro Ile Val Leu Pro Glu Lys Asp Ser Trp Thr Val
                245                 250                 255
Asn Asp Ile Gln Lys Leu Val Gly Lys Leu Asn Trp Ala Ser Gln Ile
            260                 265                 270
Tyr Pro Gly Ile Lys Val Arg Gln Leu Cys Lys Leu Leu Arg Gly Thr
        275                 280                 285
Lys Ala Leu Thr Glu Val Ile Pro Leu Thr Glu Glu Ala Glu Leu Glu
    290                 295                 300
Leu Ala Glu Asn Arg Glu Ile Leu Lys Glu Pro Val His Gly Val Tyr
305                 310                 315                 320
Tyr Asp Pro Ser Lys Asp Leu Ile Ala Glu Ile Gln Lys Gln Gly Gln
                325                 330                 335
Gly Gln Trp Thr Tyr Gln Ile Tyr Gln Glu Pro Phe Lys Asn Leu Lys
            340                 345                 350
Thr Gly Lys Tyr Ala Arg Met Arg Gly Ala His Thr Asn Asp Val Lys
        355                 360                 365
Gln Leu Thr Glu Ala Val Gln Lys Ile Thr Thr Glu Ser Ile Val Ile
    370                 375                 380
Trp Gly Lys Thr Pro Lys Phe Lys Leu Pro Ile Gln Lys Glu Thr Trp
385                 390                 395                 400
Glu Thr Trp Trp Thr Glu Tyr Trp Gln Ala Thr Trp Ile Pro Glu Trp
                405                 410                 415
Glu Phe Val Asn Thr Pro Pro Leu Val Lys Leu Trp Tyr Gln Leu Glu
            420                 425                 430
Lys Glu Pro Ile Val Gly Ala Glu Thr Phe Tyr Val Asp Gly Ala Ala
            435                 440                 445
```

```
Asn Arg Glu Thr Lys Leu Gly Lys Ala Gly Tyr Val Thr Asn Arg Gly
    450                 455                 460
Arg Gln Lys Val Val Thr Leu Thr Asp Thr Thr Asn Gln Lys Thr Glu
465                 470                 475                 480
Leu Gln Ala Ile Tyr Leu Ala Leu Gln Asp Ser Gly Leu Glu Val Asn
                485                 490                 495
Ile Val Thr Asp Ser Gln Tyr Ala Leu Gly Ile Ile Gln Ala Gln Pro
                500                 505                 510
Asp Gln Ser Glu Ser Glu Leu Val Asn Gln Ile Ile Glu Gln Leu Ile
            515                 520                 525
Lys Lys Glu Lys Val Tyr Leu Ala Trp Val Pro Ala His Lys Gly Ile
        530                 535                 540
Gly Gly Asn Glu Gln Val Asp Lys Leu Val Ser Ala Gly Ile Arg Lys
545                 550                 555                 560
Val Leu Phe Leu Asp Gly Ile Asp Lys Ala Gln Asp Glu His Glu Lys
                565                 570                 575
Tyr His Ser Asn Trp Arg Ala Met Ala Ser Asp Phe Asn Leu Pro Pro
            580                 585                 590
Val Val Ala Lys Glu Ile Val Ala Ser Cys Asp Lys Cys Gln Leu Lys
            595                 600                 605
Gly Glu Ala Met His Gly Gln Val Asp Cys Ser Pro Gly Ile Trp Gln
    610                 615                 620
Leu Asp Cys Thr His Leu Glu Gly Lys Val Ile Leu Val Ala Val His
625                 630                 635                 640
Val Ala Ser Gly Tyr Ile Glu Ala Glu Val Ile Pro Ala Glu Thr Gly
                645                 650                 655
Gln Glu Thr Ala Tyr Phe Leu Leu Lys Leu Ala Gly Arg Trp Pro Val
            660                 665                 670
Lys Thr Ile His Thr Asp Asn Gly Ser Asn Phe Thr Gly Ala Thr Val
        675                 680                 685
Arg Ala Ala Cys Trp Trp Ala Gly Ile Lys Gln Glu Phe Gly Ile Pro
    690                 695                 700
Tyr Asn Pro Gln Ser Gln Gly Val Val Glu Ser Met Asn Lys Glu Leu
705                 710                 715                 720
Lys Lys Ile Ile Gly Gln Val Arg Asp Gln Ala Glu His Leu Lys Thr
                725                 730                 735
Ala Val Gln Met Ala Val Phe Ile His Asn Phe Lys Arg Lys Gly Gly
            740                 745                 750
Ile Gly Gly Tyr Ser Ala Gly Glu Arg Ile Val Asp Ile Ile Ala Thr
        755                 760                 765
Asp Ile Gln Thr Lys Glu Leu Gln Lys Gln Ile Thr Lys Ile Gln Asn
    770                 775                 780
Phe Arg Val Tyr Tyr Arg Asp Ser Arg Asn Pro Leu Trp Lys Gly Pro
785                 790                 795                 800
Ala Lys Leu Leu Trp Lys Gly Glu Gly Ala Val Val Ile Gln Asp Asn
                805                 810                 815
Ser Asp Ile Lys Val Val Pro Arg Arg Lys Ala Lys Ile Ile Arg Asp
            820                 825                 830
Tyr Gly Lys Gln Met Ala Gly Asp Asp Cys Val Ala Ser Arg Gln Asp
        835                 840                 845
Glu Asp
    850
```

```
<210> 3
<211> 2577
<212> DNA
<213> Human Immunodeficiency Virus-1

<220>
<221> CDS
<222> (10)...(2562)
```

```
<400> 3
agatctacc atg gcc ccc atc tcc ccc att gag act gtg cct gtg aag ctg      51
          Met Ala Pro Ile Ser Pro Ile Glu Thr Val Pro Val Lys Leu
          1           5                   10

aag cct ggc atg gat ggc ccc aag gtg aag cag tgg ccc ctg act gag        99
Lys Pro Gly Met Asp Gly Pro Lys Val Lys Gln Trp Pro Leu Thr Glu
15                  20                  25                  30

gag aag atc aag gcc ctg gtg gaa atc tgc act gag atg gag aag gag       147
Glu Lys Ile Lys Ala Leu Val Glu Ile Cys Thr Glu Met Glu Lys Glu
                35                  40                  45

ggc aaa atc tcc aag att ggc ccc gag aac ccc tac aac acc cct gtg       195
Gly Lys Ile Ser Lys Ile Gly Pro Glu Asn Pro Tyr Asn Thr Pro Val
            50                  55                  60

ttt gcc atc aag aag aag gac tcc acc aag tgg agg aag ctg gtg gac       243
Phe Ala Ile Lys Lys Lys Asp Ser Thr Lys Trp Arg Lys Leu Val Asp
        65                  70                  75

ttc agg gag ctg aac aag agg acc cag gac ttc tgg gag gtg cag ctg       291
Phe Arg Glu Leu Asn Lys Arg Thr Gln Asp Phe Trp Glu Val Gln Leu
    80                  85                  90

ggc atc ccc cac ccc gct ggc ctg aag aag aag aag tct gtg act gtg       339
Gly Ile Pro His Pro Ala Gly Leu Lys Lys Lys Lys Ser Val Thr Val
95                  100                 105                 110

ctg gct gtg ggg gat gcc tac ttc tct gtg ccc ctg gat gag gac ttc       387
Leu Ala Val Gly Asp Ala Tyr Phe Ser Val Pro Leu Asp Glu Asp Phe
                115                 120                 125

agg aag tac act gcc ttc acc atc ccc tcc atc aac aat gag acc cct       435
Arg Lys Tyr Thr Ala Phe Thr Ile Pro Ser Ile Asn Asn Glu Thr Pro
            130                 135                 140

ggc atc agg tac cag tac aat gtg ctg ccc cag ggc tgg aag ggc tcc       483
Gly Ile Arg Tyr Gln Tyr Asn Val Leu Pro Gln Gly Trp Lys Gly Ser
        145                 150                 155

cct gcc atc ttc cag tcc tcc atg acc aag atc ctg gag ccc ttc agg       531
Pro Ala Ile Phe Gln Ser Ser Met Thr Lys Ile Leu Glu Pro Phe Arg
    160                 165                 170

aag cag aac cct gac att gtg atc tac cag tac atg gct gcc ctg tat       579
Lys Gln Asn Pro Asp Ile Val Ile Tyr Gln Tyr Met Ala Ala Leu Tyr
175                 180                 185                 190

gtg ggc tct gac ctg gag att ggg cag cac agg acc aag att gag gag       627
Val Gly Ser Asp Leu Glu Ile Gly Gln His Arg Thr Lys Ile Glu Glu
                195                 200                 205

ctg agg cag cac ctg ctg agg tgg ggc ctg acc acc cct gac aag aag       675
Leu Arg Gln His Leu Leu Arg Trp Gly Leu Thr Thr Pro Asp Lys Lys
            210                 215                 220

cac cag aag gag ccc ccc ttc ctg tgg atg ggc tat gag ctg cac ccc       723
His Gln Lys Glu Pro Pro Phe Leu Trp Met Gly Tyr Glu Leu His Pro
        225                 230                 235
```

```
gac aag tgg act gtg cag ccc att gtg ctg cct gag aag gac tcc tgg      771
Asp Lys Trp Thr Val Gln Pro Ile Val Leu Pro Glu Lys Asp Ser Trp
    240             245             250

act gtg aat gac atc cag aag ctg gtg ggc aag ctg aac tgg gcc tcc      819
Thr Val Asn Asp Ile Gln Lys Leu Val Gly Lys Leu Asn Trp Ala Ser
255             260             265             270

caa atc tac cct ggc atc aag gtg agg cag ctg tgc aag ctg ctg agg      867
Gln Ile Tyr Pro Gly Ile Lys Val Arg Gln Leu Cys Lys Leu Leu Arg
            275             280             285

ggc acc aag gcc ctg act gag gtg atc ccc ctg act gag gag gct gag      915
Gly Thr Lys Ala Leu Thr Glu Val Ile Pro Leu Thr Glu Glu Ala Glu
        290             295             300

ctg gag ctg gct gag aac agg gag atc ctg aag gag cct gtg cat ggg      963
Leu Glu Leu Ala Glu Asn Arg Glu Ile Leu Lys Glu Pro Val His Gly
    305             310             315

gtg tac tat gac ccc tcc aag gac ctg att gct gag atc cag aag cag      1011
Val Tyr Tyr Asp Pro Ser Lys Asp Leu Ile Ala Glu Ile Gln Lys Gln
    320             325             330

ggc cag ggc cag tgg acc tac caa atc tac cag gag ccc ttc aag aac      1059
Gly Gln Gly Gln Trp Thr Tyr Gln Ile Tyr Gln Glu Pro Phe Lys Asn
335             340             345             350

ctg aag act ggc aag tat gcc agg atg agg ggg gcc cac acc aat gat      1107
Leu Lys Thr Gly Lys Tyr Ala Arg Met Arg Gly Ala His Thr Asn Asp
            355             360             365

gtg aag cag ctg act gag gct gtg cag aag atc acc act gag tcc att      1155
Val Lys Gln Leu Thr Glu Ala Val Gln Lys Ile Thr Thr Glu Ser Ile
        370             375             380

gtg atc tgg ggc aag acc ccc aag ttc aag ctg ccc atc cag aag gag      1203
Val Ile Trp Gly Lys Thr Pro Lys Phe Lys Leu Pro Ile Gln Lys Glu
        385             390             395

acc tgg gag acc tgg tgg act gag tac tgg cag gcc acc tgg atc cct      1251
Thr Trp Glu Thr Trp Trp Thr Glu Tyr Trp Gln Ala Thr Trp Ile Pro
    400             405             410

gag tgg gag ttt gtg aac acc ccc ccc ctg gtg aag ctg tgg tac cag      1299
Glu Trp Glu Phe Val Asn Thr Pro Pro Leu Val Lys Leu Trp Tyr Gln
415             420             425             430

ctg gag aag gag ccc att gtg ggg gct gag acc ttc tat gtg gct ggg      1347
Leu Glu Lys Glu Pro Ile Val Gly Ala Glu Thr Phe Tyr Val Ala Gly
            435             440             445

gct gcc aac agg gag acc aag ctg ggc aag gct ggc tat gtg acc aac      1395
Ala Ala Asn Arg Glu Thr Lys Leu Gly Lys Ala Gly Tyr Val Thr Asn
        450             455             460

agg ggc agg cag aag gtg gtg acc ctg act gac acc acc aac cag aag      1443
Arg Gly Arg Gln Lys Val Val Thr Leu Thr Asp Thr Thr Asn Gln Lys
465             470             475
```

```
act gcc ctc cag gcc atc tac ctg gcc ctc cag gac tct ggc ctg gag    1491
Thr Ala Leu Gln Ala Ile Tyr Leu Ala Leu Gln Asp Ser Gly Leu Glu
    480             485             490

gtg aac att gtg act gcc tcc cag tat gcc ctg ggc atc atc cag gcc    1539
Val Asn Ile Val Thr Ala Ser Gln Tyr Ala Leu Gly Ile Ile Gln Ala
495             500             505             510

cag cct gat cag tct gag tct gag ctg gtg aac cag atc att gag cag    1587
Gln Pro Asp Gln Ser Glu Ser Glu Leu Val Asn Gln Ile Ile Glu Gln
            515             520             525

ctg atc aag aag gag aag gtg tac ctg gcc tgg gtg cct gcc cac aag    1635
Leu Ile Lys Lys Glu Lys Val Tyr Leu Ala Trp Val Pro Ala His Lys
            530             535             540

ggc att ggg ggc aat gag cag gtg gac aag ctg gtg tct gct ggc atc    1683
Gly Ile Gly Gly Asn Glu Gln Val Asp Lys Leu Val Ser Ala Gly Ile
            545             550             555

agg aag gtg ctg ttc ctg gat ggc att gac aag gcc cag gat gag cat    1731
Arg Lys Val Leu Phe Leu Asp Gly Ile Asp Lys Ala Gln Asp Glu His
            560             565             570

gag aag tac cac tcc aac tgg agg gct atg gcc tct gac ttc aac ctg    1779
Glu Lys Tyr His Ser Asn Trp Arg Ala Met Ala Ser Asp Phe Asn Leu
575             580             585             590

ccc cct gtg gtg gct aag gag att gtg gcc tcc tgt gac aag tgc cag    1827
Pro Pro Val Val Ala Lys Glu Ile Val Ala Ser Cys Asp Lys Cys Gln
            595             600             605

ctg aag ggg gag gcc atg cat ggg cag gtg gac tgc tcc cct ggc atc    1875
Leu Lys Gly Glu Ala Met His Gly Gln Val Asp Cys Ser Pro Gly Ile
            610             615             620

tgg cag ctg gcc tgc acc cac ctg gag ggc aag gtg atc ctg gtg gct    1923
Trp Gln Leu Ala Cys Thr His Leu Glu Gly Lys Val Ile Leu Val Ala
            625             630             635

gtg cat gtg gcc tcc ggc tac att gag gct gag gtg atc cct gct gag    1971
Val His Val Ala Ser Gly Tyr Ile Glu Ala Glu Val Ile Pro Ala Glu
            640             645             650

aca ggc cag gag act gcc tac ttc ctg ctg aag ctg gct ggc agg tgg    2019
Thr Gly Gln Glu Thr Ala Tyr Phe Leu Leu Lys Leu Ala Gly Arg Trp
655             660             665             670

cct gtg aag acc atc cac act gcc aat ggc tcc aac ttc act ggg gcc    2067
Pro Val Lys Thr Ile His Thr Ala Asn Gly Ser Asn Phe Thr Gly Ala
            675             680             685

aca gtg agg gct gcc tgc tgg tgg gct ggc atc aag cag gag ttt ggc    2115
Thr Val Arg Ala Ala Cys Trp Trp Ala Gly Ile Lys Gln Glu Phe Gly
            690             695             700

atc ccc tac aac ccc cag tcc cag ggg gtg gtg gcc tcc atg aac aag    2163
Ile Pro Tyr Asn Pro Gln Ser Gln Gly Val Val Ala Ser Met Asn Lys
            705             710             715
```

```
gag ctg aag aag atc att ggg cag gtg agg gac cag gct gag cac ctg        2211
Glu Leu Lys Lys Ile Ile Gly Gln Val Arg Asp Gln Ala Glu His Leu
    720             725             730

aag aca gct gtg cag atg gct gtg ttc atc cac aac ttc aag agg aag        2259
Lys Thr Ala Val Gln Met Ala Val Phe Ile His Asn Phe Lys Arg Lys
735             740             745             750

ggg ggc atc ggg ggc tac tcc gct ggg gag agg att gtg gac atc att        2307
Gly Gly Ile Gly Gly Tyr Ser Ala Gly Glu Arg Ile Val Asp Ile Ile
                755             760             765

gcc aca gac atc cag acc aag gag ctc cag aag cag atc acc aag atc        2355
Ala Thr Asp Ile Gln Thr Lys Glu Leu Gln Lys Gln Ile Thr Lys Ile
            770             775             780

cag aac ttc agg gtg tac tac agg gac tcc agg aac ccc ctg tgg aag        2403
Gln Asn Phe Arg Val Tyr Tyr Arg Asp Ser Arg Asn Pro Leu Trp Lys
            785             790             795

ggc cct gcc aag ctg ctg tgg aag ggg gag ggg gct gtg gtg atc cag        2451
Gly Pro Ala Lys Leu Leu Trp Lys Gly Glu Gly Ala Val Val Ile Gln
    800             805             810

gac aac tct gac atc aag gtg gtg ccc agg agg aag gcc aag atc atc        2499
Asp Asn Ser Asp Ile Lys Val Val Pro Arg Arg Lys Ala Lys Ile Ile
815             820             825             830

agg gac tat ggc aag cag atg gct ggg gat gac tgt gtg gcc tcc agg        2547
Arg Asp Tyr Gly Lys Gln Met Ala Gly Asp Asp Cys Val Ala Ser Arg
                835             840             845

cag gat gag gac taa agcccgggca gatct                                    2577
Gln Asp Glu Asp  *
                850
```

```
<210> 4
<211> 850
<212> PRT
<213> Human Immunodeficiency Virus-1

<400> 4
Met Ala Pro Ile Ser Pro Ile Glu Thr Val Pro Val Lys Leu Lys Pro
1               5               10              15
Gly Met Asp Gly Pro Lys Val Lys Gln Trp Pro Leu Thr Glu Glu Lys
            20              25              30
Ile Lys Ala Leu Val Glu Ile Cys Thr Glu Met Glu Lys Glu Gly Lys
        35              40              45
Ile Ser Lys Ile Gly Pro Glu Asn Pro Tyr Asn Thr Pro Val Phe Ala
    50              55              60
Ile Lys Lys Lys Asp Ser Thr Lys Trp Arg Lys Leu Val Asp Phe Arg
65              70              75              80
Glu Leu Asn Lys Arg Thr Gln Asp Phe Trp Glu Val Gln Leu Gly Ile
            85              90              95
Pro His Pro Ala Gly Leu Lys Lys Lys Ser Val Thr Val Leu Ala
        100             105             110
Val Gly Asp Ala Tyr Phe Ser Val Pro Leu Asp Glu Asp Phe Arg Lys
        115             120             125
Tyr Thr Ala Phe Thr Ile Pro Ser Ile Asn Asn Glu Thr Pro Gly Ile
        130             135             140
```

Arg Tyr Gln Tyr Asn Val Leu Pro Gln Gly Trp Lys Gly Ser Pro Ala
145   150   155   160
Ile Phe Gln Ser Ser Met Thr Lys Ile Leu Glu Pro Phe Arg Lys Gln
                165   170   175
Asn Pro Asp Ile Val Ile Tyr Gln Tyr Met Ala Ala Leu Tyr Val Gly
                180   185   190
Ser Asp Leu Glu Ile Gly Gln His Arg Thr Lys Ile Glu Glu Leu Arg
            195   200   205
Gln His Leu Leu Arg Trp Gly Leu Thr Thr Pro Asp Lys Lys His Gln
    210   215   220
Lys Glu Pro Pro Phe Leu Trp Met Gly Tyr Glu Leu His Pro Asp Lys
225   230   235   240
Trp Thr Val Gln Pro Ile Val Leu Pro Glu Lys Asp Ser Trp Thr Val
                245   250   255
Asn Asp Ile Gln Lys Leu Val Gly Lys Leu Asn Trp Ala Ser Gln Ile
                260   265   270
Tyr Pro Gly Ile Lys Val Arg Gln Leu Cys Lys Leu Leu Arg Gly Thr
            275   280   285
Lys Ala Leu Thr Glu Val Ile Pro Leu Thr Glu Glu Ala Glu Leu Glu
    290   295   300
Leu Ala Glu Asn Arg Glu Ile Leu Lys Glu Pro Val His Gly Val Tyr
305   310   315   320
Tyr Asp Pro Ser Lys Asp Leu Ile Ala Glu Ile Gln Lys Gln Gly Gln
                325   330   335
Gly Gln Trp Thr Tyr Gln Ile Tyr Gln Glu Pro Phe Lys Asn Leu Lys
            340   345   350
Thr Gly Lys Tyr Ala Arg Met Arg Gly Ala His Thr Asn Asp Val Lys
    355   360   365
Gln Leu Thr Glu Ala Val Gln Lys Ile Thr Thr Glu Ser Ile Val Ile
    370   375   380
Trp Gly Lys Thr Pro Lys Phe Lys Leu Pro Ile Gln Lys Glu Thr Trp
385   390   395   400
Glu Thr Trp Trp Thr Glu Tyr Trp Gln Ala Thr Trp Ile Pro Glu Trp
                405   410   415
Glu Phe Val Asn Thr Pro Pro Leu Val Lys Leu Trp Tyr Gln Leu Glu
                420   425   430
Lys Glu Pro Ile Val Gly Ala Glu Thr Phe Tyr Val Ala Gly Ala Ala
            435   440   445
Asn Arg Glu Thr Lys Leu Gly Lys Ala Gly Tyr Val Thr Asn Arg Gly
    450   455   460
Arg Gln Lys Val Val Thr Leu Thr Asp Thr Thr Asn Gln Lys Thr Ala
465   470   475   480
Leu Gln Ala Ile Tyr Leu Ala Leu Gln Asp Ser Gly Leu Glu Val Asn
                485   490   495
Ile Val Thr Ala Ser Gln Tyr Ala Leu Gly Ile Ile Gln Ala Gln Pro
                500   505   510
Asp Gln Ser Glu Ser Glu Leu Val Asn Gln Ile Ile Glu Gln Leu Ile
            515   520   525
Lys Lys Glu Lys Val Tyr Leu Ala Trp Val Pro Ala His Lys Gly Ile
    530   535   540
Gly Gly Asn Glu Gln Val Asp Lys Leu Val Ser Ala Gly Ile Arg Lys
545   550   555   560
Val Leu Phe Leu Asp Gly Ile Asp Lys Ala Gln Asp Glu His Glu Lys
                565   570   575
Tyr His Ser Asn Trp Arg Ala Met Ala Ser Asp Phe Asn Leu Pro Pro
            580   585   590
Val Val Ala Lys Glu Ile Val Ala Ser Cys Asp Lys Cys Gln Leu Lys
    595   600   605
Gly Glu Ala Met His Gly Gln Val Asp Cys Ser Pro Gly Ile Trp Gln
    610   615   620
Leu Ala Cys Thr His Leu Glu Gly Lys Val Ile Leu Val Ala Val His
625   630   635   640

-11-

```
Val Ala Ser Gly Tyr Ile Glu Ala Glu Val Ile Pro Ala Glu Thr Gly
              645                 650                 655
Gln Glu Thr Ala Tyr Phe Leu Leu Lys Leu Ala Gly Arg Trp Pro Val
              660                 665                 670
Lys Thr Ile His Thr Ala Asn Gly Ser Asn Phe Thr Gly Ala Thr Val
              675                 680                 685
Arg Ala Ala Cys Trp Trp Ala Gly Ile Lys Gln Glu Phe Gly Ile Pro
              690                 695                 700
Tyr Asn Pro Gln Ser Gln Gly Val Val Ala Ser Met Asn Lys Glu Leu
705                 710                 715                 720
Lys Lys Ile Ile Gly Gln Val Arg Asp Gln Ala Glu His Leu Lys Thr
              725                 730                 735
Ala Val Gln Met Ala Val Phe Ile His Asn Phe Lys Arg Lys Gly Gly
              740                 745                 750
Ile Gly Gly Tyr Ser Ala Gly Glu Arg Ile Val Asp Ile Ile Ala Thr
              755                 760                 765
Asp Ile Gln Thr Lys Glu Leu Gln Lys Gln Ile Thr Lys Ile Gln Asn
        770                 775                 780
Phe Arg Val Tyr Tyr Arg Asp Ser Arg Asn Pro Leu Trp Lys Gly Pro
785                 790                 795                 800
Ala Lys Leu Leu Trp Lys Gly Glu Gly Ala Val Val Ile Gln Asp Asn
              805                 810                 815
Ser Asp Ile Lys Val Val Pro Arg Arg Lys Ala Lys Ile Ile Arg Asp
              820                 825                 830
Tyr Gly Lys Gln Met Ala Gly Asp Asp Cys Val Ala Ser Arg Gln Asp
        835                 840                 845
Glu Asp
    850
```

```
<210> 5
<211> 2650
<212> DNA
<213> Human Immunodeficiency Virus-1

<220>
<221> CDS
<222> (8)...(2635)

<400> 5
gatcacc atg gat gca atg aag aga ggg ctc tgc tgt gtg ctg ctg ctg      49
        Met Asp Ala Met Lys Arg Gly Leu Cys Cys Val Leu Leu Leu
        1               5                   10

tgt gga gca gtc ttc gtt tcg ccc agc gag atc tcc gcc ccc atc tcc      97
Cys Gly Ala Val Phe Val Ser Pro Ser Glu Ile Ser Ala Pro Ile Ser
15                  20                  25                  30

ccc att gag act gtg cct gtg aag ctg aag cct ggc atg gat ggc ccc     145
Pro Ile Glu Thr Val Pro Val Lys Leu Lys Pro Gly Met Asp Gly Pro
                35                  40                  45

aag gtg aag cag tgg ccc ctg act gag gag aag atc aag gcc ctg gtg     193
Lys Val Lys Gln Trp Pro Leu Thr Glu Glu Lys Ile Lys Ala Leu Val
            50                  55                  60

gaa atc tgc act gag atg gag aag gag ggc aaa atc tcc aag att ggc     241
Glu Ile Cys Thr Glu Met Glu Lys Glu Gly Lys Ile Ser Lys Ile Gly
            65                  70                  75

ccc gag aac ccc tac aac acc cct gtg ttt gcc atc aag aag aag gac     289
Pro Glu Asn Pro Tyr Asn Thr Pro Val Phe Ala Ile Lys Lys Lys Asp
        80                  85                  90
```

```
tcc acc aag tgg agg aag ctg gtg gac ttc agg gag ctg aac aag agg     337
Ser Thr Lys Trp Arg Lys Leu Val Asp Phe Arg Glu Leu Asn Lys Arg
95                  100                 105                 110

acc cag gac ttc tgg gag gtg cag ctg ggc atc ccc cac ccc gct ggc     385
Thr Gln Asp Phe Trp Glu Val Gln Leu Gly Ile Pro His Pro Ala Gly
                115                 120                 125

ctg aag aag aag aag tct gtg act gtg ctg gat gtg ggg gat gcc tac     433
Leu Lys Lys Lys Lys Ser Val Thr Val Leu Asp Val Gly Asp Ala Tyr
            130                 135                 140

ttc tct gtg ccc ctg gat gag gac ttc agg aag tac act gcc ttc acc     481
Phe Ser Val Pro Leu Asp Glu Asp Phe Arg Lys Tyr Thr Ala Phe Thr
            145                 150                 155

atc ccc tcc atc aac aat gag acc cct ggc atc agg tac cag tac aat     529
Ile Pro Ser Ile Asn Asn Glu Thr Pro Gly Ile Arg Tyr Gln Tyr Asn
        160                 165                 170

gtg ctg ccc cag ggc tgg aag ggc tcc cct gcc atc ttc cag tcc tcc     577
Val Leu Pro Gln Gly Trp Lys Gly Ser Pro Ala Ile Phe Gln Ser Ser
175                 180                 185                 190

atg acc aag atc ctg gag ccc ttc agg aag cag aac cct gac att gtg     625
Met Thr Lys Ile Leu Glu Pro Phe Arg Lys Gln Asn Pro Asp Ile Val
                195                 200                 205

atc tac cag tac atg gat gac ctg tat gtg ggc tct gac ctg gag att     673
Ile Tyr Gln Tyr Met Asp Asp Leu Tyr Val Gly Ser Asp Leu Glu Ile
                210                 215                 220

ggg cag cac agg acc aag att gag gag ctg agg cag cac ctg ctg agg     721
Gly Gln His Arg Thr Lys Ile Glu Glu Leu Arg Gln His Leu Leu Arg
        225                 230                 235

tgg ggc ctg acc acc cct gac aag aag cac cag aag gag ccc ccc ttc     769
Trp Gly Leu Thr Thr Pro Asp Lys Lys His Gln Lys Glu Pro Pro Phe
    240                 245                 250

ctg tgg atg ggc tat gag ctg cac ccc gac aag tgg act gtg cag ccc     817
Leu Trp Met Gly Tyr Glu Leu His Pro Asp Lys Trp Thr Val Gln Pro
255                 260                 265                 270

att gtg ctg cct gag aag gac tcc tgg act gtg aat gac atc cag aag     865
Ile Val Leu Pro Glu Lys Asp Ser Trp Thr Val Asn Asp Ile Gln Lys
                275                 280                 285

ctg gtg ggc aag ctg aac tgg gcc tcc caa atc tac cct ggc atc aag     913
Leu Val Gly Lys Leu Asn Trp Ala Ser Gln Ile Tyr Pro Gly Ile Lys
            290                 295                 300

gtg agg cag ctg tgc aag ctg ctg agg ggc acc aag gcc ctg act gag     961
Val Arg Gln Leu Cys Lys Leu Leu Arg Gly Thr Lys Ala Leu Thr Glu
        305                 310                 315

gtg atc ccc ctg act gag gag gct gag ctg gag ctg gct gag aac agg     1009
Val Ile Pro Leu Thr Glu Glu Ala Glu Leu Glu Leu Ala Glu Asn Arg
        320                 325                 330
```

```
gag atc ctg aag gag cct gtg cat ggg gtg tac tat gac ccc tcc aag        1057
Glu Ile Leu Lys Glu Pro Val His Gly Val Tyr Tyr Asp Pro Ser Lys
335             340             345             350

gac ctg att gct gag atc cag aag cag ggc cag ggc cag tgg acc tac        1105
Asp Leu Ile Ala Glu Ile Gln Lys Gln Gly Gln Gly Gln Trp Thr Tyr
                355             360             365

caa atc tac cag gag ccc ttc aag aac ctg aag act ggc aag tat gcc        1153
Gln Ile Tyr Gln Glu Pro Phe Lys Asn Leu Lys Thr Gly Lys Tyr Ala
            370             375             380

agg atg agg ggg gcc cac acc aat gat gtg aag cag ctg act gag gct        1201
Arg Met Arg Gly Ala His Thr Asn Asp Val Lys Gln Leu Thr Glu Ala
            385             390             395

gtg cag aag atc acc act gag tcc att gtg atc tgg ggc aag acc ccc        1249
Val Gln Lys Ile Thr Thr Glu Ser Ile Val Ile Trp Gly Lys Thr Pro
        400             405             410

aag ttc aag ctg ccc atc cag aag gag acc tgg gag acc tgg tgg act        1297
Lys Phe Lys Leu Pro Ile Gln Lys Glu Thr Trp Glu Thr Trp Trp Thr
415             420             425             430

gag tac tgg cag gcc acc tgg atc cct gag tgg gag ttt gtg aac acc        1345
Glu Tyr Trp Gln Ala Thr Trp Ile Pro Glu Trp Glu Phe Val Asn Thr
            435             440             445

ccc ccc ctg gtg aag ctg tgg tac cag ctg gag aag gag ccc att gtg        1393
Pro Pro Leu Val Lys Leu Trp Tyr Gln Leu Glu Lys Glu Pro Ile Val
            450             455             460

ggg gct gag acc ttc tat gtg gat ggg gct gcc aac agg gag acc aag        1441
Gly Ala Glu Thr Phe Tyr Val Asp Gly Ala Ala Asn Arg Glu Thr Lys
            465             470             475

ctg ggc aag gct ggc tat gtg acc aac agg ggc agg cag aag gtg gtg        1489
Leu Gly Lys Ala Gly Tyr Val Thr Asn Arg Gly Arg Gln Lys Val Val
            480             485             490

acc ctg act gac acc acc aac cag aag act gag ctc cag gcc atc tac        1537
Thr Leu Thr Asp Thr Thr Asn Gln Lys Thr Glu Leu Gln Ala Ile Tyr
495             500             505             510

ctg gcc ctc cag gac tct ggc ctg gag gtg aac att gtg act gac tcc        1585
Leu Ala Leu Gln Asp Ser Gly Leu Glu Val Asn Ile Val Thr Asp Ser
            515             520             525

cag tat gcc ctg ggc atc atc cag gcc cag cct gat cag tct gag tct        1633
Gln Tyr Ala Leu Gly Ile Ile Gln Ala Gln Pro Asp Gln Ser Glu Ser
            530             535             540

gag ctg gtg aac cag atc att gag cag ctg atc aag aag gag aag gtg        1681
Glu Leu Val Asn Gln Ile Ile Glu Gln Leu Ile Lys Lys Glu Lys Val
            545             550             555

tac ctg gcc tgg gtg cct gcc cac aag ggc att ggg ggc aat gag cag        1729
Tyr Leu Ala Trp Val Pro Ala His Lys Gly Ile Gly Gly Asn Glu Gln
            560             565             570
```

- 14 -

```
gtg gac aag ctg gtg tct gct ggc atc agg aag gtg ctg ttc ctg gat      1777
Val Asp Lys Leu Val Ser Ala Gly Ile Arg Lys Val Leu Phe Leu Asp
575             580             585             590

ggc att gac aag gcc cag gat gag cat gag aag tac cac tcc aac tgg      1825
Gly Ile Asp Lys Ala Gln Asp Glu His Glu Lys Tyr His Ser Asn Trp
            595             600             605

agg gct atg gcc tct gac ttc aac ctg ccc cct gtg gtg gct aag gag      1873
Arg Ala Met Ala Ser Asp Phe Asn Leu Pro Pro Val Val Ala Lys Glu
            610             615             620

att gtg gcc tcc tgt gac aag tgc cag ctg aag ggg gag gcc atg cat      1921
Ile Val Ala Ser Cys Asp Lys Cys Gln Leu Lys Gly Glu Ala Met His
            625             630             635

ggg cag gtg gac tgc tcc cct ggc atc tgg cag ctg gac tgc acc cac      1969
Gly Gln Val Asp Cys Ser Pro Gly Ile Trp Gln Leu Asp Cys Thr His
640             645             650

ctg gag ggc aag gtg atc ctg gtg gct gtg cat gtg gcc tcc ggc tac      2017
Leu Glu Gly Lys Val Ile Leu Val Ala Val His Val Ala Ser Gly Tyr
655             660             665             670

att gag gct gag gtg atc cct gct gag aca ggc cag gag act gcc tac      2065
Ile Glu Ala Glu Val Ile Pro Ala Glu Thr Gly Gln Glu Thr Ala Tyr
                675             680             685

ttc ctg ctg aag ctg gct ggc agg tgg cct gtg aag acc atc cac act      2113
Phe Leu Leu Lys Leu Ala Gly Arg Trp Pro Val Lys Thr Ile His Thr
            690             695             700

gac aat ggc tcc aac ttc act ggg gcc aca gtg agg gct gcc tgc tgg      2161
Asp Asn Gly Ser Asn Phe Thr Gly Ala Thr Val Arg Ala Ala Cys Trp
            705             710             715

tgg gct ggc atc aag cag gag ttt ggc atc ccc tac aac ccc cag tcc      2209
Trp Ala Gly Ile Lys Gln Glu Phe Gly Ile Pro Tyr Asn Pro Gln Ser
            720             725             730

cag ggg gtg gtg gag tcc atg aac aag gag ctg aag aag atc att ggg      2257
Gln Gly Val Val Glu Ser Met Asn Lys Glu Leu Lys Lys Ile Ile Gly
735             740             745             750

cag gtg agg gac cag gct gag cac ctg aag aca gct gtg cag atg gct      2305
Gln Val Arg Asp Gln Ala Glu His Leu Lys Thr Ala Val Gln Met Ala
            755             760             765

gtg ttc atc cac aac ttc aag agg aag ggg ggc atc ggg ggc tac tcc      2353
Val Phe Ile His Asn Phe Lys Arg Lys Gly Gly Ile Gly Gly Tyr Ser
            770             775             780

gct ggg gag agg att gtg gac atc att gcc aca gac atc cag acc aag      2401
Ala Gly Glu Arg Ile Val Asp Ile Ile Ala Thr Asp Ile Gln Thr Lys
            785             790             795

gag ctc cag aag cag atc acc aag atc cag aac ttc agg gtg tac tac      2449
Glu Leu Gln Lys Gln Ile Thr Lys Ile Gln Asn Phe Arg Val Tyr Tyr
800             805             810
```

```
agg gac tcc agg aac ccc ctg tgg aag ggc cct gcc aag ctg ctg tgg    2497
Arg Asp Ser Arg Asn Pro Leu Trp Lys Gly Pro Ala Lys Leu Leu Trp
815                 820             825                     830

aag ggg gag ggg gct gtg gtg atc cag gac aac tct gac atc aag gtg    2545
Lys Gly Glu Gly Ala Val Val Ile Gln Asp Asn Ser Asp Ile Lys Val
                835             840             845

gtg ccc agg agg aag gcc aag atc atc agg gac tat ggc aag cag atg    2593
Val Pro Arg Arg Lys Ala Lys Ile Ile Arg Asp Tyr Gly Lys Gln Met
            850             855             860

gct ggg gat gac tgt gtg gcc tcc agg cag gat gag gac taa            2635
Ala Gly Asp Asp Cys Val Ala Ser Arg Gln Asp Glu Asp *
            865             870             875

agcccgggca gatct                                                    2650
```

<210> 6
<211> 875
<212> PRT
<213> Human Immunodeficiency Virus-1

<400> 6
```
Met Asp Ala Met Lys Arg Gly Leu Cys Cys Val Leu Leu Leu Cys Gly
1               5               10                  15
Ala Val Phe Val Ser Pro Ser Glu Ile Ser Ala Pro Ile Ser Pro Ile
            20              25              30
Glu Thr Val Pro Val Lys Leu Lys Pro Gly Met Asp Gly Pro Lys Val
        35              40              45
Lys Gln Trp Pro Leu Thr Glu Glu Lys Ile Lys Ala Leu Val Glu Ile
    50              55              60
Cys Thr Glu Met Glu Lys Glu Gly Lys Ile Ser Lys Ile Gly Pro Glu
65              70              75                  80
Asn Pro Tyr Asn Thr Pro Val Phe Ala Ile Lys Lys Lys Asp Ser Thr
            85              90                  95
Lys Trp Arg Lys Leu Val Asp Phe Arg Glu Leu Asn Lys Arg Thr Gln
            100             105             110
Asp Phe Trp Glu Val Gln Leu Gly Ile Pro His Pro Ala Gly Leu Lys
        115             120             125
Lys Lys Lys Ser Val Thr Val Leu Asp Val Gly Asp Ala Tyr Phe Ser
    130             135             140
Val Pro Leu Asp Glu Asp Phe Arg Lys Tyr Thr Ala Phe Thr Ile Pro
145             150             155             160
Ser Ile Asn Asn Glu Thr Pro Gly Ile Arg Tyr Gln Tyr Asn Val Leu
            165             170             175
Pro Gln Gly Trp Lys Gly Ser Pro Ala Ile Phe Gln Ser Ser Met Thr
        180             185             190
Lys Ile Leu Glu Pro Phe Arg Lys Gln Asn Pro Asp Ile Val Ile Tyr
    195             200             205
Gln Tyr Met Asp Asp Leu Tyr Val Gly Ser Asp Leu Glu Ile Gly Gln
    210             215             220
His Arg Thr Lys Ile Glu Glu Leu Arg Gln His Leu Leu Arg Trp Gly
225             230             235             240
Leu Thr Thr Pro Asp Lys Lys His Gln Lys Glu Pro Pro Phe Leu Trp
            245             250             255
Met Gly Tyr Glu Leu His Pro Asp Lys Trp Thr Val Gln Pro Ile Val
            260             265             270
Leu Pro Glu Lys Asp Ser Trp Thr Val Asn Asp Ile Gln Lys Leu Val
        275             280             285
Gly Lys Leu Asn Trp Ala Ser Gln Ile Tyr Pro Gly Ile Lys Val Arg
    290             295             300
```

Gln Leu Cys Lys Leu Leu Arg Gly Thr Lys Ala Leu Thr Glu Val Ile
305   310   315   320
Pro Leu Thr Glu Glu Ala Glu Leu Glu Leu Ala Glu Asn Arg Glu Ile
                325   330   335
Leu Lys Glu Pro Val His Gly Val Tyr Tyr Asp Pro Ser Lys Asp Leu
                340   345   350
Ile Ala Glu Ile Gln Lys Gln Gly Gln Gly Gln Trp Thr Tyr Gln Ile
                355   360   365
Tyr Gln Glu Pro Phe Lys Asn Leu Lys Thr Gly Lys Tyr Ala Arg Met
        370   375   380
Arg Gly Ala His Thr Asn Asp Val Lys Gln Leu Thr Glu Ala Val Gln
385   390   395   400
Lys Ile Thr Thr Glu Ser Ile Val Ile Trp Gly Lys Thr Pro Lys Phe
                405   410   415
Lys Leu Pro Ile Gln Lys Glu Thr Trp Glu Thr Trp Trp Thr Glu Tyr
                420   425   430
Trp Gln Ala Thr Trp Ile Pro Glu Trp Glu Phe Val Asn Thr Pro Pro
        435   440   445
Leu Val Lys Leu Trp Tyr Gln Leu Glu Lys Glu Pro Ile Val Gly Ala
        450   455   460
Glu Thr Phe Tyr Val Asp Gly Ala Ala Asn Arg Glu Thr Lys Leu Gly
465   470   475   480
Lys Ala Gly Tyr Val Thr Asn Arg Gly Arg Gln Lys Val Val Thr Leu
                485   490   495
Thr Asp Thr Thr Asn Gln Lys Thr Glu Leu Gln Ala Ile Tyr Leu Ala
        500   505   510
Leu Gln Asp Ser Gly Leu Glu Val Asn Ile Val Thr Asp Ser Gln Tyr
        515   520   525
Ala Leu Gly Ile Ile Gln Ala Gln Pro Asp Gln Ser Glu Ser Glu Leu
        530   535   540
Val Asn Gln Ile Ile Glu Gln Leu Ile Lys Lys Glu Lys Val Tyr Leu
545   550   555   560
Ala Trp Val Pro Ala His Lys Gly Ile Gly Gly Asn Glu Gln Val Asp
                565   570   575
Lys Leu Val Ser Ala Gly Ile Arg Lys Val Leu Phe Leu Asp Gly Ile
                580   585   590
Asp Lys Ala Gln Asp Glu His Glu Lys Tyr His Ser Asn Trp Arg Ala
        595   600   605
Met Ala Ser Asp Phe Asn Leu Pro Pro Val Val Ala Lys Glu Ile Val
        610   615   620
Ala Ser Cys Asp Lys Cys Gln Leu Lys Gly Glu Ala Met His Gly Gln
625   630   635   640
Val Asp Cys Ser Pro Gly Ile Trp Gln Leu Asp Cys Thr His Leu Glu
                645   650   655
Gly Lys Val Ile Leu Val Ala Val His Val Ala Ser Gly Tyr Ile Glu
                660   665   670
Ala Glu Val Ile Pro Ala Glu Thr Gly Gln Glu Thr Ala Tyr Phe Leu
        675   680   685
Leu Lys Leu Ala Gly Arg Trp Pro Val Lys Thr Ile His Thr Asp Asn
        690   695   700
Gly Ser Asn Phe Thr Gly Ala Thr Val Arg Ala Ala Cys Trp Trp Ala
705   710   715   720
Gly Ile Lys Gln Glu Phe Gly Ile Pro Tyr Asn Pro Gln Ser Gln Gly
                725   730   735
Val Val Glu Ser Met Asn Lys Glu Leu Lys Lys Ile Ile Gly Gln Val
                740   745   750
Arg Asp Gln Ala Glu His Leu Lys Thr Ala Val Gln Met Ala Val Phe
        755   760   765
Ile His Asn Phe Lys Arg Lys Gly Gly Ile Gly Gly Tyr Ser Ala Gly
        770   775   780
Glu Arg Ile Val Asp Ile Ile Ala Thr Asp Ile Gln Thr Lys Glu Leu
785   790   795   800

```
Gln Lys Gln Ile Thr Lys Ile Gln Asn Phe Arg Val Tyr Tyr Arg Asp
              805                 810                 815
Ser Arg Asn Pro Leu Trp Lys Gly Pro Ala Lys Leu Leu Trp Lys Gly
          820                 825                 830
Glu Gly Ala Val Val Ile Gln Asp Asn Ser Asp Ile Lys Val Val Pro
          835                 840                 845
Arg Arg Lys Ala Lys Ile Ile Arg Asp Tyr Gly Lys Gln Met Ala Gly
      850                 855                 860
Asp Asp Cys Val Ala Ser Arg Gln Asp Glu Asp
865                 870                 875
```

<210> 7
<211> 2650
<212> DNA
<213> Human Immunodeficiency Virus-1

<220>
<221> CDS
<222> (8)...(2635)

<400> 7
```
gatcacc atg gat gca atg aag aga ggg ctc tgc tgt gtg ctg ctg ctg         49
        Met Asp Ala Met Lys Arg Gly Leu Cys Cys Val Leu Leu Leu
        1               5                   10

tgt gga gca gtc ttc gtt tcg ccc agc gag atc tcc gcc ccc atc tcc         97
Cys Gly Ala Val Phe Val Ser Pro Ser Glu Ile Ser Ala Pro Ile Ser
 15                  20                  25                  30

ccc att gag act gtg cct gtg aag ctg aag cct ggc atg gat ggc ccc        145
Pro Ile Glu Thr Val Pro Val Lys Leu Lys Pro Gly Met Asp Gly Pro
                35                  40                  45

aag gtg aag cag tgg ccc ctg act gag gag aag atc aag gcc ctg gtg        193
Lys Val Lys Gln Trp Pro Leu Thr Glu Glu Lys Ile Lys Ala Leu Val
            50                  55                  60

gaa atc tgc act gag atg gag aag gag ggc aaa atc tcc aag att ggc        241
Glu Ile Cys Thr Glu Met Glu Lys Glu Gly Lys Ile Ser Lys Ile Gly
            65                  70                  75

ccc gag aac ccc tac aac acc cct gtg ttt gcc atc aag aag aag gac        289
Pro Glu Asn Pro Tyr Asn Thr Pro Val Phe Ala Ile Lys Lys Lys Asp
        80                  85                  90

tcc acc aag tgg agg aag ctg gtg gac ttc agg gag ctg aac aag agg        337
Ser Thr Lys Trp Arg Lys Leu Val Asp Phe Arg Glu Leu Asn Lys Arg
 95                 100                 105                 110

acc cag gac ttc tgg gag gtg cag ctg ggc atc ccc cac ccc gct ggc        385
Thr Gln Asp Phe Trp Glu Val Gln Leu Gly Ile Pro His Pro Ala Gly
                115                 120                 125

ctg aag aag aag aag tct gtg act gtg ctg gct gtg ggg gat gcc tac        433
Leu Lys Lys Lys Lys Ser Val Thr Val Leu Ala Val Gly Asp Ala Tyr
            130                 135                 140

ttc tct gtg ccc ctg gat gag gac ttc agg aag tac act gcc ttc acc        481
Phe Ser Val Pro Leu Asp Glu Asp Phe Arg Lys Tyr Thr Ala Phe Thr
            145                 150                 155
```

```
atc ccc tcc atc aac aat gag acc cct ggc atc agg tac cag tac aat      529
Ile Pro Ser Ile Asn Asn Glu Thr Pro Gly Ile Arg Tyr Gln Tyr Asn
    160             165             170

gtg ctg ccc cag ggc tgg aag ggc tcc cct gcc atc ttc cag tcc tcc      577
Val Leu Pro Gln Gly Trp Lys Gly Ser Pro Ala Ile Phe Gln Ser Ser
175             180             185             190

atg acc aag atc ctg gag ccc ttc agg aag cag aac cct gac att gtg      625
Met Thr Lys Ile Leu Glu Pro Phe Arg Lys Gln Asn Pro Asp Ile Val
            195             200             205

atc tac cag tac atg gct gcc ctg tat gtg ggc tct gac ctg gag att      673
Ile Tyr Gln Tyr Met Ala Ala Leu Tyr Val Gly Ser Asp Leu Glu Ile
            210             215             220

ggg cag cac agg acc aag att gag gag ctg agg cag cac ctg ctg agg      721
Gly Gln His Arg Thr Lys Ile Glu Glu Leu Arg Gln His Leu Leu Arg
        225             230             235

tgg ggc ctg acc acc cct gac aag aag cac cag aag gag ccc ccc ttc      769
Trp Gly Leu Thr Thr Pro Asp Lys Lys His Gln Lys Glu Pro Pro Phe
        240             245             250

ctg tgg atg ggc tat gag ctg cac ccc gac aag tgg act gtg cag ccc      817
Leu Trp Met Gly Tyr Glu Leu His Pro Asp Lys Trp Thr Val Gln Pro
255             260             265             270

att gtg ctg cct gag aag gac tcc tgg act gtg aat gac atc cag aag      865
Ile Val Leu Pro Glu Lys Asp Ser Trp Thr Val Asn Asp Ile Gln Lys
            275             280             285

ctg gtg ggc aag ctg aac tgg gcc tcc caa atc tac cct ggc atc aag      913
Leu Val Gly Lys Leu Asn Trp Ala Ser Gln Ile Tyr Pro Gly Ile Lys
            290             295             300

gtg agg cag ctg tgc aag ctg ctg agg ggc acc aag gcc ctg act gag      961
Val Arg Gln Leu Cys Lys Leu Leu Arg Gly Thr Lys Ala Leu Thr Glu
        305             310             315

gtg atc ccc ctg act gag gag gct gag ctg gag ctg gct gag aac agg     1009
Val Ile Pro Leu Thr Glu Glu Ala Glu Leu Glu Leu Ala Glu Asn Arg
        320             325             330

gag atc ctg aag gag cct gtg cat ggg gtg tac tat gac ccc tcc aag     1057
Glu Ile Leu Lys Glu Pro Val His Gly Val Tyr Tyr Asp Pro Ser Lys
335             340             345             350

gac ctg att gct gag atc cag aag cag ggc cag ggc cag tgg acc tac     1105
Asp Leu Ile Ala Glu Ile Gln Lys Gln Gly Gln Gly Gln Trp Thr Tyr
            355             360             365

caa atc tac cag gag ccc ttc aag aac ctg aag act ggc aag tat gcc     1153
Gln Ile Tyr Gln Glu Pro Phe Lys Asn Leu Lys Thr Gly Lys Tyr Ala
            370             375             380

agg atg agg ggg gcc cac acc aat gat gtg aag cag ctg act gag gct     1201
Arg Met Arg Gly Ala His Thr Asn Asp Val Lys Gln Leu Thr Glu Ala
        385             390             395
```

```
gtg cag aag atc acc act gag tcc att gtg atc tgg ggc aag acc ccc      1249
Val Gln Lys Ile Thr Thr Glu Ser Ile Val Ile Trp Gly Lys Thr Pro
    400             405              410

aag ttc aag ctg ccc atc cag aag gag acc tgg gag acc tgg tgg act      1297
Lys Phe Lys Leu Pro Ile Gln Lys Glu Thr Trp Glu Thr Trp Trp Thr
415             420              425              430

gag tac tgg cag gcc acc tgg atc cct gag tgg gag ttt gtg aac acc      1345
Glu Tyr Trp Gln Ala Thr Trp Ile Pro Glu Trp Glu Phe Val Asn Thr
            435              440              445

ccc ccc ctg gtg aag ctg tgg tac cag ctg gag aag gag ccc att gtg      1393
Pro Pro Leu Val Lys Leu Trp Tyr Gln Leu Glu Lys Glu Pro Ile Val
            450              455              460

ggg gct gag acc ttc tat gtg gct ggg gct gcc aac agg gag acc aag      1441
Gly Ala Glu Thr Phe Tyr Val Ala Gly Ala Ala Asn Arg Glu Thr Lys
            465              470              475

ctg ggc aag gct ggc tat gtg acc aac agg ggc agg cag aag gtg gtg      1489
Leu Gly Lys Ala Gly Tyr Val Thr Asn Arg Gly Arg Gln Lys Val Val
    480             485              490

acc ctg act gac acc acc aac cag aag act gcc ctc cag gcc atc tac      1537
Thr Leu Thr Asp Thr Thr Asn Gln Lys Thr Ala Leu Gln Ala Ile Tyr
495             500              505              510

ctg gcc ctc cag gac tct ggc ctg gag gtg aac att gtg act gcc tcc      1585
Leu Ala Leu Gln Asp Ser Gly Leu Glu Val Asn Ile Val Thr Ala Ser
            515              520              525

cag tat gcc ctg ggc atc atc cag gcc cag cct gat cag tct gag tct     ·1633
Gln Tyr Ala Leu Gly Ile Ile Gln Ala Gln Pro Asp Gln Ser Glu Ser
            530              535              540

gag ctg gtg aac cag atc att gag cag ctg atc aag aag gag aag gtg      1681
Glu Leu Val Asn Gln Ile Ile Glu Gln Leu Ile Lys Lys Glu Lys Val
            545              550              555

tac ctg gcc tgg gtg cct gcc cac aag ggc att ggg ggc aat gag cag      1729
Tyr Leu Ala Trp Val Pro Ala His Lys Gly Ile Gly Gly Asn Glu Gln
    560             565              570

gtg gac aag ctg gtg tct gct ggc atc agg aag gtg ctg ttc ctg gat      1777
Val Asp Lys Leu Val Ser Ala Gly Ile Arg Lys Val Leu Phe Leu Asp
575             580              585              590

ggc att gac aag gcc cag gat gag cat gag aag tac cac tcc aac tgg      1825
Gly Ile Asp Lys Ala Gln Asp Glu His Glu Lys Tyr His Ser Asn Trp
            595              600              605

agg gct atg gcc tct gac ttc aac ctg ccc cct gtg gtg gct aag gag      1873
Arg Ala Met Ala Ser Asp Phe Asn Leu Pro Pro Val Val Ala Lys Glu
            610              615              620

att gtg gcc tcc tgt gac aag tgc cag ctg aag ggg gag gcc atg cat      1921
Ile Val Ala Ser Cys Asp Lys Cys Gln Leu Lys Gly Glu Ala Met His
            625              630              635
```

```
ggg cag gtg gac tgc tcc cct ggc atc tgg cag ctg gcc tgc acc cac       1969
Gly Gln Val Asp Cys Ser Pro Gly Ile Trp Gln Leu Ala Cys Thr His
    640             645                 650

ctg gag ggc aag gtg atc ctg gtg gct gtg cat gtg gcc tcc ggc tac       2017
Leu Glu Gly Lys Val Ile Leu Val Ala Val His Val Ala Ser Gly Tyr
655             660                 665                 670

att gag gct gag gtg atc cct gct gag aca ggc cag gag act gcc tac      .2065
Ile Glu Ala Glu Val Ile Pro Ala Glu Thr Gly Gln Glu Thr Ala Tyr
                675                 680                 685

ttc ctg ctg aag ctg gct ggc agg tgg cct gtg aag acc atc cac act       2113
Phe Leu Leu Lys Leu Ala Gly Arg Trp Pro Val Lys Thr Ile His Thr
            690                 695                 700

gcc aat ggc tcc aac ttc act ggg gcc aca gtg agg gct gcc tgc tgg       2161
Ala Asn Gly Ser Asn Phe Thr Gly Ala Thr Val Arg Ala Ala Cys Trp
    705                 710                 715

tgg gct ggc atc aag cag gag ttt ggc atc ccc tac aac ccc cag tcc       2209
Trp Ala Gly Ile Lys Gln Glu Phe Gly Ile Pro Tyr Asn Pro Gln Ser
    720                 725                 730

cag ggg gtg gtg gcc tcc atg aac aag gag ctg aag aag atc att ggg       2257
Gln Gly Val Val Ala Ser Met Asn Lys Glu Leu Lys Lys Ile Ile Gly
735                 740                 745                 750

cag gtg agg gac cag gct gag cac ctg aag aca gct gtg cag atg gct       2305
Gln Val Arg Asp Gln Ala Glu His Leu Lys Thr Ala Val Gln Met Ala
                755                 760                 765

gtg ttc atc cac aac ttc aag agg aag ggg ggc atc ggg ggc tac tcc       2353
Val Phe Ile His Asn Phe Lys Arg Lys Gly Gly Ile Gly Gly Tyr Ser
            770                 775                 780

gct ggg gag agg att gtg gac atc att gcc aca gac atc cag acc aag       2401
Ala Gly Glu Arg Ile Val Asp Ile Ile Ala Thr Asp Ile Gln Thr Lys
        785                 790                 795

gag ctc cag aag cag atc acc aag atc cag aac ttc agg gtg tac tac       2449
Glu Leu Gln Lys Gln Ile Thr Lys Ile Gln Asn Phe Arg Val Tyr Tyr
    800                 805                 810

agg gac tcc agg aac ccc ctg tgg aag ggc cct gcc aag ctg ctg tgg       2497
Arg Asp Ser Arg Asn Pro Leu Trp Lys Gly Pro Ala Lys Leu Leu Trp
815                 820                 825                 830

aag ggg gag ggg gct gtg gtg atc cag gac aac tct gac atc aag gtg       2545
Lys Gly Glu Gly Ala Val Val Ile Gln Asp Asn Ser Asp Ile Lys Val
                835                 840                 845

gtg ccc agg agg aag gcc aag atc atc agg gac tat ggc aag cag atg       2593
Val Pro Arg Arg Lys Ala Lys Ile Ile Arg Asp Tyr Gly Lys Gln Met
            850                 855                 860

gct ggg gat gac tgt gtg gcc tcc agg cag gat gag gac taa              2635
Ala Gly Asp Asp Cys Val Ala Ser Arg Gln Asp Glu Asp  *
            865                 870                 875

agcccgggca gatct                                                      2650
```

-21-

<210> 8
<211> 875
<212> PRT
<213> Human Immunodeficiency Virus-1

<400> 8
Met Asp Ala Met Lys Arg Gly Leu Cys Cys Val Leu Leu Leu Cys Gly
1   5   10   15
Ala Val Phe Val Ser Pro Ser Glu Ile Ser Ala Pro Ile Ser Pro Ile
            20   25   30
Glu Thr Val Pro Val Lys Leu Lys Pro Gly Met Asp Gly Pro Lys Val
        35   40   45
Lys Gln Trp Pro Leu Thr Glu Glu Lys Ile Lys Ala Leu Val Glu Ile
    50   55   60
Cys Thr Glu Met Glu Lys Glu Gly Lys Ile Ser Lys Ile Gly Pro Glu
65   70   75   80
Asn Pro Tyr Asn Thr Pro Val Phe Ala Ile Lys Lys Lys Asp Ser Thr
                85   90   95
Lys Trp Arg Lys Leu Val Asp Phe Arg Glu Leu Asn Lys Arg Thr Gln
            100   105   110
Asp Phe Trp Glu Val Gln Leu Gly Ile Pro His Pro Ala Gly Leu Lys
        115   120   125
Lys Lys Lys Ser Val Thr Val Leu Ala Val Gly Asp Ala Tyr Phe Ser
    130   135   140
Val Pro Leu Asp Glu Asp Phe Arg Lys Tyr Thr Ala Phe Thr Ile Pro
145   150   155   160
Ser Ile Asn Asn Glu Thr Pro Gly Ile Arg Tyr Gln Tyr Asn Val Leu
                165   170   175
Pro Gln Gly Trp Lys Gly Ser Pro Ala Ile Phe Gln Ser Ser Met Thr
            180   185   190
Lys Ile Leu Glu Pro Phe Arg Lys Gln Asn Pro Asp Ile Val Ile Tyr
            195   200   205
Gln Tyr Met Ala Ala Leu Tyr Val Gly Ser Asp Leu Glu Ile Gly Gln
    210   215   220
His Arg Thr Lys Ile Glu Glu Leu Arg Gln His Leu Leu Arg Trp Gly
225   230   235   240
Leu Thr Thr Pro Asp Lys Lys His Gln Lys Glu Pro Pro Phe Leu Trp
                245   250   255
Met Gly Tyr Glu Leu His Pro Asp Lys Trp Thr Val Gln Pro Ile Val
            260   265   270
Leu Pro Glu Lys Asp Ser Trp Thr Val Asn Asp Ile Gln Lys Leu Val
        275   280   285
Gly Lys Leu Asn Trp Ala Ser Gln Ile Tyr Pro Gly Ile Lys Val Arg
    290   295   300
Gln Leu Cys Lys Leu Leu Arg Gly Thr Lys Ala Leu Thr Glu Val Ile
305   310   315   320
Pro Leu Thr Glu Glu Ala Glu Leu Glu Leu Ala Glu Asn Arg Glu Ile
                325   330   335
Leu Lys Glu Pro Val His Gly Val Tyr Tyr Asp Pro Ser Lys Asp Leu
            340   345   350
Ile Ala Glu Ile Gln Lys Gln Gly Gln Gly Gln Trp Thr Tyr Gln Ile
            355   360   365
Tyr Gln Glu Pro Phe Lys Asn Leu Lys Thr Gly Lys Tyr Ala Arg Met
    370   375   380
Arg Gly Ala His Thr Asn Asp Val Lys Gln Leu Thr Glu Ala Val Gln
385   390   395   400
Lys Ile Thr Thr Glu Ser Ile Val Ile Trp Gly Lys Thr Pro Lys Phe
                405   410   415
Lys Leu Pro Ile Gln Lys Glu Thr Trp Glu Thr Trp Trp Thr Glu Tyr
            420   425   430
Trp Gln Ala Thr Trp Ile Pro Glu Trp Glu Phe Val Asn Thr Pro Pro
        435   440   445

- 22 -

```
Leu Val Lys Leu Trp Tyr Gln Leu Glu Lys Glu Pro Ile Val Gly Ala
    450                 455                 460
Glu Thr Phe Tyr Val Ala Gly Ala Ala Asn Arg Glu Thr Lys Leu Gly
465                 470                 475                 480
Lys Ala Gly Tyr Val Thr Asn Arg Gly Arg Gln Lys Val Val Thr Leu
                485                 490                 495
Thr Asp Thr Thr Asn Gln Lys Thr Ala Leu Gln Ala Ile Tyr Leu Ala
            500                 505                 510
Leu Gln Asp Ser Gly Leu Glu Val Asn Ile Val Thr Ala Ser Gln Tyr
        515                 520                 525
Ala Leu Gly Ile Ile Gln Ala Gln Pro Asp Gln Ser Glu Ser Glu Leu
    530                 535                 540
Val Asn Gln Ile Ile Glu Gln Leu Ile Lys Lys Glu Lys Val Tyr Leu
545                 550                 555                 560
Ala Trp Val Pro Ala His Lys Gly Ile Gly Gly Asn Glu Gln Val Asp
                565                 570                 575
Lys Leu Val Ser Ala Gly Ile Arg Lys Val Leu Phe Leu Asp Gly Ile
            580                 585                 590
Asp Lys Ala Gln Asp Glu His Glu Lys Tyr His Ser Asn Trp Arg Ala
        595                 600                 605
Met Ala Ser Asp Phe Asn Leu Pro Pro Val Val Ala Lys Glu Ile Val
    610                 615                 620
Ala Ser Cys Asp Lys Cys Gln Leu Lys Gly Glu Ala Met His Gly Gln
625                 630                 635                 640
Val Asp Cys Ser Pro Gly Ile Trp Gln Leu Ala Cys Thr His Leu Glu
                645                 650                 655
Gly Lys Val Ile Leu Val Ala Val His Val Ala Ser Gly Tyr Ile Glu
            660                 665                 670
Ala Glu Val Ile Pro Ala Glu Thr Gly Gln Glu Thr Ala Tyr Phe Leu
        675                 680                 685
Leu Lys Leu Ala Gly Arg Trp Pro Val Lys Thr Ile His Thr Ala Asn
    690                 695                 700
Gly Ser Asn Phe Thr Gly Ala Thr Val Arg Ala Ala Cys Trp Trp Ala
705                 710                 715                 720
Gly Ile Lys Gln Glu Phe Gly Ile Pro Tyr Asn Pro Gln Ser Gln Gly
                725                 730                 735
Val Val Ala Ser Met Asn Lys Glu Leu Lys Lys Ile Ile Gly Gln Val
            740                 745                 750
Arg Asp Gln Ala Glu His Leu Lys Thr Ala Val Gln Met Ala Val Phe
        755                 760                 765
Ile His Asn Phe Lys Arg Lys Gly Gly Ile Gly Gly Tyr Ser Ala Gly
    770                 775                 780
Glu Arg Ile Val Asp Ile Ile Ala Thr Asp Ile Gln Thr Lys Glu Leu
785                 790                 795                 800
Gln Lys Gln Ile Thr Lys Ile Gln Asn Phe Arg Val Tyr Tyr Arg Asp
                805                 810                 815
Ser Arg Asn Pro Leu Trp Lys Gly Pro Ala Lys Leu Leu Trp Lys Gly
            820                 825                 830
Glu Gly Ala Val Val Ile Gln Asp Asn Ser Asp Ile Lys Val Val Pro
        835                 840                 845
Arg Arg Lys Ala Lys Ile Ile Arg Asp Tyr Gly Lys Gln Met Ala Gly
    850                 855                 860
Asp Asp Cys Val Ala Ser Arg Gln Asp Glu Asp
865                 870                 875
```

<210> 9
<211> 4945
<212> DNA
<213> E. coli (VlJns-tpa)

<400> 9
tcgcgcgttt cggtgatgac ggtgaaaacc tctgacacat gcagctcccg gagacggtca   60

```
cagcttgtct gtaagcggat gccgggagca gacaagcccg tcagggcgcg tcagcgggtg      120
ttggcgggtg tcggggctgg cttaactatg cggcatcaga gcagattgta ctgagagtgc      180
accatatgcg gtgtgaaata ccgcacagat gcgtaaggag aaaataccgc atcagattgg      240
ctattggcca ttgcatacgt tgtatccata tcataatatg tacatttata ttggctcatg      300
tccaacatta ccgccatgtt gacattgatt attgactagt tattaatagt aatcaattac      360
ggggtcatta gttcatagcc catatatgga gttccgcgtt acataactta cggtaaatgg      420
cccgcctggc tgaccgccca acgacccccg cccattgacg tcaataatga cgtatgttcc      480
catagtaacg ccaatanggga cttcccattg acgtcaatgg gtggagtatt tacggtaaac      540
tgcccacttg gcagtacatc aagtgtatca tatgccaagt acgccccta ttgacgtcaa      600
tgacggtaaa tggcccgcct ggcattatgc ccagtacatg accttatggg actttcctac      660
ttggcagtac atctacgtat tagtcatcgc tattaccatg gtgatgcggt tttggcagta      720
catcaatggg cgtggatagc ggtttgactc acggggattt ccaagtctcc accccattga      780
cgtcaatggg agtttgtttt ggcaccaaaa tcaacgggac tttccaaaat gtcgtaacaa      840
ctccgcccca ttgacgcaaa tgggcggtag cgtgtacgg tgggaggtct atataagcag      900
agctcgttta gtgaaccgtc agatcgcctg gagacgccat ccacgctgtt ttgacctcca      960
tagaagacac cgggaccgat ccagcctccg cggccgggaa cggtgcattg gaacgcggat     1020
tccccgtgcc aagagtgacg taagtaccgc ctatagactc tataggcaca cccctttggc     1080
tcttatgcat gctatactgt ttttggcttg gggcctatac acccccgctt ccttatgcta     1140
taggtgatgg tatagcttag cctataggtg tgggttattg accattattg accactcccc     1200
tattggtgac gatactttcc attactaatc cataacatgg ctctttgcca caactatctc     1260
tattggctat atgccaatac tctgtccttc agagactgac acggactctg tattttaca     1320
ggatggggtc ccatttatta tttacaaatt cacatataca acaacgccgt cccccgtgcc     1380
cgcagttttt attaaacata gcgtgggatc tccacgcgaa tctcgggtac gtgttccgga     1440
catgggctct tctccggtag cggcggagct tccacatccg agccctggtc ccatgcctcc     1500
agcggctcat ggtcgctcgg cagctccttg ctcctaacag tggaggccag acttaggcac     1560
agcacaatgc ccaccaccac cagtgtgccg cacaaggccg tggcggtagg gtatgtgtct     1620
gaaaatgagc gtggagattg ggctcgcacg gctgacgcac atggaagact taaggcagcg     1680
gcagaagaag atgcaggcag ctgagttgtt gtattctgat aagagtcaga ggtaactccc     1740
gttgcggtgc tgttaacggt ggagggcagt gtagtctgag cagtactcgt tgctgccgcg     1800
cgcgccacca gacataatag ctgacagact aacagactgt tcctttccat gggtctttc     1860
tgcagtcacc gtccttagat caccatggat gcaatgaaga gagggctctg ctgtgtgctg     1920
ctgctgtgtg gagcagtctt cgtttcgccc agcgagatct gctgtgcctt ctagttgcca     1980
gccatctgtt gtttgcccct cccccgtgcc ttccttgacc ctggaaggtg ccactcccac     2040
tgtcctttcc taataaaatg aggaaattgc atcgcattgt ctgagtaggt gtcattctat     2100
tctggggggt ggggtggggc aggacagcaa ggggggagga tgggaagaca atagcaggca     2160
tgctggggat gcggtgggct ctatggccgc tgcggccagg tgctgaagaa ttgacccggt     2220
tcctcctggg ccagaaagaa gcaggcacat ccccttctct gtgacacacc ctgtccacgc     2280
ccctggttct tagttccagc cccactcata ggacactcat agctcaggag ggctccgcct     2340
tcaatcccac ccgctaaagt acttggagcg gtctctccct ccctcatcag cccaccaaac     2400
caaacctagc ctccaagagt gggaagaaat taaagcaaga taggctatta agtgcagagg     2460
gagagaaaat gcctccaaca tgtgaggaag taatgagaga aatcatagaa tttcttccgc     2520
ttcctcgctc actgactcgc tgcgctcggt cgttcggctg cggcgagcgg tatcagctca     2580
ctcaaaggcg gtaatacggt tatccacaga atcaggggat aacgcaggaa agaacatgtg     2640
agcaaaaggc cagcaaaagg ccaggaaccg taaaaaggcc gcgttgctgg cgtttttcca     2700
taggctccgc ccccctgacg agcatcacaa aaatcgacgc tcaagtcaga ggtggcgaaa     2760
cccgacagga ctataaagat accaggcgtt tccccctgga agctccctcg tgcgctctcc     2820
tgttccgacc ctgccgctta ccggatacct gtccgccttt ctcccttcgg gaagcgtggc     2880
gctttctcat agctcacgct gtaggtatct cagttcggtg taggtcgttc gctccaagct     2940
gggctgtgtg cacgaacccc ccgttcagcc cgaccgctgc gccttatccg gtaactatcg     3000
tcttgagtcc aacccggtaa gacacgactt atcgccactg gcagcagcca ctggtaacag     3060
gattagcaga gcgaggtatg taggcggtgc tacagagttc ttgaagtggt ggcctaacta     3120
cggctacact agaagaacag tatttggtat ctgcgctctg ctgaagccag ttaccttcgg     3180
aaaaagagtt ggtagctctt gatccggcaa acaaaccacc gctggtagcg gtggtttttt     3240
tgtttgcaag cagcagatta cgcgcagaaa aaaggatct caagaagatc ctttgatctt     3300
ttctacgggg tctgacgctc agtggaacga aaactcacgt taagggattt tggtcatgag     3360
attatcaaaa aggatcttca cctagatcct tttaaattaa aaatgaagtt ttaaatcaat     3420
ctaaagtata tatgagtaaa cttggtctga cagttaccaa tgcttaatca gtgaggcacc     3480
tatctcagcg atctgtctat ttcgttcatc catagttgcc tgactcgggg ggggggggcg     3540
ctgaggtctg cctcgtgaag aaggtgttgc tgactcatac caggcctgaa tcgccccatc     3600
atccagccag aaagtgaggg agccacggtt gatgagagct ttgttgtagg tggaccagtt     3660
ggtgattttg aacttttgct ttgccacgga acggtctgcg ttgtcgggaa gatgcgtgat     3720
ctgatccttc aactcagcaa aagttcgatt tattcaacaa agccgccgtc ccgtcaagtc     3780
```

- 24 -

```
agcgtaatgc tctgccagtg ttacaaccaa ttaaccaatt ctgattagaa aaactcatcg    3840
agcatcaaat gaaactgcaa tttattcata tcaggattat caataccata tttttgaaaa    3900
agccgtttct gtaatgaagg agaaaactca ccgaggcagt tccataggat ggcaagatcc    3960
tggtatcggt ctgcgattcc gactcgtcca acatcaatac aacctattaa tttcccctcg    4020
tcaaaaataa ggttatcaag tgagaaatca ccatgagtga cgactgaatc cggtgagaat    4080
ggcaaaagct tatgcatttc tttccagact tgttcaacag gccagccatt acgctcgtca    4140
tcaaaatcac tcgcatcaac caaaccgtta ttcattcgtg attgcgcctg agcgagacga    4200
aatacgcgat cgctgttaaa aggacaatta caaacaggaa tcgaatgcaa ccggcgcagg    4260
aacactgcca gcgcatcaac aatattttca cctgaatcag gatattcttc taatacctgg    4320
aatgctgttt tcccggggat cgcagtggtg agtaaccatg catcatcagg agtacggata    4380
aaatgcttga tggtcggaag aggcataaat tccgtcagcc agtttagtct gaccatctca    4440
tctgtaacat cattggcaac gctacctttg ccatgtttca gaaacaactc tggcgcatcg    4500
ggcttcccat acaatcgata gattgtcgca cctgattgcc cgacattatc gcgagcccat    4560
ttatacccat ataaatcagc atccatgttg gaatttaatc gcggcctcga gcaagacgtt    4620
tcccgttgaa tatggctcat aacacccctt gtattactgt ttatgtaagc agacagtttt    4680
attgttcatg atgatatatt tttatcttgt gcaatgtaac atcagagatt ttgagacaca    4740
acgtggcttt cccccccccc ccattattga agcatttatc agggttattg tctcatgagc    4800
ggatacatat ttgaatgtat ttagaaaaat aaacaaatag gggttccgcg cacatttccc    4860
cgaaaagtgc cacctgacgt ctaagaaacc attattatca tgacattaac ctataaaaat    4920
aggcgtatca cgaggccctt tcgtc                                          4945
```

```
<210> 10
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<223> oligonucleotide

<400> 10
ctatataagc agagctcgtt tag                                             23

<210> 11
<211> 30
<212> DNA
<213> Artificial Sequence

<220>
<223> oligonucleotide

<400> 11
gtagcaaaga tctaaggacg gtgactgcag                                      30

<210> 12
<211> 39
<212> DNA
<213> Artificial Sequence

<220>
<223> oligonucleotide

<400> 12
gtatgtgtct gaaaatgagc gtggagattg ggctcgcac                            39

<210> 13
<211> 39
<212> DNA
<213> Artificial Sequence

<220>
<223> oligonucleotide
```

<400> 13
gtgcgagccc aatctccacg ctcattttca gacacatac   39

<210> 14
<211> 4432
<212> DNA
<213> E. coli (V1J plasmid)

<400> 14
```
tcgcgcgttt cggtgatgac ggtgaaaacc tctgacacat gcagctcccg gagacggtca    60
cagcttgtct gtaagcggat gccgggagca gacaagcccg tcagggcgcg tcagcgggtg   120
ttggcgggtg tcggggctgg cttaactatg cggcatcaga gcagattgta ctgagagtgc   180
accatatgcg gtgtgaaata ccgcacagat gcgtaaggag aaaataccgc atcagattgg   240
ctattggcca ttgcatacgt tgtatccata tcataatatg tacatttata ttggctcatg   300
tccaacatta ccgccatgtt gacattgatt attgactagt tattaatagt aatcaattac   360
ggggtcatta gttcatagcc catatatgga gttccgcgtt acataactta cggtaaatgg   420
cccgcctggc tgaccgccca cgacccccg cccattgacg tcaataatga cgtatgttcc   480
catagtaacg ccaataggga ctttccattg acgtcaatgg gtggagtatt tacggtaaac   540
tgcccacttg gcagtacatc aagtgtatca tatgccaagt acgcccccta ttgacgtcaa   600
tgacggtaaa tggcccgcct ggcattatgc ccagtacatg accttatggg actttcctac   660
ttggcagtac atctacgtat tagtcatcgc tattaccatg gtgatgcggt tttggcagta   720
catcaatggg cgtggatagc ggtttgactc acggggattt ccaagtctcc accccattga   780
cgtcaatggg agtttgtttt ggcaccaaaa tcaacgggac tttccaaaat gtcgtaacaa   840
ctccgcccca ttgacgcaaa tgggcggtag gcgtgtacgg tgggaggtct atataagcag   900
agctcgttta gtgaaccgtc agatcgcctg gagacgccat ccacgctgtt ttgacctcca   960
tagaagacac cgggaccgat ccagcctccg cggccgggaa cggtgcattg gaacgcggat  1020
tccccgtgcc aagagtgacg taagtaccgc ctatagagtc tataggcccc ccccccttggc  1080
ttcttatgca tgctatactg ttttggctt tttttggctt ggtgtctata cacccccgct  1140
ataggtgatg gtatagctta gcctataggt gtgggttatt gaccattatt gaccactccc  1200
ctattggtga cgatactttc cattactaat ccataacatg gctctttgcc acaactctct  1260
ttattggcta tatgccaata cactgtcctt cagagactga cacggactct gtatttttac  1320
aggatggggt ctcatttatt atttacaaat tcacatatac aacaccaccg tccccagtgc  1380
ccgcagtttt tattaaacat aacgtgggat ctccacgcga atctcgggta cgtgttccgg  1440
acatgggctc ttctccggta gcggcggagc ttctacatcc gagccctgct cccatgcctc  1500
cagcgactca tggtcgctcg gcagctcctt gctcctaaca gtggaggcca gacttaggca  1560
cagcacgatg cccaccacca ccagtgtgcc gcacaaggcc gtggcggtag ggtatgtgtc  1620
tgaaaatgag ctcggggagc gggcttgcac cgctgacgca tttggaagac ttaaggcagc  1680
ggcagaagaa gatgcaggca gctgagttgt tgtgttctga taagagtcag aggtaactcc  1740
cgttgcggtg ctgttaacgg tggagggcag tgtagtctga gcagtactcg ttgctgccgc  1800
gcgcgccacc agacataata gctgacagac taacagactg ttcctttcca tgggtctttt  1860
ctgcagtcac cgtccttaga tctgctgtgc cttctagttg ccagccatct gttgtttgcc  1920
cctcccccgt gccttccttg accctggaag gtgccactcc cactgtcctt tcctaataaa  1980
atgaggaaat tgcatcgcat tgtctgagta ggtgtcattc tattctgggg ggtggggtgg  2040
ggcagcacag caaggggag gattgggaag acaatagcag gcatgctggg gatgcggtgg  2100
gctctatggg tacccaggtg ctgaagaatt gacccggttc ctcctgggcc agaaagaagc  2160
aggcacatcc ccttctctgt gacacaccct gtccacgccc ctggttctta gttccagccc  2220
cactcatagg acactcatag ctcaggaggg ctccgccttc aatcccaccc gctaaagtac  2280
ttggagcggt ctctccctcc ctcatcagcc caccaaacca aacctagcct ccaagagtgg  2340
gaagaaatta aagcaagata ggctattaag tgcagaggga gagaaaatgc ctccaacatg  2400
tgaggaagta atgagagaaa tcatagaatt tcttccgctt cctcgctcac tgactcgctg  2460
cgctcggtcg ttcggctgcg gcgagcggta tcagctcact caaaggcggt aatacggtta  2520
tccacagaat caggggataa cgcaggaaag aacatgtgag caaaaggcca gcaaaaggcc  2580
aggaaccgta aaaaggccgc gttgctggcg ttttttccata ggctccgccc cctgacgag  2640
catcacaaaa atcgacgctc aagtcagagg tggcgaaacc cgacaggact ataaagatac  2700
caggcgtttc cccctggaag ctccctcgtg cgctctcctg ttccgaccct gccgcttacc  2760
ggatacctgt ccgcctttct cccttcggga agcgtggcgc tttctcaatg ctcacgctgt  2820
aggtatctca gttcggtgta ggtcgttcgc tccaagctgg gctgtgtgca cgaacccccc  2880
gttcagcccg accgctgcgc cttatccggt aactatcgtc ttgagtccaa cccggtaaga  2940
cacgacttat cgccactggc agcagccact ggtaacagga ttagcagagc gaggtatgta  3000
ggcggtgcta cagagttctt gaagtggtgg cctaactacg gctacactag aaggacagta  3060
tttggtatct gcgctctgct gaagccagtt accttcggaa aaagagttgg tagctcttga  3120
tccggcaaac aaaccaccgc tggtagcggt ggtttttttg tttgcaagca gcagattacg  3180
```

```
cgcagaaaaa aaggatctca agaagatcct ttgatctttt ctacggggtc tgacgctcag    3240
tggaacgaaa actcacgtta agggattttg gtcatgagat tatcaaaaag gatcttcacc    3300
tagatccttt taaattaaaa atgaagtttt aaatcaatct aaagtatata tgagtaaact    3360
tggtctgaca gttaccaatg cttaatcagt gaggcaccta tctcagcgat ctgtctattt    3420
cgttcatcca tagttgcctg actccccgtc gtgtagataa ctacgatacg ggagggctta    3480
ccatctggcc ccagtgctgc aatgataccg cgagacccac gctcaccggc tccagattta    3540
tcagcaataa accagccagc cggaagggcc gagcgcagaa gtggtcctgc aactttatcc    3600
gcctccatcc agtctattaa ttgttgccgg gaagctagag taagtagttc gccagttaat    3660
agtttgcgca acgttgttgc cattgctaca ggcatcgtgg tgtcacgctc gtcgtttggt    3720
atggcttcat tcagctccgg ttcccaacga tcaaggcgag ttacatgatc ccccatgttg    3780
tgcaaaaaag cggttagctc cttcggtcct ccgatcgttg tcagaagtaa gttggccgca    3840
gtgttatcac tcatggttat ggcagcactg cataattctc ttactgtcat gccatccgta    3900
agatgctttt ctgtgactgg tgagtactca accaagtcat tctgagaata gtgtatgcgg    3960
cgaccgagtt gctcttgccc ggcgtcaata cgggataata ccgcgccaca tagcagaact    4020
ttaaaagtgc tcatcattgg aaaacgttct tcggggcgaa aactctcaag gatcttaccg    4080
ctgttgagat ccagttcgat gtaacccact cgtgcaccca actgatcttc agcatctttt    4140
actttcacca gcgtttctgg gtgagcaaaa acaggaaggc aaaatgccgc aaaaaaggga    4200
ataagggcga cacggaaatg ttgaatactc atactcttcc ttttcaata ttattgaagc     4260
atttatcagg gttattgtct catgagcgga tacatatttg aatgtattta gaaaaataaa    4320
caaatagggg ttccgcgcac atttccccga aaagtgccac ctgacgtcta agaaaccatt    4380
attatcatga cattaaccta taaaaatagg cgtatcacga ggccctttcg tc            4432
```

<210> 15
<211> 4864
<212> DNA
<213> E. coli (V1Jneo plasmid)

<400> 15
```
tcgcgcgttt cggtgatgac ggtgaaaacc tctgacacat gcagctcccg gagacggtca     60
cagcttgtct gtaagcggat gccgggagca gacaagcccg tcagggcgcg tcagcgggtg    120
ttggcggggtg tcggggctgg cttaactatg cggcatcaga gcagattgta ctgagagtgc    180
accatatgcg gtgtgaaata ccgcacagat gcgtaaggag aaaataccgc atcagattgg    240
ctattggcca ttgcatacgt tgtatccata tcataatatg tacatttata ttggctcatg    300
tccaacatta ccgccatgtt gacattgatt attgactagt tattaatagt aatcaattac    360
ggggtcatta gttcatagcc catatatgga gttccgcgtt acataactta cggtaaatgg    420
cccgcctggc tgaccgccca cgaccccg cccattgacg tcaataatga cgtatgttcc    480
catagtaacg ccaatagggac ctttccattg acgtcaatgg gtggagtatt tacggtaaac    540
tgcccacttg gcagtacatc aagtgtatca tatgccaagt acgccccta ttgacgtcaa    600
tgacggtaaa tggcccgcct ggcattatgc ccagtacatg accttatggg actttcctac    660
ttggcagtac atctacgtat tagtcatcgc tattaccatg gtgatgcggt tttggcagta    720
catcaatggg cgtggatagc ggtttgactc acggggattt ccaagtctcc accccattga    780
cgtcaatggg agtttgtttt ggcaccaaaa tcaacgggac tttccaaaat gtcgtaacaa    840
ctccgcccca ttgacgcaaa tgggcggtag gcgtgtacgg tgggaggtct atataagcag    900
agctcgttta gtgaaccgtc agatcgcctg gagacgccat ccacgctgtt ttgacctcca    960
tagaagacac cgggaccgat ccagcctccg cggccgggaa cggtgcattc gaacgcggat    1020
tccccgtgcc aagagtgacg taagtaccgc ctatagagtc tataggccca ccccttggc    1080
ttcttatgca tgctatactg tttttggctt ggggtctata cacccccgct tcctcatgtt    1140
ataggtgatg gtatagctta gcctataggt gtgggttatt gaccattatt gaccactccc    1200
ctattggtga cgatactttc cattactaat ccataacatg gctctttgcc acaactctct    1260
ttattggcta tatgccaata cactgtcctt cagagactga cacggactct gtatttttac    1320
aggatggggt ctcatttatt atttacaaat tcacatatac aacaccaccg tccccagtgc    1380
ccgcagtttt tattaaacat aacgtgggat cttccacgcga atctcgggta cgtgttccgg    1440
acatgggctc ttctccggta gcggcggagc ttctacatcc gagccctgct cccatgcctc    1500
cagcgactca tggtcgctcg gcagctcctt gctcctaaca gtggaggcca gacttaggca    1560
cagcacgatg cccaccacca ccagtgtgcc gcacaaggcc gtggcggtag ggtatgtgtc    1620
tgaaaatgag ctcggggagc gggcttgcac cgctgacgca tttggaagac ttaaggcagc    1680
ggcagaagaa gatgcaggca gctgagttgt tgtgttctga taagagtcag aggtaactcc    1740
cgttgcggtg ctgttaacgg tggagggcag tgtagtctga gcagtactcg ttgctgccgc    1800
gcgcgccacc agacataata gctgacagac taacagactg ttcctttcca tgggtctttt    1860
ctgcagtcac cgtccttaga tctgctgtgc cttctagttg ccagccatct gttgtttgcc    1920
cctcccccgt gccttccttg accctggaag gtgccactcc cactgtcctt tcctaataaa    1980
atgaggaaat tgcatcgcat tgtctgagta ggtgtcattc tattctgggg ggtgggggtgg    2040
```
```

```
ggcagcacag caaggggggag gattgggaag acaatagcag gcatgctggg gatgcggtgg    2100
gctctatggg tacccaggtg ctgaagaatt gacccggttc ctcctgggcc agaaagaagc    2160
aggcacatcc ccttctctgt gacacaccct gtccacgccc ctggttctta gttccagccc    2220
cactcatagg acactcatag ctcaggaggg ctccgccttc aatcccaccc gctaaagtac    2280
ttggagcggt ctctccctcc ctcatcagcc caccaaacca aacctagcct ccaagagtgg    2340
gaagaaatta aagcaagata ggctattaag tgcagaggga gagaaaatgc ctccaacatg    2400
tgaggaagta atgagagaaa tcatagaatt tcttccgctt cctcgctcac tgactcgctg    2460
cgctcggtcg ttcggctgcg gcgagcggta tcagctcact caaaggcggt aatacggtta    2520
tccacagaat caggggataa cgcaggaaag aacatgtgag caaaaggcca gcaaaaggcc    2580
aggaaccgta aaaaggccgc gttgctggcg tttttccata ggctccgccc ccctgacgag    2640
catcacaaaa atcgacgctc aagtcagagg tggcgaaacc cgacaggact ataaagatac    2700
caggcgtttc cccctggaag ctccctcgtg cgctctcctg ttccgaccct gccgcttacc    2760
ggatacctgt ccgcctttct cccttcggga agcgtggcgc tttctcaatg ctcacgctgt    2820
aggtatctca gttcggtgta ggtcgttcgc tccaagctgg gctgtgtgca cgaacccccc    2880
gttcagcccg accgctgcgc cttatccggt aactatcgtc ttgagtccaa cccggtaaga    2940
cacgacttat cgccactggc agcagccact ggtaacagga ttagcagagc gaggtatgta    3000
ggcggtgcta cagagttctt gaagtggtgg cctaactacg gctacactag aaggacagta    3060
tttggtatct gcgctctgct gaagccagtt accttcggaa aaagagttgg tagctcttga    3120
tccggcaaac aaaccaccgc tggtagcggt ggtttttttg tttgcaagca gcagattacg    3180
cgcagaaaaa aaggatctca agaagatcct ttgatctttt ctacggggtc tgacgctcag    3240
tggaacgaaa actcacgtta agggattttg gtcatgagat tatcaaaaag gatcttcacc    3300
tagatccttt taaattaaaa atgaagtttt aaatcaatct aaagtatata tgagtaaact    3360
tggtctgaca gttaccaatg cttaatcagt gaggcaccta tctcagcgat ctgtctattt    3420
cgttcatcca tagttgcctg actccggggg ggggggcgc tgaggtctgc ctcgtgaaga    3480
aggtgttgct gactcatacc aggcctgaat cgccccatca tccagccaga aagtgaggga    3540
gccacggttg atgagagctt tgttgtaggt ggaccagttg gtgattttga acttttgctt    3600
tgccacggaa cggtctgcgt tgtcgggaag atgcgtgatc tgatccttca actcagcaaa    3660
agttcgattt attcaacaaa gccgccgtcc cgtcaagtca gcgtaatgct ctgccagtgt    3720
tacaaccaat taaccaattc tgattagaaa aactcatcga gcatcaaatg aaactgcaat    3780
ttattcatat caggattatc aataccatat ttttgaaaaa gccgtttctg taatgaagga    3840
gaaaactcac cgaggcagtt ccataggatg gcaagatcct ggtatcggtc tgcgattccg    3900
actcgtccaa catcaataca acctattaat ttcccctcgt caaaaataag gttatcaagt    3960
gagaaatcac catgagtgac gactgaatcc ggtgagaatg gcaaaagctt atgcatttct    4020
ttccagactt gttcaacagg ccagccatta cgctcgtcat caaaatcact cgcatcaacc    4080
aaaccgttat tcattcgtga ttgcgcctga gcgagacgaa atacgcgatc gctgttaaaa    4140
ggacaattac aaacaggaat cgaatgcaac cggcgcagga acactgccag cgcatcaaca    4200
atattttcac ctgaatcagg atattcttct aatacctgga atgctgtttt cccggggatc    4260
gcagtggtga gtaaccatgc atcatcagga gtacggataa aatgcttgat ggtcggaaga    4320
ggcataaatt ccgtcagcca gtttagtctg accatctcat ctgtaacatc attggcaacg    4380
ctacctttgc catgtttcag aaacaactct ggcgcatcgg gcttcccata caatcgatag    4440
attgtcgcac ctgattgccc gacattatcg cgagcccatt tatacccata taaatcagca    4500
tccatgttgg aatttaatcg cggcctcgag caagacgttt cccgttgaat atggctcata    4560
acaccccttg tattactgtt tatgtaagca gacagtttta ttgttcatga tgatatattt    4620
ttatcttgtg caatgtaaca tcagagattt tgagacacaa cgtggctttc cccccccccc    4680
cattattgaa gcatttatca gggttattgt ctcatgagcg gatacatatt tgaatgtatt    4740
tagaaaaata aacaaatagg ggttccgcgc acatttcccc gaaaagtgcc acctgacgtc    4800
taagaaacca ttattatcat gacattaacc tataaaaata ggcgtatcac gaggcccttt    4860
cgtc                                                                 4864
```

```
<210> 16
<211> 4867
<212> DNA
<213> E. coli (V1Jns plasmid)

<400> 16
tcgcgcgttt cggtgatgac ggtgaaaacc tctgacacat gcagctcccg gagacggtca     60
cagcttgtct gtaagcggat gccgggagca gacaagcccg tcagggcgcg tcagcggggtg   120
ttggcgggtg tcggggctgg cttaactatg cggcatcaga gcagattgta ctgagagtgc    180
accatatgcg gtgtgaaata ccgcacagat gcgtaaggag aaaataccgc atcagattgg    240
ctattggcca ttgcatacgt tgtatccata tcataatatg tacatttata ttggctcatg    300
tccaacatta ccgccatgtt gacattgatt attgactagt tattaatagt aatcaattac    360
ggggtcatta gttcatagcc catatatgga gttccgcgtt acataactta cggtaaatgg    420
```
```

```
cccgcctggc tgaccgccca acgacccccg cccattgacg tcaataatga cgtatgttcc   480
catagtaacg ccaataggga cttttccattg acgtcaatgg gtggagtatt tacggtaaac   540
tgcccacttg gcagtacatc aagtgtatca tatgccaagt acgcccccta ttgacgtcaa   600
tgacggtaaa tggcccgcct ggcattatgc ccagtacatg accttatggg actttcctac   660
ttggcagtac atctacgtat tagtcatcgc tattaccatg gtgatgcggt tttggcagta   720
catcaatggg cgtggatagc ggtttgactc acggggattt ccaagtctcc accccattga   780
cgtcaatggg agtttgtttt ggcaccaaaa tcaacgggac tttccaaaat gtcgtaacaa   840
ctccgcccca ttgacgcaaa tgggcggtag gcgtgtacgg tgggaggtct atataagcag   900
agctcgttta gtgaaccgtc agatcgcctg gagacgccat ccacgctgtt ttgacctcca   960
tagaagacac cgggaccgat ccagcctccg cggccgggaa cggtgcattg gaacgcggat  1020
tccccgtgcc aagagtgacg taagtaccgc ctatagactc tataggcaca cccctttggc  1080
tcttatgcat gctatactgt ttttggcttg gggcctatac accccgctt ccttatgcta  1140
taggtgatgg tatagcttag cctataggtg tgggttattg accattattg accactcccc  1200
tattggtgac gatactttcc attactaatc cataacatgg ctctttgcca caactatctc  1260
tattggctat atgccaatac tctgtccttc agagactgac acggactctg tatttttaca  1320
ggatggggtc ccatttatta tttacaaatt cacatataca acaacgccgt cccccgtgcc  1380
cgcagttttt attaaacata gcgtgggatc tccacgcgaa tctcgggtac gtgttccgga  1440
catgggctct tctccggtag cggcggagct tccacatccg agccctggtc ccatgcctcc  1500
agcggctcat ggtcgctcgg cagctccttg ctcctaacag tggaggccag acttaggcac  1560
agcacaatgc ccaccaccac cagtgtgccg cacaaggccg tggcggtagg gtatgtgtct  1620
gaaaatgagc gtggagattg ggctcgcacg gctgacgcag atggaagact taaggcagcg  1680
gcagaagaag atgcaggcag ctgagttgtt gtattctgat aagagtcaga ggtaactccc  1740
gttgcggtgc tgttaacggt ggagggcagt gtagtctgag cagtactcgt tgctgccgcg  1800
cgcgccacca gacataatag ctgacagact aacagactgt tcctttccat gggtcttttc  1860
tgcagtcacc gtccttagat ctgctgtgcc ttctagttgc cagccatctg ttgtttgccc  1920
ctcccccgtg ccttccttga ccctggaagg tgccactccc actgtccttt cctaataaaa  1980
tgaggaaatt gcatcgcatt gtctgagtag gtgtcattct attctggggg gtggggtggg  2040
gcaggacagc aaggggggag attgggaaga caatagcagg catgctgggg atgcggtggg  2100
ctctatggcc gctgcggcca ggtgctgaag aattgacccg gttcctcctg ggccagaaag  2160
aagcaggcac atccccttct ctgtgacaca ccctgtccac gcccctggtt cttagttcca  2220
gccccactca taggacactc atagctcagg aggtctccgg cttcaatccc acccgctaaa  2280
gtacttggag cggtctctcc ctccctcatc agcccaccaa accaaaccta gcctccaaga  2340
gtgggaagaa attaaagcaa gataggctat taagtgcaga gggagagaaa atgcctccaa  2400
catgtgagga agtaatgaga gaaatcatag aatttcttcc gcttcctcgc tcactgactc  2460
gctgcgctcg gtcgttcggc tgcggcgagc ggtatcagct cactcaaagg cggtaatacg  2520
gttatccaca gaatcagggg ataacgcagg aaagaacatg tgagcaaaag gccagcaaaa  2580
ggccaggaac cgtaaaaagg ccgcgttgct ggcgtttttc cataggctcc gcccccctga  2640
cgagcatcac aaaaatcgac gctcaagtca gaggtggcga aacccgacag gactataaag  2700
ataccaggcg tttccccctg gaagctccct cgtgcgctct cctgttccga ccctgccgct  2760
taccggatac ctgtccgcct ttctcccttc gggaagcgtg gcgctttctc atagctcacg  2820
ctgtaggtat ctcagttcgg tgtaggtcgt tcgctccaag ctgggctgtg tgcacgaacc  2880
ccccgttcag cccgaccgct gcgccttatc cggtaactat cgtcttgagt ccaacccggt  2940
aagacacgac ttatcgccac tggcagcagc cactggtaac aggattagca gagcgaggta  3000
tgtaggcggt gctacagagt tcttgaagtg gtggcctaac tacggctaca ctagaagaac  3060
agtatttggt atctgcgctc tgctgaagcc agttaccttc ggaaaaagag ttggtagctc  3120
ttgatccggc aaacaaacca ccgctggtag cggtggtttt tttgtttgca agcagcagat  3180
tacgcgcaga aaaaaaggat ctcaagaaga tcctttgatc ttttctacgg ggtctgacgc  3240
tcagtggaac gaaaactcac gttaagggat tttggtcatg agattatcaa aaaggatctt  3300
cacctagatc cttttaaatt aaaaatgaag ttttaaatca atctaaagta tatatgagta  3360
aacttggtct gacagttacc aatgcttaat cagtgaggca cctatctcag cgatctgtct  3420
atttcgttca tccatagttg cctgactcgg gggggggggg cgctgaggtc tgcctcgtga  3480
agaaggtgtt gctgactcat accaggcctg aatcgcccca tcatccagcc agaaagtgag  3540
ggagccacgg ttgatgagag ctttgttgta ggtggaccag ttggtgattt tgaacttttg  3600
ctttgccacg gaacggtctg cgttgtcggg aagatgcgtg atctgatcct tcaactcagc  3660
aaaagttcga tttattcaac aaagccgccg tcccgtcaag tcagcgtaat gctctgccag  3720
tgttacaacc aattaaccaa ttctgattag aaaaactcat cgagcatcaa atgaaactgc  3780
aatttattca tatcaggatt atcaatacca tatttttgaa aaagccgttt ctgtaatgaa  3840
ggagaaaact caccgaggca gttccatagg atggcaagat cctggtatcg gtctgcgatt  3900
ccgactcgtc caacatcaat acaacctatt aatttcccct cgtcaaaaat aaggttatca  3960
agtgagaaat caccatgagt gacgactgaa tccggtgaga atggcaaaag cttatgcatt  4020
tctttccaga cttgttcaac aggccagcca ttacgctcgt catcaaaatc actcgcatca  4080
accaaaccgt tattcattcg tgattgcgcc tgagcgagac gaaatacgcg atcgctgtta  4140
```

- 29 -

```
aaaggacaat tacaaacagg aatcgaatgc aaccggcgca ggaacactgc cagcgcatca        4200
acaatatttt cacctgaatc aggatattct tctaatacct ggaatgctgt tttcccgggg        4260
atcgcagtgg tgagtaacca tgcatcatca ggagtacgga taaaatgctt gatggtcgga        4320
agaggcataa attccgtcag ccagtttagt ctgaccatct catctgtaac atcattggca        4380
acgctacctt tgccatgttt cagaaacaac tctggcgcat cgggcttccc atacaatcga        4440
tagattgtcg cacctgattg cccgacatta tcgcgagccc atttataccc atataaatca        4500
gcatccatgt tggaatttaa tcgcggcctc gagcaagacg tttcccgttg aatatggctc        4560
ataacacccc ttgtattact gtttatgtaa gcagacagtt ttattgttca tgatgatata        4620
tttttatctt gtgcaatgta acatcagaga ttttgagaca caacgtggct ttcccccccc        4680
ccccattatt gaagcattta tcagggttat tgtctcatga gcggatacat atttgaatgt        4740
atttagaaaa ataaacaaat aggggttccg cgcacatttc cccgaaaagt gccacctgac        4800
gtctaagaaa ccattattat catgacatta acctataaaa ataggcgtat cacgaggccc        4860
tttcgtc                                                                  4867
```

```
<210> 17
<211> 75
<212> DNA
<213> Artificial Sequence

<220>
<223> oligonucleotide

<400> 17
gatcaccatg gatgcaatga agagagggct ctgtgtgctg ctgctgtgtg gagcagtctt        60
cgtttcgccc agcga                                                         75


<210> 18
<211> 78
<212> DNA
<213> Artificial Sequence

<220>
<223> oligonucleotide

<400> 18
gatctcgctg ggcgaaacga agactgctcc acacagcagc agcacacagc agagccctct        60
cttcattgca tccatggt                                                      78


<210> 19
<211> 33
<212> DNA
<213> Artificial Sequence

<220>
<223> oligonucleotide

<400> 19
ggtacaaata ttggctattg gccattgcat acg                                     33


<210> 20
<211> 36
<212> DNA
<213> Artificial Sequence

<220>
<223> oligonucleotide

<400> 20
ccacatctcg aggaaccggg tcaattcttc agcacc                                  36


<210> 21
<211> 38
```

<212> DNA
<213> Artificial Sequence

<220>
<223> oligonucleotide

<400> 21
ggtacagata tcggaaagcc acgttgtgtc tcaaaatc   38

<210> 22
<211> 36
<212> DNA
<213> Artificial Sequence

<220>
<223> oligonucleotide

<400> 22
cacatggatc cgtaatgctc tgccagtgtt acaacc   36

<210> 23
<211> 39
<212> DNA
<213> Artificial Sequence

<220>
<223> oligonucleotide

<400> 23
ggtacatgat cacgtagaaa agatcaaagg atcttcttg   39

<210> 24
<211> 35
<212> DNA
<213> Artificial Sequence

<220>
<223> oligonucleotide

<400> 24
ccacatgtcg acccgtaaaa aggccgcgtt gctgg   35

<210> 25
<211> 4864
<212> DNA
<213> E. coli (V1R plasmid)

<400> 25
tcgcgcgttt cggtgatgac ggtgaaaacc tctgacacat gcagctcccg gagacggtca   60
cagcttgtct gtaagcggat gccgggagca gacaagcccg tcagggcgcg tcagcgggtg   120
ttggcgggtg tcggggctgg cttaactatg cggcatcaga gcagattgta ctgagagtgc   180
accatatgcg gtgtgaaata ccgcacagat gcgtaaggag aaaataccgc atcagattgg   240
ctattggcca ttgcatacgt tgtatccata tcataatatg tacatttata ttggctcatg   300
tccaacatta ccgccatgtt gacattgatt attgactagt tattaatagt aatcaattac   360
ggggtcatta gttcatagcc catatatgga gttccgcgtt acataactta cggtaaatgg   420
cccgcctggc tgaccgccca cgaccccccg cccattgacg tcaataatga cgtatgttcc   480
catagtaacg ccaatagggga ctttccattg acgtcaatgg gtggagtatt tacggtaaac   540
tgcccacttg gcagtacatc aagtgtatca tatgccaagt acgccccta ttgacgtcaa   600
tgacggtaaa tggcccgcct ggcattatgc ccagtacatg accttatggg actttcctac   660
ttggcagtac atctacgtat tagtcatcgc tattaccatg gtgatgcggt tttggcagta   720
catcaatggg cgtggatagc ggtttgactc acggggattt ccaagtctcc accccattga   780
cgtcaatggg agtttgtttt ggcaccaaaa tcaacgggac tttccaaaat gtcgtaacaa   840

```
ctccgcccca ttgacgcaaa tgggcggtag gcgtgtacgg tgggaggtct atataagcag    900
agctcgttta gtgaaccgtc agatcgcctg gagacgccat ccacgctgtt ttgacctcca    960
tagaagacac cgggaccgat ccagcctccg cggccgggaa cggtgcattg gaacgcggat   1020
tccccgtgcc aagagtgacg taagtaccgc ctatagagtc tataggccca cccccttggc   1080
ttcttatgca tgctatactg ttttttggctt ggggtctata cacccccgct tcctcatgtt   1140
ataggtgatg gtatagctta gcctataggt gtgggttatt gaccattatt gaccactccc   1200
ctattggtga cgatactttc cattactaat ccataacatg gctctttgcc acaactctct   1260
ttattggcta tatgccaata cactgtcctt cagagactga cacggactct gtattttac   1320
aggatggggt ctcatttatt atttacaaat tcacatatac aacaccaccg tccccagtgc   1380
ccgcagtttt tattaaacat aacgtgggat ctccacgcga atctcgggta cgtgttccgg   1440
acatgggctc ttctccggta gcggcggagc ttctacatcc gagcccgct cccatgcctc   1500
cagcgactca tggtcgctcg gcagctcctt gctcctaaca gtggaggcca gacttaggca   1560
cagcacgatg cccaccacca ccagtgtgcc gcacaaggcc gtggcggtag ggtatgtgtc   1620
tgaaaatgag ctcggggagc gggcttgcac cgctgacgca tttggaagac ttaaggcagc   1680
ggcagaagaa gatgcaggca gctgagttgt tgtgttctga taagagtcag aggtaactcc   1740
cgttgcggtg ctgttaacgg tggagggcag tgtagtctga gcagtactcg ttgctgccgc   1800
gcgcgccacc agacataata gctgacagac taacagactg ttcctttcca tgggtctttt   1860
ctgcagtcac cgtccttaga tctgctgtgc cttctagttg ccagccatct gttgtttgcc   1920
cctcccccgt gccttccttg accctggaag gtgccactcc cactgtcctt tcctaataaa   1980
atgaggaaat tgcatcgcat tgtctgagta ggtgtcattc tattctgggg ggtggggtgg   2040
ggcagcacag caaggggag gattgggaag acaatagcag gcatgctggg gatgcggtgg   2100
gctctatggg tacccaggtg ctgaagaatt gacccggttc ctcctgggcc agaaagaagc   2160
aggcacatcc ccttctctgt gacacaccct gtccacgccc ctggttctta gttccagccc   2220
cactcatagg acactcatag ctcaggaggg ctccgccttc aatcccaccc gctaaagtac   2280
ttggagcggt ctctccctcc ctcatcagcc caccaaacca aacctagcct ccaagagtgg   2340
gaagaaatta aagcaagata ggctattaag tgcagaggga gagaaaatgc ctccaacatg   2400
tgaggaagta atgagagaaa tcatagaatt tcttccgctt cctcgctcac tgactcgctg   2460
cgctcggtcg ttcggctgcg gcgagcggta tcagctcact caaaggcggt aatacggtta   2520
tccacagaat caggggataa cgcaggaaag aacatgtgag caaaaggcca gcaaaaggcc   2580
aggaaccgta aaaaggccgc gttgctggcg ttttttccata ggctccgccc ccctgacgag   2640
catcacaaaa atcgacgctc aagtcagagg tggcgaaacc cgacaggact ataaagatac   2700
caggcgtttc cccctggaag ctccctcgtg cgctctcctg ttccgaccct gccgcttacc   2760
ggatacctgt ccgcctttct cccttcggga agcgtggcgc tttctcaatg ctcacgctgt   2820
aggtatctca gttcggtgta ggtcgttcgc tccaagctgg gctgtgtgca cgaacccccc   2880
gttcagcccg accgctgcgc cttatccggt aactatcgtc ttgagtccaa cccggtaaga   2940
cacgacttat cgccactggc agcagccact ggtaacagga ttagcagagc gaggtatgta   3000
ggcggtgcta cagagttctt gaagtggtgg cctaactacg gctacactag aaggacagta   3060
tttggtatct gcgctctgct gaagccagtt accttcggaa aaagagttgg tagctcttga   3120
tccggcaaac aaaccaccgc tggtagcggt ggtttttttg tttgcaagca gcagattacg   3180
cgcagaaaaa aaggatctca agaagatcct ttgatctttt ctacggggtc tgacgctcag   3240
tggaacgaaa actcacgtta agggattttg gtcatgagat tatcaaaaag gatcttcacc   3300
tagatccttt taaattaaaa atgaagtttt aaatcaatct aaagtatata tgagtaaact   3360
tggtctgaca gttaccaatg cttaatcagt gaggcaccta tctcagcgat ctgtctattt   3420
cgttcatcca tagttgcctg actccggggg gggggggcgc tgaggtctgc ctcgtgaaga   3480
aggtgttgct gactcatacc aggcctgaat cgccccatca tccagccaga aagtgaggga   3540
gccacggttg atgagagctt tgttgtaggt ggaccagttg gtgattttga actttttgctt   3600
tgccacggaa cggtctgcgt tgtcgggaag atgcgtgatc tgatccttca actcagcaaa   3660
agttcgattt attcaacaaa gccgccgtcc cgtcaagtca gcgtaatgct ctgccagtgt   3720
tacaaccaat taaccaattc tgattagaaa aactcatcga gcatcaaatg aaactgcaat   3780
ttattcatat caggattatc aataccatat ttttgaaaaa gccgtttctg taatgaagga   3840
gaaaactcac cgaggcagtt ccataggatg gcaagatcct ggtatcggtc tgcgattccg   3900
actcgtccaa catcaataca acctattaat ttccctcgt caaaaataag gttatcaagt   3960
gagaaatcac catgagtgac gactgaatcc ggtgagaatg gcaaaagctt atgcatttct   4020
ttccagactt gttcaacagg ccagccatta cgctcgtcat caaaatcact cgcatcaacc   4080
aaaccgttat tcattcgtga ttgcgcctga gcgagacgaa atacgcgatc gctgttaaaa   4140
ggacaattac aaacaggaat cgaatgcaac cggcgcagga acactgccag cgcatcaaca   4200
atattttcac ctgaatcagg atattcttct aatacctgga atgctgtttt cccggggatc   4260
gcagtggtga gtaaccatgc atcatcagga gtacggataa aatgcttgat ggtcggaaga   4320
ggcataaatt ccgtcagcca gtttagtctg accatctcat ctgtaacatc attggcaacg   4380
ctacctttgc catgtttcag aaacaactct ggcgcatcgg gcttcccata caatcgatag   4440
attgtcgcac ctgattgccc gacattatcg cgagcccatt tatacccata taaatcagca   4500
tccatgttgg aatttaatcg cggcctcgag caagacgttt cccgttgaat atggctcata   4560
```

-32-

```
acaccccttg tattactgtt tatgtaagca gacagtttta ttgttcatga tgatatattt    4620
ttatcttgtg caatgtaaca tcagagattt tgagacacaa cgtggctttc cccccccccc    4680
cattattgaa gcatttatca gggttattgt ctcatgagcg gatacatatt tgaatgtatt    4740
tagaaaaata aacaaatagg ggttccgcgc acatttcccc gaaaagtgcc acctgacgtc    4800
taagaaacca ttattatcat gacattaacc tataaaaata ggcgtatcac gaggcccttt    4860
cgtc                                                                 4864
```

```
<210> 26
<211> 36
<212> DNA
<213> Artificial Sequence

<220>
<223> oligonucleotide

<400> 26
ggtacaagat ctccgccccc atctcccca ttgaga                                 36

<210> 27
<211> 33
<212> DNA
<213> Artificial Sequence

<220>
<223> oligonucleotide

<400> 27
ccacatagat ctgcccgggc tttagtcctc atc                                   33

<210> 28
<211> 27
<212> PRT
<213> Homo sapien

<400> 28
Met Asp Ala Met Lys Arg Gly Leu Cys Cys Val Leu Leu Leu Cys Gly
 1               5                  10                  15
Ala Val Phe Val Ser Pro Ser Glu Ile Ser Ser
            20                  25

<210> 29
<211> 45
<212> DNA
<213> Artificial Sequence

<220>
<223> oligonucleotide

<400> 29
caggcgagat ctaccatggc ccccattagc cctattgaga ctgta                      45

<210> 30
<211> 48
<212> DNA
<213> Artificial Sequence

<220>
<223> oligonucleotide

<400> 30
caggcgagat ctgcccgggc tttaatcctc atcctgtcta cttgccac                   48
```

INTERNATIONAL SEARCH REPORT

A.   CLASSIFICATION OF SUBJECT MATTER

IPC(7)   :   A61K 48/00; C12Q 1/70.
US CL   :   514/44; 435/5; 424/93.1.

According to International Patent Classification (IPC) or to both national classification and IPC

B.   FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
    U.S. : 514/44; 435/5; 424/93.1.

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)
Medline, embase, scisearch, biosis, caplus and WEST

C.   DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y,P	US 6,099,848 A (FRANKEL et al) 08 August 2000 (08.08.2000), page 12 paragraph 6.	1-14, 17
Y	WO 97/31115 A2 (MERCK & CO. INC.), 28 August 1997, page 36.	4
X	WO 90/10230 A1 (UNIVERSITY OF OTTAWA) 07 September 1990, page 11.	17
Y	US 5,858,646 A (KANG) 12 January 1999 (12.01.1999), col. 2, lines 10-17	1-14, 17

☐ Further documents are listed in the continuation of Box C.   ☐   See patent family annex.

*	Special categories of cited documents:	"T"	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"A"	document defining the general state of the art which is not considered to be of particular relevance		
"E"	earlier application or patent published on or after the international filing date	"X"	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"L"	document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"Y"	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"O"	document referring to an oral disclosure, use, exhibition or other means		
"P"	document published prior to the international filing date but later than the priority date claimed	"&"	document member of the same patent family

Date of the actual completion of the international search	Date of mailing of the international search report
22 February 2001	09 MAR 2001
Name and mailing address of the ISA/US	Authorized officer **TERRY J. DEY**
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231	Eleanor Sorbello **PARALEGAL SPECIALIST**
Facsimile No. (703)305-3230	Telephone No. 703-308-0196 **TECHNOLOGY CENTER 1600**

Form PCT/ISA/210 (second sheet) (July 1998)

INTERNATIONAL SEARCH REPORT

Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)

This international report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claim Nos.:
   because they relate to subject matter not required to be searched by this Authority, namely:

2. ☐ Claim Nos.:
   because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

3. ☒ Claim Nos.: 15 & 16
   because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II   Observations where unity of invention is lacking (Continuation of Item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.

2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.

3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:

4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest   ☐   The additional search fees were accompanied by the applicant's protest.
   ☐   No protest accompanied the payment of additional search fees.

Form PCT/ISA/210 (continuation of first sheet(1)) (July 1998)

THIS PAGE BLANK (USPTO)